category,datetime,headline,id,image,related,source,summary,url
company,1629211183,5 Stocks Insiders Are Selling,69703412,,BMY,Yahoo,"When insiders sell shares, it indicates their concern in the company’s prospects or that they view the stock as being overpriced. Either way, this signals an opportunity to go short on the stock. Insider sales should not be taken as the only indicator for making an investment or trading decision. At best, it can lend conviction to a selling decision. Below is a look at a few recent notable insider sales. For more, check out Benzinga's insider transactions platform. Pinterest The Trade: Pinterest",https://finnhub.io/api/news?id=82d782c635c0ae23b0b0a3393f0da138027325a2ae138df8eaa01870fa151e3b
company,1629204540,Got $100? Here Are 3 Top Dividend Growth Stocks to Jump-Start Your Portfolio,69693901,,BMY,Yahoo,"Drugmaker Bristol Myers Squibb increased its dividend payments for the 12th straight year in 2020.  Its quarterly dividend of $0.49 is 8.9% higher than the $0.45 the company was paying out a year earlier.  Going back five years to 2016, Bristol Myers Squibb was paying its shareholders $0.38 per quarter, meaning the company has increased the dividend by 29% since then, averaging a compounded annual growth rate (CAGR) of 5.2%.",https://finnhub.io/api/news?id=a08ab7c244f6d4e600b40768297804b1933a1d1cc0840fb75e02ee7837e77464
company,1629197940,"EMA Validates Bristol Myers Squibb’s Applications for Opdivo (nivolumab) + Yervoy (ipilimumab) and Opdivo + Chemotherapy as First-Line Treatments for Unresectable Advanced, Recurrent or Metastatic Esophageal Squamous Cell Carcinoma",69693008,https://s.yimg.com/uu/api/res/1.2/hai3eleZHbkgqMs5F5BwLA--~B/aD02Njt3PTQ4MDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/business-wire.com/5f72b4ed452e125e9c10b2c38c4713e2,BMY,Yahoo,"PRINCETON, N.J., August 17, 2021--European Medicines Agency Validates Bristol Myers Squibb’s Applications for Opdivo+ Yervoy and Opdivo + Chemotherapy as First-Line Treatments for....",https://finnhub.io/api/news?id=6a3b089e699f7c9ee4934e025b647a6a1c803f148b69c28f7e1feef6fcbc8792
company,1629196740,5 Stocks Insiders Are Selling,69701572,https://cdn.benzinga.com/files/imagecache/og_image_social_share_1200x630/images/story/2012/insider-selling_9.jpg,BMY,Benzinga,"When insiders sell shares, it indicates their concern in the company’s prospects or that they view the stock as being overpriced. Either way, this signals an opportunity to...",https://finnhub.io/api/news?id=9a867cc032a04950affb009a40dba80720f1d6a798452089adcccbff15377a0f
company,1629188880,"The Daily Biotech Pulse: Lilly Reorganizes Business Units In Neuroscience Focus, Helius Medical Spikes On Breakthrough Designation, Ra Medical Sells Dermatology Business",69696484,https://cdn.benzinga.com/files/imagecache/og_image_social_share_1200x630/images/story/2012/cells-1872666_1920_86.jpg,BMY,Benzinga,"Here's a roundup of top developments in the biotech space over the last 24 hours:
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Aug. 16)

Bio-Rad Laboratories, Inc...",https://finnhub.io/api/news?id=05dbaa731e5879ae8257a9deade3e4709469b9c725264c7c31c6ff745ecbd891
company,1629184500,"Forget Moderna, 3 Pharma Stocks That Are Better Picks",69692292,https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1292778249/medium_image_1292778249.jpg,BMY,SeekingAlpha,"Moderna has been a great investment over the last year, but past returns do not equate to future returns. Check out the 3 better Pharma plays in this article.",https://finnhub.io/api/news?id=74c84d1e6a32bc5fc339c2c9be5dc60a2fd7a4bc4055fec5a00141c56584a547
company,1629183540,"EMA Validates Bristol Myers Squibb’s Applications for Opdivo (nivolumab) + Yervoy (ipilimumab) and Opdivo + Chemotherapy as First-Line Treatments for Unresectable Advanced, Recurrent or Metastatic Esophageal Squamous Cell Carcinoma",69694306,,BMY,Business Wire,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=de564d772d5902ebc1c95f2386531a2eba92afafae24a78f59e77f361b3610a6
company,1629180759,"Apple, GM, Kroger, AbbVie, Merck, Bristol Myers Squibb, Biogen — How Warren Buffett's Berkshire Adjusted Its Portfolio In Q2",69694889,https://s.yimg.com/uu/api/res/1.2/g7Dy51aEr0qUJyrqh2Xmog--~B/aD00MDA7dz02MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/Benzinga/278cb940d05d470e0fa95b7c185db9e8,BMY,Yahoo,"Warren Buffett-led Berkshire Hathaway Inc (NYSE: BRK-A) (NYSE: BRK-B) sharply lowered its exposure in General Motors Co (NYSE: GM), Merck & Co Inc (NYSE: MRK), AbbVie Inc (NYSE: ABBV), Bristol-Myers Squibb Co (NYSE: BMY) and added positions in Kroger Inc (NYSE: KR) and Aon Plc (NYSE: AON), in the second quarter, regulatory filings revealed on Monday. What Happened: The Omaha, Nebraska-based conglomerate disclosed it has trimmed its position in the legacy automaker GM by 10.44%, as it shed 60 mil",https://finnhub.io/api/news?id=6b3e04fe31be2d459b8627aafefa7b12137f49a60696f4f80668bc3778132110
company,1629180180,Bristol-Myers receives MAA validation from EMA for Opdivo combined with Yervoy,69694307,,BMY,Thefly.com,Bristol Myers Squibb anno... BMY,https://finnhub.io/api/news?id=c9e7d14cf96ed5d1dcd7384f5eca87da60fe36012de22a650f46b91d64519278
company,1629166320,"Apple, GM, Kroger, AbbVie, Merck, Bristol Myers Squibb, Biogen — How Warren Buffett's Berkshire Adjusted Its Portfolio In Q2",69696488,https://cdn.benzinga.com/files/imagecache/og_image_social_share_1200x630/images/story/2012/6212236504_9ebe2db744_o.jpg,BMY,Benzinga,"Warren Buffett-led Berkshire Hathaway Inc (NYSE: BRK-A) (NYSE: BRK-B) sharply lowered its exposure in General Motors Co (NYSE: GM), Merck & Co Inc (NYSE: MRK), AbbVie Inc (...",https://finnhub.io/api/news?id=a40ccc0d4d73dbdc054160bdfe2626af95516c1da55b5a2650f7f1de6a359782
company,1629155940,"Warren Buffett’s Berkshire Hathaway Cuts Stakes in 3 Drugmakers and GM, Adds to Kroger",69686819,https://s.yimg.com/uu/api/res/1.2/80dhI3FK8tsmaauneqXx7Q--~B/aD02NDA7dz0xMjgwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/Barrons.com/caab5f7cba3e6e42bea999b1b945240e,BMY,Yahoo,"Overall, Warren Buffett and his investment lieutenants made few notable changes to Berkshire’s equity portfolio.",https://finnhub.io/api/news?id=0a055e74ed60d2caa6cd4f56cd72f7c2b44aacc8dfca8b2cfc192a3696388555
company,1629152013,"Hedge Funds Coatue, D1 Added Pandemic Stocks Before Delta Spread",69703806,https://s.yimg.com/uu/api/res/1.2/1YpOwcbXbltPBaFlPOfuow--~B/aD02NzU7dz0xMjAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/bloomberg_markets_842/2fb7660a3dc455b6fe93a43972a1995b,BMY,Yahoo,"(Bloomberg) -- Hedge funds loaded up on companies that would benefit from a resurgent Covid-19 pandemic even before the delta variant began to rapidly spread throughout the U.S.Chase Coleman’s Tiger Global Management and Philippe Laffont’s Coatue Management both increased their stakes in food delivery service DoorDash Inc. in the second quarter. Coatue also added to its bet on vaccine maker Moderna Inc., while Stephen Mandel’s Lone Pine Capital took a new stake in the biotech company worth more",https://finnhub.io/api/news?id=26e2da465dbb336d0d6ad1049d47479410f85379586fbbd079ff68a952280ca1
company,1629141025,Jim Cramer says Fed policy tightening should be low on list of investor worries,69687112,https://image.cnbcfm.com/api/v1/image/104766841-IMG_9442r-jim-cramer.jpg?v=1507753257,BMY,CNBC,CNBC's Jim Cramer said Monday that investors shouldn't base every buy and sell decision on predictions of Federal Reserve policy moves.,https://finnhub.io/api/news?id=152929e9df0c9462c02899b3f298841dc55a6e97599f02a520da98b40c1b4ecf
company,1629138780,Buffett's firm ups Kroger stake while trimming drug holdings,69694224,,BMY,"Associated Press, The",Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=25ba87269b8cfd62b4d5e2010ed98a82b102fbaa15c91cbe39701368064c81a9
company,1629120360,Novavax Appoints New CFO Amid Inordinate Delay In COVID-19 Vaccine Authorization,69684920,https://cdn.benzinga.com/files/imagecache/og_image_social_share_1200x630/images/story/2012/novavax_vaccine_press_event_5_26_20_cut_7.jpg,BMY,Benzinga,"Novavax, Inc. (NASDAQ: NVAX) announced new hires to its executive team even as it is stymied by the delay in getting authorization for its COVID-19 vaccine in the U.S.
What...",https://finnhub.io/api/news?id=8fac405e1aa13540987268db1e6d1630a04c1ffac400bc194e71a48850ee0595
company,1629114300,Bristol Myers Squibb call volume above normal and directionally bullish,69694309,,BMY,Thefly.com,Bullish option flow detec... BMY,https://finnhub.io/api/news?id=ff0f921437cafd717eb086d31484a19d36444ea7bce222705b0f49ea7f339572
company,1629112560,"Bristol-myers Squibb Company (BMY) EVP, CFO David V Elkins Sold $6.7 million of Shares",69694310,,BMY,GuruFocus,,https://finnhub.io/api/news?id=24dc4e77dfe91368a69bf993322e08b62768fd42ec4d3924f10a8340d8b653df
company,1629108180,Large Cap Biopharma Stocks provide Growth and Value,69681531,,BMY,TalkMarkets,,https://finnhub.io/api/news?id=3b7f5e8c01a281dc2bb9d1b59a8a0c160feccdd7d5e8e9aacee1d01c840c2f53
company,1629095940,"Wilen Investment Management Corp. Buys Trinseo SA, Universal Security Instruments Inc, Koppers Holdings Inc, Sells Cooper Tire & Rubber Co, The Shyft Group Inc, SMTC Corp",69694311,,BMY,GuruFocus,,https://finnhub.io/api/news?id=34c28f848566216a6a259b88ff0a53c9a78d084aa4f290f73ce919a38e8d67fd
company,1629083520,"Berkshire Hathaway exits Biogen, boosts Kroger in Q2",69694229,,BMY,Thefly.com,"Warren Buffett's Ber... BRK.A, BRK.B, AXTA, BIIB, LBTYA, KR, RH, AON, GM, BMY, ABBV, LBTYK, CVX, AAPL, BAC, AXP, KO, KHC",https://finnhub.io/api/news?id=037a6f2673c6a7942b8503c317fad1f055795df50eb92a55758183391fddd237
company,1629078420,"David Rolfe Plugs Into Taiwan Semiconductor, Trims Several Top Holdings",69694313,https://static.gurufocus.com/photos/others/conference_david_rolfe_speaking.jpg,BMY,GuruFocus,Guru reports 2nd-quarter portfolio,https://finnhub.io/api/news?id=e7189bad19ec3397bff6c06ea627fcc88576b5dfc1bdd7f306676f40bb32cb66
company,1629077940,"Independent Franchise Partners LLP Buys Intercontinental Exchange Inc, Bristol-Myers Squibb Company, Alphabet Inc, Sells Altria Group Inc, Oracle Corp, Autodesk Inc",69694314,,BMY,GuruFocus,,https://finnhub.io/api/news?id=8341826a5c59335c9fda2ca9119698b85dc869261e65788ad47544208ccc02c5
company,1629025380,4 Pharma Stocks You Can Buy and Hold for 20 Years,69675228,https://s.yimg.com/cv/apiv2/social/images/yahoo_default_logo-1200x1200.png,BMY,Yahoo,"A buy-and-hold strategy can work really well -- if you pick the right stocks.  In this Motley Fool Live video recorded on Aug. 4, 2021, Motley Fool contributors Keith Speights and Brian Orelli discuss their top pharma stocks to buy and hold for 20 years.  Keith Speights: We had another question on Monday.",https://finnhub.io/api/news?id=0f6effb53da855b0f32079a256ddc3ecca3138a06f317d5cd35112d993b79614
company,1629021600,10 Dividend Growth Stocks For August 2021,69675849,https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1254359872/medium_image_1254359872.jpg,BMY,SeekingAlpha,This monthly series ranks a selection of dividend growth stocks in Dividend Radar and presents the ten top-ranked stocks for consideration. Click to see the list.,https://finnhub.io/api/news?id=97212b49d0dbcfc8ce936703b7951150b7d21b50aca93762f7f25020a70dd5ef
company,1628983614,Buffett August Holdings Include 3 Ideal Dogs Of 28 Dividend Payers,69673009,https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1329264503/medium_image_1329264503.jpg,BMY,SeekingAlpha,This Buffett holdings list from Kiplinger appeared online. Click here to read the Buffett august holdings including 3 ideal dogs of 28 dividend payers.,https://finnhub.io/api/news?id=859ed302183229078796abe75696fc4d317b3008f8c6085f0081eaa52c7a4af6
company,1628878145,Is BMY Stock A Buy After A Second-Quarter Beat As Revlimid Rivals Loom?,69658462,,BMY,Yahoo,Is BMY stock a buy after its second-quarter earnings beat forecasts and as investors look ahead to Revlimid generics?,https://finnhub.io/api/news?id=de97a167b58d6bb52b3a53d5e904bfb5b694a930d7a3bfff13ed0f6fc71cc8b1
company,1628872860,"Bristol Myers Squibb Co. stock rises Friday, outperforms market",69663569,https://images.mktw.net/im-220105/social,BMY,MarketWatch,"Shares of Bristol Myers Squibb Co. inched 0.84% higher to $67.51 Friday, on what proved to be an all-around positive trading session for the stock market,...",https://finnhub.io/api/news?id=518b60a31275d2216b1c3a431a80cc7a459b4f852fdfc0c0295cc3a681dd00d0
company,1628850366,Value Stock Selections: A Simpler Benjamin Graham,69653097,https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1166581794/medium_image_1166581794.jpg,BMY,SeekingAlpha,"Benjamin Graham is known for developing a fairly complex set of rules and formulas to determine a stock’s intrinsic value. In his final year, he offered a much simpler way of finding value.",https://finnhub.io/api/news?id=7bae55629c52c492c07110027bb22e8e439d21f7f06a4c8d21bf43867b11cb6a
company,1628786460,"Bristol Myers Squibb Co. stock rises Thursday, still underperforms market",69663579,https://images.mktw.net/im-220105/social,BMY,MarketWatch,"Shares of Bristol Myers Squibb Co. inched 0.12% higher to $66.95 Thursday, on what proved to be an all-around favorable trading session for the stock market,...",https://finnhub.io/api/news?id=0ad4786f70cad7aae5167124edeefe12aa80dc00b1a8ea5c0f25592728c20893
company,1628781439,Horizon Therapeutics Will Offer Above Average Returns,69640707,https://static.seekingalpha.com/cdn/s3/uploads/getty_images/160306742/medium_image_160306742.jpg,BMY,SeekingAlpha,Horizon Therapeutics has now reached a growth point that is supportive of long-term success due to multiple eggs in the basket. Read more about HZNP stock here.,https://finnhub.io/api/news?id=f5c8a7bce0b5a6539710ca2888f215a146a3f0d8621f3a8cfb58d56a0bc3e436
company,1628762820,CytoSorbents' Antithrombotic Removal System Scores Second FDA Breakthrough Device Tag,69638547,https://cdn.benzinga.com/files/imagecache/og_image_social_share_1200x630/images/story/2012/aapharma_1453.png,BMY,Benzinga,The FDA has granted a second Breakthrough Device designation to  CytoSorbents Corporation's (NASDAQ: CTSO) DrugSorb-ATR Antithrombotic Removal System...,https://finnhub.io/api/news?id=b78fd62d4902b9e354179c7ced8cdb08acd6843a370a078cd3e0043ec523617f
company,1628756659,Moderna: The Rally Is Over For Now,69631962,https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1303673684/medium_image_1303673684.jpg,BMY,SeekingAlpha,Moderna stock is down over 22% from its peak. Click here to read our trading plan for MRNA stock and possible upside and downside considerations.,https://finnhub.io/api/news?id=158a4037e16133ad5ed5f2b21b41aacc41b9367fa49626bba7ed5a75be61a151
company,1628754720,20 Dividend Growth Stocks A Rated Or Better Attractively Valued Blue-Chip,69651945,,BMY,TalkMarkets,,https://finnhub.io/api/news?id=02e738957867b3db0eba472b5855eb7958e8235333924e37dfbdcd13e4d3a59c
company,1628744700,3 Best Biotech Stocks To Buy for Upcoming Catalysts,69632944,https://investorplace.com/wp-content/uploads/2020/03/ibio1600.jpg,BMY,InvestorPlace,The next few months are critical for these biotech stocks which could witness a massive increase in their stock prices this year.,https://finnhub.io/api/news?id=2e420f6caf86fc0cd822ae1bc9f3438b9004615950d0adbd9509b455721315ef
company,1628700060,"Bristol Myers Squibb Co. stock falls Wednesday, underperforms market",69623939,https://images.mktw.net/im-220105/social,BMY,MarketWatch,"Shares of Bristol Myers Squibb Co. slipped 0.76% to $66.87 Wednesday, on what proved to be an all-around great trading session for the stock market, with the...",https://finnhub.io/api/news?id=dc14a6a6f49144a6e97a38394723b708baf37b6e6e7e06f541869244ee30a1fb
company,1628696460,Moderna Stock Is Down 15%. Investors Are Questioning This Year’s Spectacular Surge.,69623941,https://images.barrons.com/im-383907/social,BMY,MarketWatch,"The stock was up more than 300% year to date last week, the biggest gain in the S&P 500. Then the vaccine manufacturer disclosed its latest earnings.",https://finnhub.io/api/news?id=56e84e7fec75bb0e15bcbe6bbbe29e817d2b6b6097d133492e2dc7ee5a355161
company,1628654100,Cowen to hold a virtual bus tour,69614008,,BMY,Thefly.com,"Hot Wheels Virtual Tour t... ABBV, AZN, BMY, GSK, INCY, JNJ, LLY, NVO, PFE, RHHBY, SNY",https://finnhub.io/api/news?id=e44eba9b33fab4b3c6aa61499c61d45f9cfef8274a3e6940bf06dc4dab51bd93
company,1628634427,Nicholas Ward's Dividend Growth Portfolio: July 2021 Update,69608093,https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1272890161/medium_image_1272890161.jpg,BMY,SeekingAlpha,My passive income was up 3.76% y/y in July. My portfolio's total returns were 3.74% in July.,https://finnhub.io/api/news?id=9292b486622e65aef54e6a42c2b3cb2115792462875bba67450d0553822ae847
company,1628613660,"Bristol Myers Squibb Co. stock remains steady Tuesday, underperforms market",69623942,https://images.mktw.net/im-220105/social,BMY,MarketWatch,"Shares of Bristol Myers Squibb Co. were unchanged Tuesday, on what proved to be an all-around favorable trading session for the stock market, with the S&P...",https://finnhub.io/api/news?id=4bcd4db60eefb4b059a747783876b0f44a9653f36d5f80ea4888057e98faca64
company,1628593140,Bristol Myers Squibb and Five Leading Historically Black Colleges and Universities Launch Tomorrow’s Innovators to Create Custom Biopharma Educational Programming and Increase Recruitment of Black Talent in the Biopharma Industry,69597990,https://s.yimg.com/uu/api/res/1.2/IfbmwQXtl5ngxd.oZjWEIA--~B/aD02Njt3PTQ4MDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/business-wire.com/98a5569ad2a2415cf986db3358ecde77,BMY,Yahoo,"PRINCETON, N.J., August 10, 2021--BMS and Five Leading Historically Black Colleges and Universities Launch Tomorrow’s Innovators to Create Custom Biopharma Educational Programming and",https://finnhub.io/api/news?id=1906a9a3ebdac4ea4d56f9e7218a1b3d73c1b6555a030acad015473d17aa0dfc
company,1628578740,Bristol Myers Squibb and Five Leading Historically Black Colleges and Universities Launch Tomorrow’s Innovators to Create Custom Biopharma Educational Programming and Increase Recruitment of Black Talent in the Biopharma Industry,69597388,,BMY,Business Wire,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=e348e85d6ee6b9f17d09d9c1ebd2421e8f3a315f8bb4166de1bff021ceeeab64
company,1628567700,Cowen to hold a virtual bus tour,69594502,,BMY,Thefly.com,"Hot Wheels Virtual Tour t... ABBV, AZN, BMY, GSK, INCY, JNJ, LLY, NVO, PFE, RHHBY, SNY",https://finnhub.io/api/news?id=eb90ad361c4b0a486568c757144ca08b66e7b0eca0dbcf822a0ec4db7d3dab62
company,1628550438,Why Agenus Fell by Over 4% on Monday,69588441,https://s.yimg.com/uu/api/res/1.2/Wk.P9Q1VsZn3oRvURZb_Ig--~B/aD05MzM7dz0xNDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/motleyfool.com/43c32dd614962737853315b80f4fa547,BMY,Yahoo,"For the quarter, Agenus saw its revenue shrink to $10.7 million from the year-ago result of nearly $27 million.  Meanwhile, Agenus' net loss deepened considerably, to almost $84 million ($0.37 per share) from the year-ago shortfall of $48.2 million.  On average, according to Zack's, prognosticators following the stock were anticipating a revenue figure nearly 37% higher, and a per-share net loss of only $0.24.",https://finnhub.io/api/news?id=0b7085205bd2de53f194652d20d9b8e463152eeebfcfaae7ff574cb26fe8192e
company,1628528945,"bluebird (BLUE) Q2 Loss Wider Than Expected, Revenues Fall Y/Y",69589979,https://s.yimg.com/uu/api/res/1.2/b7YQi_HTDu1GkQZqPUqgyw--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/59b208c03ab625710a229f805a232093,BMY,Yahoo,bluebird (BLUE) reports a wider-than-expected loss in second-quarter 2021 and also misses revenue estimates. Shares down in pre-market trading as FDA places clinical hold eli-cel.,https://finnhub.io/api/news?id=a18f41cbd2681e4d19720b78ba5a95ee4e30a7326c8a0f33b169bbecd71c96f4
company,1628527260,Bristol Myers Squibb Co. stock underperforms Monday when compared to competitors,69587579,https://images.mktw.net/im-220105/social,BMY,MarketWatch,"Shares of Bristol Myers Squibb Co. shed 1.09% to $67.38 Monday, on what proved to be an all-around poor trading session for the stock market, with the S&P...",https://finnhub.io/api/news?id=101621003ab9e1978df361578e3f1d5a54edcb64bdae197ac6308e263518b87d
company,1628527200,Bluebird Bio Stock Is Dropping. A Trial Was Halted for Safety.,69587580,https://images.barrons.com/im-382688/social,BMY,MarketWatch,"Biotech bluebird bio saw shares plunge more than 25% on news of safety issues, and the suspension of its European commercial operations.",https://finnhub.io/api/news?id=2a394dbe589484299d96be17cc9fa98596f1556580c4818b22e7dd204e503cb9
company,1628518439,Were Hedge Funds Right About Bristol Myers Squibb Company (BMY)?,69582213,https://s.yimg.com/uu/api/res/1.2/Cqr5YFwbMuUFojqDAgBQFw--~B/aD0yMDQ4O3c9MTYxMzthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/insidermonkey.com/c92746c3d2f9abb725b99f3c1c8a8123,BMY,Yahoo,"How do you pick the next stock to invest in? One way would be to spend days of research browsing through thousands of publicly traded companies. However, an easier way is to look at the stocks that smart money investors are collectively bullish on. Hedge funds and other institutional investors usually invest large amounts of […]",https://finnhub.io/api/news?id=fce25a679ad4c7d5b0b4f33873d018dd2d2fdbbe1233e676bd18852fa3930bfb
company,1628484480,Cowen to hold a virtual bus tour,69594506,,BMY,Thefly.com,"Hot Wheels Virtual Tour t... ABBV, AZN, BMY, GSK, INCY, JNJ, LLY, NVO, PFE, RHHBY, SNY",https://finnhub.io/api/news?id=dced5862454ef36e1cf903232cfe029b10131eaffa3d975723558d5616c5dd4c
company,1628416320,Here Are the 12 Best Dividend Stocks I Own Right Now,69569517,https://s.yimg.com/uu/api/res/1.2/2f5X2V6AiSXFWEe30vv_JQ--~B/aD05NjE7dz0xNDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/motleyfool.com/f283a4b48db28bcdb971a81d9895d488,BMY,Yahoo,"Some investors concentrate their portfolios on just a handful of stocks. I like too many businesses to limit my choices. As a result, my portfolio is rather large -- typically between 40 and 50 stocks.",https://finnhub.io/api/news?id=40c37b40851e4332323b2bd7dfbad7cdfaa53cc52307e18b15f7b91c7087fa41
company,1628415300,"3 Big Dividends, Paying Monthly, For Your Retirement Basea",69570410,https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1227497549/medium_image_1227497549.jpg,BMY,SeekingAlpha,Monthly dividend payers make an excellent base for an income portfolio. Read more to see our three picks that pay a reliable dividend each month.,https://finnhub.io/api/news?id=3f9f565946b632cff18fd50735dcd7cb5494646f14ccff3dd70078075c8d81a7
company,1628330760,4 Perfect Dividend Stocks That'll Help You Crush Inflation,69560518,https://s.yimg.com/uu/api/res/1.2/LL74FYSwdr3jOclHFWUeFQ--~B/aD05MzM7dz0xNDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/motleyfool.com/1b072515605dd6ec608327e390b7a036,BMY,Yahoo,"According to data released last month by the U.S. Bureau of Labor Statistics, the Consumer Price Index for All Urban Consumers (CPI-U) rose by 5.4% in June from the previous year.  What's more, the Core CPI, which takes into account a predetermined basket of goods and services, minus food and energy, rose by 4.5%.  One of the smartest ways investors can counteract the effects of inflation is with dividend stocks.",https://finnhub.io/api/news?id=eb8d7773fe10f2513e7acba4adb1cf767c8b08cc2b6705f2c382d67593f27042
company,1628300545,Novo Nordisk: Exceptional Performance But Overvalued,69558537,https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1288508386/medium_image_1288508386.jpg,BMY,SeekingAlpha,Novo Nordisk reported excellent numbers that confirm several long-term growth drivers. But the stock is overvalued by roughly 25% based on historical multiples.,https://finnhub.io/api/news?id=a3e764f11c10fed3d6f742f4c2e2b5b412a26a1e3afe82c39405b3ef82d94b33
company,1628268064,"Prothena (PRTA) Q2 Earnings Top Estimates, Pipeline in Focus",69551049,https://s.yimg.com/uu/api/res/1.2/b7YQi_HTDu1GkQZqPUqgyw--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/59b208c03ab625710a229f805a232093,BMY,Yahoo,Prothena's (PRTA) earnings for the second quarter of 2021 beat estimates. Its pipeline remains in focus as the company expects to receive milestone payments from partners.,https://finnhub.io/api/news?id=6f843d72b945c414ab69f43152fd1a7fe431343a0e7886b6bcfb80c1a0b00309
company,1628268060,Bristol Myers Squibb Co. stock underperforms Friday when compared to competitors,69566369,https://images.mktw.net/im-220105/social,BMY,MarketWatch,"Shares of Bristol Myers Squibb Co. slipped 0.44% to $68.12 Friday, on what proved to be an all-around positive trading session for the stock market, with the...",https://finnhub.io/api/news?id=7209b7702ad8ceb45fd72bab18e7c7bac14f20f52b2cb35a217bfbbb9c77e6eb
company,1628267464,"Nektar (NKTR) Q2 Earnings and Revenues Top, Pipeline On Track",69550283,https://s.yimg.com/uu/api/res/1.2/64xdIOK_EeJIDCc2iX7R2Q--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/ab5d1a5fdb8391cec32b7ecdc768d2fc,BMY,Yahoo,Nektar (NKTR) reports encouraging second-quarter 2021 results. The company remains on track to report top-line data from three registrational studies on bempegaldesleukin in the first half of 2022.,https://finnhub.io/api/news?id=cc94b66abbd1f27fcf8ad4bb2c206dcfb6392873ba063f5e3a2ac83fc1850977
company,1628264763,"Acceleron (XLRN) Q2 Loss Wider Than Expected, Revenues Miss",69551177,https://s.yimg.com/uu/api/res/1.2/ShfhwtDyA2WzDBKdAL7M8Q--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/6f2cab89bf2cbad1966358e04258e202,BMY,Yahoo,Acceleron (XLRN) reports a wider loss in the second quarter of 2021 on higher costs and lower revenues.,https://finnhub.io/api/news?id=810e2ff54f5650e4f767f785b9e5ca8b383d350eceeda6e442d236ba306aabe4
company,1628259644,10 Biotech Penny Stocks to Buy According to Reddit,69543129,https://s.yimg.com/uu/api/res/1.2/RqAKkC.S5mdZgyAUtzNS4g--~B/aD01MDA7dz03NTA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/insidermonkey.com/20f5140b0d6593c9f87e143fb6bf21b3,BMY,Yahoo,"In this article, we discuss the 10 biotech penny stocks to buy according to Reddit. If you want to skip our detailed analysis of these stocks, go directly to the 5 Biotech Penny Stocks to Buy According to Reddit. Innovation and advancements in science and technology over the past few decades have transformed the field […]",https://finnhub.io/api/news?id=590325e5823c8ca9bc6d32d5f7ae7dc412201c7f539b62fb8fe6829455c8d247
company,1628235720,"The Daily Biotech Pulse: Dicerna Slips On Data, Novavax Tightlipped On US Vaccine Approval, Adagio IPO",69543450,https://cdn.benzinga.com/files/imagecache/og_image_social_share_1200x630/images/story/2012/medicine-1309148_1920_361.jpg,BMY,Benzinga,"Here's a roundup of top developments in the biotech space over the last 24 hours.
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Aug. 5)

Alkermes plc (NASDAQ: ALKS)...",https://finnhub.io/api/news?id=fc866c061703f5c3107bb1c98c3c859ef0019520786492341dcc951df6ab1626
company,1628213381,Tracking Kahn Brothers Portfolio - Q2 2021 Update,69535671,https://static.seekingalpha.com/cdn/s3/uploads/getty_images/186805810/medium_image_186805810.jpg,BMY,SeekingAlpha,Kahn Brothers’ 13F portfolio value increased from $646M to $698M this quarter. BP plc and Pfizer were increased while decreasing Nam Tai Property and BlackBerry during the quarter.,https://finnhub.io/api/news?id=f74d9e7f981755ec7c616ae0dc17c5c362285f72de275854bb5e18c72487321a
company,1628199886,10 High Yield Dividend Stocks to Buy in August,69530014,https://s.yimg.com/uu/api/res/1.2/4D26rV3_qT.qeyIVVts0lA--~B/aD01MDA7dz03NTA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/insidermonkey.com/371f5be91eb9db12bee001f07135a8bf,BMY,Yahoo,"In this article, we will be looking at 10 high yield dividend stocks to buy in August. If you want to skip our detailed analysis of dividend investing, you can go directly to the 5 High Yield Dividend Stocks to Buy in August. As we enter into a new month this year, it is only […]",https://finnhub.io/api/news?id=ad665348129d6721a011b09a4d649a24c331e8ae3f9298d8daebc970b08b3d40
company,1628181660,"Bristol Myers Squibb Co. stock falls Thursday, underperforms market",69566390,https://images.mktw.net/im-220105/social,BMY,MarketWatch,"Shares of Bristol Myers Squibb Co. slumped 0.10% to $68.42 Thursday, on what proved to be an all-around favorable trading session for the stock market, with...",https://finnhub.io/api/news?id=749c21221c7a85db1a521c6a8308338adba240bd76df24e36f0841d971f0199c
company,1628179330,Expert Panel Issues Recommendations for Addressing Inequities in Cancer Care,69528590,https://s.yimg.com/cv/apiv2/social/images/yahoo_default_logo-1200x1200.png,BMY,Yahoo,New recommendations published by Doykos et al in Health Equity call for a significant expansion of the National Cancer Institute (NCI) and NCI-designated comprehensive cancer centers to understand ...,https://finnhub.io/api/news?id=07f5ba99a2a24f3a0d615ad1ffaf059973e835285dc119534a8b35884fa7643b
company,1628157840,BMY September 24th Options Begin Trading,69541634,,BMY,Stock Options Channel,"Staff article entitled BMY September 24th Options Begin Trading, about stock options, from Stock Options Channel.",https://finnhub.io/api/news?id=2e766cd80fa95f4d8153185df0435ce4043959bb9b67eebf8176e3617c09b785
company,1628150640,"The Daily Biotech Pulse: Merck Reports Positive Keytruda Readout, Moderna Slips Despite Q2 Beat, Bayer To Buy Vividion For Up To $2B, GlycoMimetics Gets New CEO",69516716,https://cdn.benzinga.com/files/imagecache/og_image_social_share_1200x630/images/story/2012/cells-1872666_1920_84.jpg,BMY,Benzinga,"Here's a roundup of top developments in the biotech space over the last 24 hours:
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Aug. 4)

Absci, CORP (NASDAQ: ABSI) (...",https://finnhub.io/api/news?id=e7fa0a93910ee6fe615a2c9c061d6b426ac3fafbc37ef9b3ebd5c7fddc8498d6
company,1628147990,"Build This $95,000, 20% Undervalued Income Machine With 5% Yield",69512679,,BMY,SeekingAlpha,,https://finnhub.io/api/news?id=3261a2462603eec054f7f17517e7448de69d587582507dd79c7e99c6f9bdad7c
company,1628133420,"Acceleron reports Q2 EPS ($1.05), consensus (88c)",69541635,,BMY,Thefly.com,"Reports Q2 revenue $27.9M... XLRN, BMY",https://finnhub.io/api/news?id=be5e39dd02fe644db45e690c96cc86b4e43309f8e5c84feddb983b1162233a58
company,1628095260,"Bristol Myers Squibb Co. stock falls Wednesday, underperforms market",69571484,https://images.mktw.net/im-220105/social,BMY,MarketWatch,"Shares of Bristol Myers Squibb Co. shed 1.18% to $68.49 Wednesday, on what proved to be an all-around grim trading session for the stock market, with the S&P...",https://finnhub.io/api/news?id=961735bb49ca53175461d19e83dcd497a78e6835f87921e5809a34446e67a30a
company,1628080740,"Sector Gamma As Buys Organon, Henry Schein Inc, Bristol-Myers Squibb Company, Sells LivaNova PLC, Ionis Pharmaceuticals Inc, Alexion Pharmaceuticals Inc",69517072,,BMY,GuruFocus,,https://finnhub.io/api/news?id=e07e9712186de22cfa480a79b8fb897ab3d229f1418cbdf713af261b146a322f
company,1628071440,4 Stocks Insiders Are Selling,69498326,https://cdn.benzinga.com/files/imagecache/og_image_social_share_1200x630/images/story/2012/insider-selling.jpg,BMY,Benzinga,"When insiders sell shares, it indicates their concern in the company’s prospects or that they view the stock as being overpriced. Either way, this signals an opportunity to...",https://finnhub.io/api/news?id=0f4692ed97fc5840c5b327dd2c0ef2b32e1b945314d25e33eab803b2ee6cbf59
company,1628063520,"The Daily Biotech Pulse: Pfizer's Positive Readout, NRx Strikes R&D Collaboration With Mannkind, Cerus & Invitae Jump On Earnings",69491565,https://cdn.benzinga.com/files/imagecache/og_image_social_share_1200x630/images/story/2012/medicine-1309148_1920_360.jpg,BMY,Benzinga,"Here's a roundup of top developments in the biotech space over the last 24 hours.
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Aug. 3)

Absci, CORP (NASDAQ: ABSI) (...",https://finnhub.io/api/news?id=fff81a64320513a14b61b062441c2da5beeeb873aff8c31da7ffe1142ff4e688
company,1628060160,4 Big Pharma Dividend Stocks to Buy as Yields Near 2021 Lows,69491150,https://247wallst.com/wp-content/uploads/2018/12/imageForEntry15-15.jpg,BMY,247WallSt,"These four big pharmaceutical stocks are rated Buy by top Wall Street firms and look like very good ideas for investors, especially now that the market is overbought and the slow seasonal market months are right around the corner. They are classic defensive names that will hold up much better than crowded momentum stocks when the inevitable correction comes.",https://finnhub.io/api/news?id=47c6df56d9ae9946992b67a6a7d3d4afa1b1575d96a545f26c878048509f41f4
company,1628059140,"Nan Fung Trinity (hk) Ltd Buys iShares MSCI Indonesia ETF, iQIYI Inc, ViacomCBS Inc, Sells iShares MSCI Singapore ETF, ON Semiconductor Corp, Vulcan Materials Co",69489346,,BMY,GuruFocus,,https://finnhub.io/api/news?id=832b76b1be72df0d24ba319b2d6950f5788662e5bea659ee12bceecf922650d7
company,1628008860,"Bristol Myers Squibb Co. stock rises Tuesday, outperforms market",69500608,https://images.mktw.net/im-220105/social,BMY,MarketWatch,"Shares of Bristol Myers Squibb Co. rallied 1.90% to $69.31 Tuesday, on what proved to be an all-around great trading session for the stock market, with the...",https://finnhub.io/api/news?id=e619a9da8b514ff4c246182696f2b4483396eb4d6681be492f02d05151060b07
company,1627996556,"Final Trades: NXP Semiconductors, Bristol Myers, FedEx & more",69473407,https://image.cnbcfm.com/api/v1/image/106921244-3ED1-FMHR-080321-Final-jpg?v=1628010548,BMY,CNBC,"The ""Halftime Report"" traders give their top picks to watch for the second half.",https://finnhub.io/api/news?id=dd65913b108a6102285824ad19e597bce925059eae1d913db26d564fa04cd550
company,1627988400,"Bristol Myers Squibb Completes Sale of Manufacturing Facility in Couvet, Switzerland",69462305,https://s.yimg.com/uu/api/res/1.2/wkN3pNuu1VO1.UjnstBAeQ--~B/aD02Njt3PTQ4MDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/business-wire.com/fb233ef02e02d7635ae05be629178b72,BMY,Yahoo,"NEW YORK, August 03, 2021--Bristol Myers Squibb Completes Sale of Manufacturing Facility in Couvet, Switzerland",https://finnhub.io/api/news?id=127bd42dda5595faf37935e96699779dc52c2eab9bfe58f01ac7c01213c7c5d6
company,1627977300,"The Daily Biotech Pulse: Sanofi Buys Translate Bio In $3.2B Deal, Lilly's Q2 Earnings Disappoint, Bausch To Spin Off Medical Aesthetics Business",69466434,https://cdn.benzinga.com/files/imagecache/og_image_social_share_1200x630/images/story/2012/cells-1872666_1920_83.jpg,BMY,Benzinga,"Here's a roundup of top developments in the biotech space over the last 24 hours:
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Aug. 2)

Absci, CORP (NASDAQ: ABSI) (...",https://finnhub.io/api/news?id=def0bc1087a5bd5d9292d080e587c64d66fb862a95c80897ebf3043460e75dfb
company,1627974000,"WuXi STA Completes Acquisition of Bristol Myers Squibb Manufacturing Facility in Couvet, Switzerland",69464394,,BMY,PR Newswire,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=c0038025882387ab571bc84cd84c1673beff41689771198959ee073f2a863a5b
company,1627974000,"Bristol Myers Squibb Completes Sale of Manufacturing Facility in Couvet, Switzerland",69464393,,BMY,Business Wire,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=6ad1b87977ee7cce02e62b828d65728c21115a62d1f929e7f1dd4c27d59f1bde
company,1627972740,"Bridgeworth, LLC Buys Dimensional U.S. Core Equity 2 ETF, iShares Russell 2500 ETF, Target Corp, Sells iShares Gold Trust, Tilray Inc, Tilray Inc",69464396,,BMY,GuruFocus,,https://finnhub.io/api/news?id=37dcbd886ff5129e9b38f5e6858e37a59b43bb971964f1ff18bea8b350a21943
company,1627972740,"Gabalex Capital Management LLC Buys Visa Inc, Royal Dutch Shell PLC, Coca-Cola Co, Sells Johnson & Johnson, Oracle Corp, Bristol-Myers Squibb Company",69464193,,BMY,GuruFocus,,https://finnhub.io/api/news?id=04d2f12625ea0ad68f5802058c13997da1f3e432e3069dbee695c7a3049c21ac
company,1627922460,"Bristol Myers Squibb Co. stock rises Monday, outperforms market",69475456,https://images.mktw.net/im-220105/social,BMY,MarketWatch,"Shares of Bristol Myers Squibb Co. inched 0.22% higher to $68.02 Monday, on what proved to be an all-around dismal trading session for the stock market, with...",https://finnhub.io/api/news?id=1d6d4922e23bb8d3963df7a18013cd4aab48c912cf46ac43b27a4d750255712f
company,1627888440,"AstraZeneca' Saphnelo Wins FDA Nod For Systemic Lupus Erythematosus, Marking New Treatment Approval In 10 Years",69449118,https://cdn.benzinga.com/files/imagecache/og_image_social_share_1200x630/images/story/2012/aapharma_1279.png,BMY,Benzinga,The FDA has approved AstraZeneca Plc's (NASDAQ: AZN) Saphnelo (anifrolumab-fnia) for adult patients with moderate to severe systemic lupus erythematosus (SLE)...,https://finnhub.io/api/news?id=d5c1a1433331ed41d9654678b3307b2271609bab0d954007daab72ad017efd46
company,1627743047,12 Best Bear Market Stocks to Buy Now,69420969,https://s.yimg.com/uu/api/res/1.2/rdzTZyE6sJ45Qw_Lrn20eg--~B/aD01MDA7dz03NTA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/insidermonkey.com/3cdb976bd070f18337184c3550dd49b8,BMY,Yahoo,"In this article, we discuss the 12 best bear market stocks to buy now. If you want to skip our detailed analysis of these stocks, go directly to the 5 Best Bear Market Stocks to Buy Now. The Centers for Disease Control and Prevention (CDC) in the United States on July 28 asked Americans who […]",https://finnhub.io/api/news?id=08249ce4a7d971a311ce8c2a7fca1e4cc413a608743e52aabaaf568abbd85d50
company,1627663260,"Bristol Myers Squibb Co. stock falls Friday, still outperforms market",69428507,https://images.mktw.net/im-220105/social,BMY,MarketWatch,"Shares of Bristol Myers Squibb Co. slid 0.41% to $67.87 Friday, on what proved to be an all-around rough trading session for the stock market, with the S&P...",https://finnhub.io/api/news?id=e5ada955eed36a1f0463040e401693e3cbb37da41f24a55bc08709193c4d1996
company,1627662666,15 Most Valuable Biotech Companies in the World,69409867,https://s.yimg.com/uu/api/res/1.2/D5q.gX4DGstCLVF2aa.aQg--~B/aD00MjI7dz03NTA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/insidermonkey.com/bc5c0aa326cd992c6cfc17df24721821,BMY,Yahoo,"In this article we will take a look at the 15 most valuable biotech companies in the world. You can skip our detailed analysis of the biotechnology industry’s outlook for 2021, and some of the major growth catalysts for biotech stocks, and go directly to the 5 Most Valuable Biotech Companies in the World. Mankind […]",https://finnhub.io/api/news?id=67ee9d45be404c860feab02ecbcf10654757e040b4e0121610fc27d40016d5c7
company,1627647720,Biogen: Does Aduhelm Make it the Next Dendreon?,69419819,https://investorplace.com/wp-content/uploads/2021/06/biogen-biib.jpg,BMY,InvestorPlace,Biogen's Aduhelm puts the new pharma strategy of pricing for life under threat.,https://finnhub.io/api/news?id=62795a2c90b77bacccf1872649e5a2493767dbe029462b03832f31d05fde840b
company,1627642740,Bristol Myers Squibb Receives European Commission Approval for Opdivo (nivolumab) as Adjuvant Treatment for Esophageal or Gastroesophageal Junction Cancer Patients with Residual Pathologic Disease Following Chemoradiotherapy,69404400,https://s.yimg.com/uu/api/res/1.2/r4KyBskYoELYpijZRDcYUQ--~B/aD02Njt3PTQ4MDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/business-wire.com/f4c45941ea60543c47bcfb984f2ab688,BMY,Yahoo,"PRINCETON, N.J., July 30, 2021--BMS Receives European Commission Approval for Opdivo As Adjuvant Treatment for Esophageal or Gastroesophageal Junction Cancer Patients....",https://finnhub.io/api/news?id=7b9bc561709b4102d60da7ac7535084b9ddbca944bb91af84ed61eb1de091e27
company,1627635900,Bristol Myers' Opdivo Scores European Approval As Adjuvant Treatment For Gastric Cancer,69411784,https://cdn.benzinga.com/files/imagecache/og_image_social_share_1200x630/images/story/2012/aapharma_1269.png,BMY,Benzinga,The European Commission (EC) has approved Bristol Myers Squibb & Co's (NYSE: BMY) Opdivo (nivolumab) as adjuvant treatment of adult patients with...,https://finnhub.io/api/news?id=275a0826ed5c65b5664c86a89b3d501ee1ea5291b89749390c723580c0821323
company,1627635600,"Virpax® Pharmaceuticals Strengthens Board of Directors with the Appointment of Gerald W. Bruce and Michael F. Dubin, CPA to its Board",69409683,,BMY,Business Wire,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=7bcebc385ce6e6f4dc80d1acbae4307e24c9f8d3668772dd71bc8773511c0385
company,1627632000,Bristol Myers Says EC Approves Opdivo as Adjuvant Treatment in Esophageal or Gastroesophageal Junction Cancer,69428509,https://mw3.wsj.net/mw5/content/logos/mw_logo_social.png,BMY,MarketWatch,By Michael Dabaie Bristol Myers Squibb said the European Commission approved Opdivo for the adjuvant treatment of adult patients with esophageal or...,https://finnhub.io/api/news?id=039e9ab7f49391e028ee9f33588173eba493a2d529a31e7faa06c6401015a5e2
company,1627631580,"The Daily Biotech Pulse: Erytech Jumps On Fast Track Designation, GlaxoSmithKline FDA Nod, Alnylam's Clinical Collaboration, 4 IPOs",69405718,https://cdn.benzinga.com/files/imagecache/og_image_social_share_1200x630/images/story/2012/medicine-1309148_1920_359.jpg,BMY,Benzinga,"Here's a roundup of top developments in the biotech space over the last 24 hours.
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs July 29)

AbbVie Inc. (NYSE: ABBV)...",https://finnhub.io/api/news?id=b91171da7776a7b237a7759548ef4907883a44904f233038b245ba1224cebc79
company,1627628400,6 Goldman Sachs Top Stock Picks Also Pay Big-Time Dependable Dividends,69405900,https://247wallst.com/wp-content/uploads/2019/02/imageforentry16-zox.jpg,BMY,247WallSt,These six top Goldman Sachs stock picks all pay healthy dividends and offer great total return potential and less potential volatility in a very overbought stock market that may be poised for a long-needed correction.,https://finnhub.io/api/news?id=07eec62e281d29d2e612ae3a56991ddea95472c4568e1b8a8f5b6e925ff7fecc
company,1627628340,Bristol Myers Squibb Receives European Commission Approval for Opdivo (nivolumab) as Adjuvant Treatment for Esophageal or Gastroesophageal Junction Cancer Patients with Residual Pathologic Disease Following Chemoradiotherapy,69410617,,BMY,Business Wire,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=96c24d6bb048ffd31aeebbd6f3fdbf4580dea35f4358169a293af8450c02c2c4
company,1627625100,Bristol-Myers receives EC approval for Opdivo as treatment for GEJ cancer,69410618,,BMY,Thefly.com,Bristol Myers Squibb anno... BMY,https://finnhub.io/api/news?id=278125216a87d975ede5006b5216f6c9dc3204c17afe50658d5ebfda8c88f387
company,1627576860,Bristol Myers Squibb Co. stock underperforms Thursday when compared to competitors,69428510,https://images.mktw.net/im-220105/social,BMY,MarketWatch,"Shares of Bristol Myers Squibb Co. slipped 0.84% to $68.15 Thursday, on what proved to be an all-around great trading session for the stock market, with the...",https://finnhub.io/api/news?id=a9b2569d88ee2c90ceb43229ad7d146314bd3cb44f90bd07e16b4483559f5b6c
company,1627573279,Why Compugen Stock Is Rising Again Today,69384389,,BMY,Yahoo,Shares of Compugen (NASDAQ: CGEN) were rising 4% as of 11:05 a.m. EDT on Thursday.  The drugmaker's shares jumped on Wednesday after Compugen provided its second-quarter update.  Compugen recently initiated patient dosing in three early stage studies evaluating experimental drug COM701.,https://finnhub.io/api/news?id=6ae5a046f25d95c85b8a3d5c8b0c88ae08f98b1e7674ca094aa2c47f0c959d77
company,1627553400,Stocks That Hit 52-Week Highs On Thursday,69377824,https://cdn.benzinga.com/files/imagecache/og_image_social_share_1200x630/sites/all/themes/bz2/images/bz-icon.png,BMY,Benzinga," 
Thursday's morning session saw 167 companies set new 52-week highs.
Points of Interest:

ASML Holding (NASDAQ:ASML) was the largest company by market cap to set a new...",https://finnhub.io/api/news?id=df5d9100211bb4f0d3f82c3f8562e5803d02cb654ce6e7c62bda20be63f3cc35
company,1627552920,BMY September 10th Options Begin Trading,69410619,,BMY,Stock Options Channel,"Staff article entitled BMY September 10th Options Begin Trading, about stock options, from Stock Options Channel.",https://finnhub.io/api/news?id=3d2a0f94b5495230d8adc37b6c2c58448ddb13cbbf4612b97f9c6f94d8936702
company,1627546422,Bristol-Myers Squibb Company 2021 Q2 - Results - Earnings Call Presentation,69376161,https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png,BMY,SeekingAlpha,The following slide deck was published by Bristol-Myers Squibb Company in conjunction with their 2021 Q2 earnings call.,https://finnhub.io/api/news?id=06e14979e248e8bd067e1db3ab3bfb3e4eb7b9545009c0adfdd005df92d329f8
company,1627540740,"Holloway Wealth Management, LLC Buys Bristol-Myers Squibb Company, Taiwan Semiconductor Manufacturing Co, FIRST TR EXCH TRD, Sells First Trust Enhanced Short Maturity ETF, Procter & Gamble Co, General Motors Co",69406184,,BMY,GuruFocus,,https://finnhub.io/api/news?id=80811fce737e5507710ce56ff459038966c2d532bb60c04ec058dff4fe6b35b2
company,1627540474,Bristol Myers Squibb Q2 2021 Shows Strength And Value,69376080,https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1253227748/medium_image_1253227748.jpg,BMY,SeekingAlpha,"Bristol Myers Squibb reported strong Q2 earnings results. Despite the competition and its dependence on Revlimid revenue, see why I remain bullish on BMY stock.",https://finnhub.io/api/news?id=62a1d49bd701b899b65a8d93cb6da71b8efa6bc5e6ddf93e6a356cbf3b31d52d
company,1627499645,Is BMY Stock A Buy After A Second-Quarter Beat As Revlimid Rivals Loom?,69373453,,BMY,Yahoo,Is BMY stock a buy after its second-quarter earnings beat forecasts and as investors look ahead to Revlimid generics?,https://finnhub.io/api/news?id=cb7de0fa481ef9610117c7a054b47ae440f7f610ec54392766b7034ead967d7b
company,1627495025,"Bristol-Myers' (BMY) Q2 Earnings Beat, Opdivo Sales Grow",69373454,https://s.yimg.com/uu/api/res/1.2/SlGE5JR4xp73Vb5zTu29cQ--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/52b6d392b63705aefb517365eab38a95,BMY,Yahoo,Bristol-Myers (BMY) beats on earnings and sales in the second quarter as Opdivo sales revive.,https://finnhub.io/api/news?id=6b6a971d1bff299a9c414703aeac8f22842ff4f2c1317ca82da3d7a4936ea0cf
company,1627490460,"Bristol Myers Squibb Co. stock rises Wednesday, outperforms market",69428512,https://images.mktw.net/im-220105/social,BMY,MarketWatch,"Shares of Bristol Myers Squibb Co. advanced 1.84% to $68.73 Wednesday, on what proved to be an all-around dismal trading session for the stock market, with...",https://finnhub.io/api/news?id=ef52d6ddf9cd57606db6319f7dd4c06a89fa0fb0e0653faa9366229689ac32bd
company,1627488058,Bristol-Myers Squibb (BMY) Q2 2021 Earnings Call Transcript,69367732,https://s.yimg.com/uu/api/res/1.2/zmj.74VZmDKFyMQXCAbujg--~B/aD0xNDk0O3c9MTQwMDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/motleyfool.com/e48e86dda35543079ee2080fd9208b73,BMY,Yahoo,"BMY earnings call for the period ending June 30, 2021.",https://finnhub.io/api/news?id=615319dad24ba4d864a190ac5d272aeac7910dedb7e7aec0f39386b4f5d221b4
company,1627487546,"Bristol Myers Retakes Buy Point After 'Solid' Quarter, Though Generics Loom",69367733,https://s.yimg.com/uu/api/res/1.2/1vovMzvSzF.dsh5iTosJzA--~B/aD02MDA7dz0xMDY1O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/ibd.com/c86151a606376a1cfc78202e4a0ae9c6,BMY,Yahoo,Bristol Myers Squibb notched a second-quarter beat Wednesday and reiterated its outlook for 2021. BMY stock retook a buy point.,https://finnhub.io/api/news?id=02ccf783155b80966727123be0126a77b73c51bee0a25ba38e131f8daea1fdcd
company,1627481280,Bristol Myers Squibb Stock Rises After Modest Earnings Beat,69367141,https://s.yimg.com/uu/api/res/1.2/ez0HMiRmE0Hj5FccZLJTjQ--~B/aD02NDA7dz0xMjgwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/Barrons.com/dba4d672ffcf4f4675165b299331ff76,BMY,Yahoo,"Shares of Bristol Myers Squibb rose early Wednesday, after the company reported earnings that just beat Wall Street expectations.",https://finnhub.io/api/news?id=0f445491548fa99d43720338e399dc6622e945083a994cc41724dd00e475549e
company,1627479000,GLOBAL BUSINESS: Bristol Myers and Carrefour swing to interim profit,69376477,,BMY,Alliance News,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=c1760d5a7292c279b866d4c18b91caa7a0525931dc7262c4f2c148c44e3703c1
company,1627478354,Bristol Myers Squibb (BMY) CEO Giovanni Caforio on Q2 2021 Results - Earnings Call Transcript,69367419,https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png,BMY,SeekingAlpha,"Call start: 8:00 Call End: 8:57 Bristol Myers Squibb (NYSE:BMY) Q2 2021 Earnings Conference Call July 28, 2021 8:00 AM ET Company Participants Tim Power – Vice President Investor Relations...",https://finnhub.io/api/news?id=4d70e363bb519fa2008bcf004f3fb5cc8701b00f772d12eb2b9f274aabe1cc36
company,1627474512,Bristol Myers Squibb (BMY) Q2 Earnings and Revenues Beat Estimates,69367735,https://s.yimg.com/uu/api/res/1.2/Tw87WEC1wh0JNb8.IBuFMA--~B/aD02MDA7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/03fca48475577988aa4e0db94f484b4e,BMY,Yahoo,"Bristol Myers (BMY) delivered earnings and revenue surprises of 2.66% and 4.12%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?",https://finnhub.io/api/news?id=3ad0a0c67d8e71bd85fa32168f97b282afdd652b8d1fc3dd3125d4ec54c78c0d
company,1627472520,"Bristol Myers Q2 Earnings Slightly Ahead Of Estimates, Trims FY21 GAAP EPS Guidance",69367736,https://s.yimg.com/uu/api/res/1.2/SLqGFkOoG1iS.6xT19G7_g--~B/aD00MDA7dz02MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/Benzinga/c3edf6dc136c26540592034e69a7b1df,BMY,Yahoo,"View more earnings on BMYSee more from BenzingaClick here for options trades from BenzingaInfinity Pharma Stock Drops After Updated Data From Bladder & Breast Cancer Trials, Q2 EarningsBristol Myers Pulls Accelerated Approval For Opdivo In Post-Nexavar Liver Cancer© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.",https://finnhub.io/api/news?id=b7961b8790018658a830b2c7095df611127626306f7ad063e350f113261a8456
company,1627470753,Bristol Myers swings to profit to beat second-quarter estimates as Opdivo returns to growth,69367737,https://s.yimg.com/uu/api/res/1.2/S8SCotpO9m2XQyQUIGU5dw--~B/aD02MzA7dz0xMjAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/marketwatch.com/96d076434b2a015a3010bd2787b8c856,BMY,Yahoo,"Bristol Myers Squibb Co. said Wednesday it swung to a profit of $1.055 billion, or 47 cents a share, in the second quarter, after a loss of $85 million, or 4 cents a share, in the year-earlier period. Adjusted per-share earnings came to $1.93, ahead of the $1.89 FactSet consensus. Revenue rose to $11.703 billion from $10.129 billion, also ahead of the $11.269 billion FactSet consensus. ""We delivered a strong quarter across each of our four therapeutic areas, including building momentum for our n",https://finnhub.io/api/news?id=6f20411b0c53dca4a617a6aef2c805095b67d41f256f95a1a6b201755b7b8108
company,1627470180,UK dividends calendar - next 7 days,69363461,,BMY,Alliance News,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=ea60436ad5a2d83cade44b21bc2256e00759b643b90dfcc8472c89bbb7d98291
company,1627470013,"Bristol Myers sees return to growth for Opdivo, tops estimates",69367738,https://s.yimg.com/uu/api/res/1.2/_Bt8XOfaglGRebIMTXse5g--~B/aD01MzQ7dz04MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/reuters-finance.com/051bace4b6837b34d964efbe39f69928,BMY,Yahoo,"Bristol Myers Squibb Co reported second quarter earnings that topped Wall Street estimates, as sales of flagship cancer treatment Opdivo returned to growth after missing estimates in the previous quarter.  Bristol Myers reported second quarter revenues of $11.7 billion, 16% higher than in the same period last year, driven in part by sales of Opdivo that exceeded $1.9 billion for the quarter, 16% higher than in the quarter ended June 30, 2020.  ""The highlight that is driving that strong performance is Opdivo and its return to growth,"" said David Elkins, Bristol-Myers' chief financial officer.",https://finnhub.io/api/news?id=5df007fc0601f743a815d8828cd2cda1c728a89347d07f036afbc1877e392a4a
company,1627469940,Bristol Myers Squibb Reports Second Quarter Financial Results for 2021,69361942,https://s.yimg.com/uu/api/res/1.2/jwFnYJ_HvK0FtYFmqa8T3Q--~B/aD02Njt3PTQ4MDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/business-wire.com/61ac51a5e6e18bc91a0cfc58c45efc96,BMY,Yahoo,"NEW YORK, July 28, 2021--Bristol Myers Squibb Reports Second Quarter Financial Results for 2021",https://finnhub.io/api/news?id=002ffaa785610f87776fe481ebdff18272eaf07575f4c63212f575b178755342
company,1627466880,Bristol Myers Squibb Stock Rises After Modest Earnings Beat,69388908,https://images.barrons.com/im-376465/social,BMY,MarketWatch,"Shares of Bristol Myers Squibb rose early Wednesday, after the company reported earnings that just beat Wall Street expectations.",https://finnhub.io/api/news?id=6d190751ef937225b0c6704459fbc9b2bffaa44cef76c435547e208c068b8bf0
company,1627462020,Bristol Myers Posts Stronger-Than-Expected Earnings but Lowers Guidance,69367740,https://s.yimg.com/cv/apiv2/social/images/yahoo_default_logo-1200x1200.png,BMY,Yahoo,Bristol Myers lowers its full-year profit guidance to a range of $2.77 to $2.97 a share from the previous range of $3.18 to $3.38.,https://finnhub.io/api/news?id=09141885ec48d7baa5ee9a78adce2f0c71f7d93d9bacb8b880c619eada782fc7
company,1627458360,Full News Day,69376478,,BMY,TalkMarkets,,https://finnhub.io/api/news?id=6b9297af2d9489ed2cab89057192fc23bd410cc49207f2973e3613b6bd4bb270
company,1627458120,"Bristol Myers Q2 Earnings Slightly Ahead Of Estimates, Trims FY21 GAAP EPS Guidance",69365212,https://cdn.benzinga.com/files/imagecache/og_image_social_share_1200x630/images/story/2012/aapharma_1225.png,BMY,Benzinga,"Bristol Myers Squibb & Co (NYSE: BMY) posted Q2 revenues of $11.7 billion, an increase of 16%, or 13%, when adjusted for foreign exchange, slightly above the...",https://finnhub.io/api/news?id=508e3a6674ca1557017bb322da6511d98dbdde9dfaf56502b8fc80706d556233
company,1627457580,"The Daily Biotech Pulse: Pfizer, Bristol-Myers Squibb Earnings, Amgen Goes Shopping, GlaxoSmithKline-Vir's COVID-19 Antibody Treatment Supply Deal",69362409,https://cdn.benzinga.com/files/imagecache/og_image_social_share_1200x630/images/story/2012/medicine-1309148_1920_358.jpg,BMY,Benzinga,"Here's a roundup of top developments in the biotech space over the last 24 hours.
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs July 27)

Bio-Rad Laboratories, Inc...",https://finnhub.io/api/news?id=6364129aadb2df59e21d37a77fdc7f76d2d28d73a0643681fd6c2379eea43065
company,1627456920,Recap: Bristol-Myers Squibb Q2 Earnings,69365214,https://cdn.benzinga.com/files/imagecache/og_image_social_share_1200x630/sites/all/themes/bz2/images/bz-icon.png,BMY,Benzinga," 
Shares of Bristol-Myers Squibb (NYSE:BMY) decreased 0.1% in pre-market trading after the company reported Q2 results.
Quarterly Results
Earnings per share rose 18.40% over...",https://finnhub.io/api/news?id=6b6182b6f6032113006db535cf787622b379defd037e1568571c9a1ae592bb5d
company,1627456353,Bristol Myers swings to profit to beat second-quarter estimates as Opdivo returns to growth,69428515,https://s.wsj.net/public/resources/MWimages/MW-GP644_MicroS_ZG_20180906154215.jpg,BMY,MarketWatch,"Bristol Myers Squibb Co. undefined said Wednesday it swung to a profit of $1.055 billion, or 47 cents a share, in the second quarter, after a loss of $85...",https://finnhub.io/api/news?id=c7614382cfeb537932cc3e193a062abbc3b71776bcba4180f715b6c5621866d1
company,1627456080,Bristol Myers: Q2 Earnings Snapshot,69363462,,BMY,"Associated Press, The",Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=9e71e496edf85be797772f6c4cfd5583d9187bda058b57ef53e17201a56480d4
company,1627455540,Bristol Myers Squibb Reports Second Quarter Financial Results for 2021,69363130,,BMY,Business Wire,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=4d72896fbb575a7aa4b587517c71f944fe0930e3f413e3d7a9afdd1a15aeaa98
company,1627454340,"Beck Mack & Oliver Llc Buys Arthur J. Gallagher, Berkshire Hathaway Inc, AllianceBernstein Holding LP, Sells Grifols SA, BlackBerry, Grupo Televisa SAB",69360424,,BMY,GuruFocus,,https://finnhub.io/api/news?id=eb5037952a9a3163550a66cc7532558abdc300ef14515aadff1164e3e83edd52
company,1627453800,Acceleron sees Q2  REBLOZYL royalty revenue $25.6M vs.  $22.4 last quarter,69363286,,BMY,Thefly.com,"Acceleron Pharma (XLRN) a... XLRN, BMY",https://finnhub.io/api/news?id=03f35c21bb7d4be770c7c77f76411962727a247b6155c37ef6a258bf2adcd884
company,1627452420,"Fed Meeting, Big Tech's Big Quarter, Mask Warning - What's Moving Markets By Investing.com",69360355,https://i-invdn-com.investing.com/news/LYNXMPEDAR0AQ_L.jpg,BMY,Investing.com,"Fed Meeting, Big Tech's Big Quarter, Mask Warning - What's Moving Markets",https://finnhub.io/api/news?id=20ccc3b32ea9ed49a17446f8aa94f75a48f8a75a59bd6de6271f1eea8bd1c6f1
company,1627452120,"Bristol-Myers backs FY21 adjusted EPS view $7.35-$7.55, consensus $7.46",69363467,,BMY,Thefly.com,Bristol Myers Squibb is u... BMY,https://finnhub.io/api/news?id=4b4ea6e476de4ab7659bf02559f3e658c121ec1619a61128faef522e390f55e0
company,1627452060,"Bristol-Myers reports Q2 adjusted EPS $1.93, consensus $1.91",69363468,,BMY,Thefly.com,Reports Q2 revenue $11.7B... BMY,https://finnhub.io/api/news?id=7fa90cbe87bec267d258298d3d6036cc03e55beb700b793d3513b23afd7d293f
company,1627448580,Bristol-Myers' Celgene granted FDA orphan drug designation for Azacitidine,69376479,,BMY,Thefly.com,Bristol-Myers' Celge... BMY,https://finnhub.io/api/news?id=e8a02e0c689a057e06ab1c72a685a689d2c91c090998bd47895b9ef58fe9e42a
company,1627442100,Wednesday Morning Whirlwind,69361922,,BMY,TalkMarkets,,https://finnhub.io/api/news?id=bf7db59538a6ea8ccc60653021419a6922c5fdac68c0832527f8a7fc23e07b60
company,1627410006,"Top Analyst Reports for Comcast, Coca-Cola & Bristol-Myers Squibb",69346499,,BMY,Yahoo,"Today's Research Daily features new research reports on 16 major stocks, including Comcast (CMCSA), The Coca-Cola Company (KO), and Bristol-Myers Squibb (BMY).",https://finnhub.io/api/news?id=cc57ce761d35115daa4325e91832132bc0f22f6270a3a5cd0c1ac11e4549391e
company,1627404060,"Bristol Myers Squibb Co. stock falls Tuesday, still outperforms market",69428516,https://images.mktw.net/im-220105/social,BMY,MarketWatch,"Shares of Bristol Myers Squibb Co. slid 0.30% to $67.49 Tuesday, on what proved to be an all-around dismal trading session for the stock market, with the S&P...",https://finnhub.io/api/news?id=54b3a550beda82f91983776ced008144953c55c896aa3713b143178fa46a852d
company,1627398843,"Drug/Biotech Stock Earnings on Jul 28: PFE, GSK, BMY, BMRN & TLRY",69339245,https://s.yimg.com/uu/api/res/1.2/gw9hjYsV9oVXUgeEGEfgLQ--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/f91db6bb14dedc17d5edb20f29c41da3,BMY,Yahoo,"Let us take a look at five drug/biotech companies - PFE, GSK, BMY, BMRN and TLRY - which are gearing up for their earnings release.",https://finnhub.io/api/news?id=3cccd7ea91eef1ad11e09a1a9cc7fb7fb415256b10dcdd78f94677903bd287c2
company,1627396808,"Infinity Pharma Stock Drops After Updated Data From Bladder & Breast Cancer Trials, Q2 Earnings",69340912,,BMY,Yahoo,"Infinity Pharmaceuticals Inc (NASDAQ: INFI) has issued data updates from two mid-stage trials for eganelisib, its oral immuno-oncology candidate. Data: 49 patients were enrolled in the MARIO-275 study designed to evaluate it as a combination therapy with Bristol-Myers Squibb Co's (NYSE: BMY) Opdivo (nivolumab) in platinum-refractory, I/O naïve patients with advanced urothelial cancer. In the combination arm, the median overall survival (mOS) in the intent to treat (ITT) population stood at 15.4",https://finnhub.io/api/news?id=8aa0ae9e826cedfc361f2ff5a12ac18007b2e5df47e00b755979aef2f5a42d2b
company,1627390620,Notable companies reporting before tomorrow's open,69361976,,BMY,Thefly.com,"Notable companies reporti... PFE, TMO, SHOP, MCD, BMY, BA, ADP, HUM, GD, DT, NYCB, SIX",https://finnhub.io/api/news?id=0c7eb496c5a5e8b63961ced06ee537be04b6d4a6c364a80d85aa59b681f7643a
company,1627389540,"Cordant, Inc. Buys iShares Core MSCI International Developed Markets , Nano X Imaging, FireEye Inc, Sells Ubiquiti Inc, Vericel Corp, MiMedx Group Inc",69360281,,BMY,GuruFocus,,https://finnhub.io/api/news?id=5a9bdac5d2cad7fb4d75ff7c3b96c95842fd832fe66247dfb999e3d942beb3f6
company,1627383240,UK dividends calendar - next 7 days,69333435,,BMY,Alliance News,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=52f768645ed17cfee3dae8b54fb8a7d4c1c117b421ae6799211d63f8b67dbf5a
company,1627382400,"Infinity Pharma Stock Drops After Updated Data From Bladder & Breast Cancer Trials, Q2 Earnings",69339152,https://cdn.benzinga.com/files/imagecache/og_image_social_share_1200x630/images/story/2012/breast_cancer-3713192_1920.jpg,BMY,Benzinga,"Infinity Pharmaceuticals Inc (NASDAQ: INFI) has issued data updates from two mid-stage trials for eganelisib, its oral immuno-oncology candidate.
Data: 49...",https://finnhub.io/api/news?id=5d71eba607a01f9ef0f66d30905fa3b6b4ee39cb3c1b92ff595c8e5dd0602f2d
company,1627382340,"Stephenson National Bank & Trust Buys Raytheon Technologies Corp, Verizon Communications Inc, Tesla Inc, Sells Nucor Corp, Bio-Rad Laboratories Inc, Berkshire Hathaway Inc",69337104,,BMY,GuruFocus,,https://finnhub.io/api/news?id=454ce7d504ded54638d2710db9e490e2fdd2b13000166bbffcfb6025e61b6d0a
company,1627381860,"Bristol-Myers deal a positive signal about BridgeBio's BBP-398, says Mizuho",69362180,,BMY,Thefly.com,"After BridgeBio (BBIO) an... BBIO, BMY",https://finnhub.io/api/news?id=9eead461d01be108fcc2548d407da40e6a5fd7b5d4ca5f12b5849c144952ce37
company,1627380000,Why It’s Hard to Go Wrong With Bristol Myers Stock,69347558,https://s.yimg.com/uu/api/res/1.2/s97HQ1Bje8cznMUkl_.u3w--~B/aD02NDA7dz0xMjgwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/Barrons.com/92616ba500b2a8128cc648e67f7d5439,BMY,Yahoo,"(BMY) Squibb is a good company whose stock has underperformed the stock market.  It’s not that 2021 has been unkind to Bristol Myers Squibb (BMY).  Bristol Myers now trades at 8.8 times 12-month forward earnings, a discount to peers  (PFE) (PFE) and  (MRK) (MRK), which both trade at 12 times.",https://finnhub.io/api/news?id=0169f48e592df936d17916d6384ddaa7f13b96380e5b7646d144c4d9f4ac0202
company,1627373400,"Tuesday’s Top Analyst Upgrades and Downgrades: AbbVie, Alibaba, American Airlines, Chipotle, JD.com, Pfizer, Starbucks and More",69332015,https://247wallst.com/wp-content/uploads/2019/02/imageforentry2-ajg.jpg,BMY,247WallSt,"Tuesday's top analyst upgrades and downgrades included AbbVie, Alibaba, American Airlines, AT&T, Chipotle Mexican Grill, JD.com, Kimberly-Clark, Pfizer, Starbucks and Weyerhaeuser.",https://finnhub.io/api/news?id=eac684146d0b1dc3ba561cf437d0ee4ba7eab90b4d05324097b40b9985d351fd
company,1627367580,BridgeBio announces collaboration with Bristol-Myers to study BBP-398,69331183,,BMY,Thefly.com,"BridgeBio (BBIO) announce... BBIO, BMY",https://finnhub.io/api/news?id=a9dce4033c5d23f3d41e4257447d39f7f3b076a134f22adce3b31d5b37db423c
company,1627365780,Banned Merger,69360482,,BMY,TalkMarkets,,https://finnhub.io/api/news?id=aa9e7a3b1963ee15491aa72a0297c84238230d29c4e406d1a76aee6843f800e7
company,1627365600,Why It’s Hard to Go Wrong With Bristol Myers Stock,69340401,https://images.barrons.com/im-375498/social,BMY,MarketWatch,A combination of solid earnings and a decent-size dividend make the drugmakers shares a solid bet.,https://finnhub.io/api/news?id=b0aea70452eba1c27a10743e3bf14913129adf5fc77d8deb7619460408ffcd2e
company,1627355580,"Boeing, Pharma, McDonald's Earnings: 3 Things to Watch By Investing.com",69363476,https://i-invdn-com.investing.com/news/McDonalds_800x533_L_1611937670.jpg,BMY,Investing.com,"Boeing, Pharma, McDonald's Earnings: 3 Things to Watch",https://finnhub.io/api/news?id=5b3e7641d806a063b9b778bd924999964089ea52391450199274cbbc004fe488
company,1627324146,Is a Beat in Store for Bristol-Myers (BMY) in Q2 Earnings?,69347559,,BMY,Yahoo,Investors will focus on regular top and bottom-line numbers along with key pipeline updates when Bristol-Myers (BMY) reports second-quarter 2021 results.,https://finnhub.io/api/news?id=976c3fbab6813d58d188d17709f47778a3b367a9c82ebcb971ecf34979dfb2ed
company,1627317660,"Bristol Myers Squibb Co. stock falls Monday, underperforms market",69340402,https://images.mktw.net/im-220105/social,BMY,MarketWatch,"Shares of Bristol Myers Squibb Co. sank 0.95% to $67.69 Monday, on what proved to be an all-around favorable trading session for the stock market, with the...",https://finnhub.io/api/news?id=861206b9b15131c3c3c71ceeff0ad3eed60de73469f2e58a37623906bcf87d66
company,1627316498,Bristol Myers Pulls Accelerated Approval For Opdivo In Post-Nexavar Liver Cancer,69347560,,BMY,Yahoo,"Bristol Myers Squibb & Co (NYSE: BMY) on Friday said it's voluntarily withdrawing Opdivo's approval in hepatocellular carcinoma (HCC) patients who previously received Bayer AG's (OTC: BAYRY) standard-of-care Nexavar. The decision came about three months after an independent FDA advisory committee voted 5-4 to remove the Opdivo accelerated approval, which the company scored back in 2017 based on tumor shrinkage data. For Opdivo, concerns about its use in second-line liver cancer use cropped up af",https://finnhub.io/api/news?id=a4fa339ef698e6cf7497e71061fd25ec2602435e0528fa61ffe090953474e4c0
company,1627302060,Bristol Myers Pulls Accelerated Approval For Opdivo In Post-Nexavar Liver Cancer,69325910,https://cdn.benzinga.com/files/imagecache/og_image_social_share_1200x630/images/story/2012/aapharma_1191.png,BMY,Benzinga,Bristol Myers Squibb & Co (NYSE: BMY) on Friday said it's voluntarily withdrawing Opdivo's approval in hepatocellular carcinoma (HCC) patients who...,https://finnhub.io/api/news?id=0c14cb1553ddc3cb7e4c7255eac1a599804c20772a104d34d5b79277191a6146
company,1627297140,UK dividends calendar - next 7 days,69323018,,BMY,Alliance News,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=93a3306829a3077ff4ccb36039e325334565e7cb602f410111f7b53b99ad8daf
company,1627295940,"Abundance Wealth Counselors Buys iShares 0-5 Year TIPS Bond ETF, Enbridge Inc, Citigroup Inc, Sells BTC iShares MSCI USA Quality Factor ETF, Vanguard Total Stock Market ETF, BTC iShares U.S. Treasury Bond ETF",69332318,,BMY,GuruFocus,,https://finnhub.io/api/news?id=29c5d40f144dd5370b55e22c88359f579e1a1f3653ff627aaebd01d11098a81c
company,1627293960,3 Warren Buffett Stocks That Are Screaming Summer Buys,69329905,https://s.yimg.com/uu/api/res/1.2/cug7bzymXKdRNw3x4yb1oA--~B/aD05MzM7dz0xNDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/motleyfool.com/4b182b496934bcdb1f3c1c5b26075eb1,BMY,Yahoo,"If you've ever wondered why Wall Street pays such close attention to 90-year-old investor who believes in buying and holding stakes in great businesses for a really long time, look no further than Warren Buffett's track record.  As CEO of Berkshire Hathaway (NYSE: BRK.A)(NYSE: BRK.B), Buffett has led his company to an average annual return of 20% since taking the helm in 1965.  Through 2020, this worked out to an aggregate return of more than 2,800,000%, and it's created over $500 billion in value for Berkshire Hathaway's shareholders.",https://finnhub.io/api/news?id=bc34eebb8974de488844f0ddece13d90118a47cc97ada954c2e71374cb7ed96b
company,1627286580,Prothena presents new data from Alzheimer's portfolio at AAIC,69323330,,BMY,Thefly.com,"Prothena (PRTA) announced... PRTA, BMY",https://finnhub.io/api/news?id=c005682172cfb467f2aa38261b5e1d7056bf4e27f32ef86f9f76b4c19e75935e
company,1627273380,Bristol-Myers assumed with a Buy at Truist,69332319,,BMY,Thefly.com,Truist analyst Robyn Karn... BMY,https://finnhub.io/api/news?id=7492f8de338466df918fbcd0c554abcd6ace55e9ca7ff9f26a49ee26434ab488
company,1627271880,Bristol-Myers assumed with a Buy at Truist,69332320,,BMY,Thefly.com,Truist analyst Robyn Karn... BMY,https://finnhub.io/api/news?id=5eb1a32034df0dbd4d293d9809062c52525e8e693e3b85031bdaf9fb9615b0e2
company,1627263300,Bristol-Myers withdraws indication for Opdivo after US watchdog review,69324071,,BMY,Alliance News,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=e0115254f519213a42a9627f41549e1d32996a8356c8c074f6956918479437d6
company,1627206996,Bristol-Myers Squibb Company: A Good Combination Of Value And Growth,69316556,https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1077050386/medium_image_1077050386.jpg,BMY,SeekingAlpha,"Bristol-Myers Squibb stock features a good combination of value and growth, and offers double digit return potential. Learn more about BMY and healthcare sector.",https://finnhub.io/api/news?id=227b069eede751b7593ad5f3a0c21ec6243389ea0022f0580fc607c89334866e
company,1627205160,"The Week Ahead In Biotech: Big Pharma Earnings, Iterum FDA Decision, Alzheimer's Conference, IPOs and More",69323762,https://cdn.benzinga.com/files/imagecache/og_image_social_share_1200x630/images/story/2012/national-cancer-institute-xknubmnjbkg-unsplash_0.jpg,BMY,Benzinga,"Biotech stocks rebounded in the week ended July 23, thanks to the broader market strength. The sector also benefitted from the optimism that was set in motion by the solid start...",https://finnhub.io/api/news?id=73b040394ffb2f260f12952d54dee6f34afd6be5097b2bf36d3aa170662faa73
company,1627176734,Dividend Champion And Contender Highlights: Week Of July 25,69314136,https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1072593728/medium_image_1072593728.jpg,BMY,SeekingAlpha,A weekly summary of dividend activity for Dividend Champions and Contenders. Companies which changed their dividends. Companies with upcoming ex-dividend dates.,https://finnhub.io/api/news?id=48c7a5748ba7935a7f6e0cca12fc5320d36aa8beea5e94775023b152751940bb
company,1627121348,A Decade Of Outperformance May Be Followed By A Decade Of Underperformance,69307118,,BMY,SeekingAlpha,,https://finnhub.io/api/news?id=524c0fc76a771c80df4cdceffe7ec8e1f95ced9c4e72d3a7655e96b5ee9d8bb9
company,1627117200,Bristol Myers Squibb: An Undervalued Dividend Stock With Growth Potential,69306348,https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1077050386/medium_image_1077050386.jpg,BMY,SeekingAlpha,Bristol Myers Squibb is one of the largest pharmaceutical companies backed by a pristine Balance Sheet.,https://finnhub.io/api/news?id=2aa809ba301814a2782c9658d833ca123f316245f28fb88f7fdd48423eb7c17c
company,1627076709,Bristol Myers Squibb (BMY) Gains But Lags Market: What You Should Know,69300325,,BMY,Yahoo,"Bristol Myers Squibb (BMY) closed at $68.34 in the latest trading session, marking a +0.56% move from the prior day.",https://finnhub.io/api/news?id=70582a7529581d25f03e4ed322121db076e9b8a182621c274b81ddb86c5b7e21
company,1627064971,Cramer's week ahead: The most important week of earnings season,69299970,https://image.cnbcfm.com/api/v1/image/106808759-1607537250576-wall.jpg?v=1611699313,BMY,CNBC,"""This is the toughest week of the quarter when it comes to making informed financial decisions,"" CNBC's Jim Cramer said ahead of reports from Apple and others.",https://finnhub.io/api/news?id=3b828aa9b1815116146cebe4cea1dbb00408528cc4ff7c38b7c2a5bce4410ac6
company,1627058460,"Bristol Myers Squibb Co. stock rises Friday, still underperforms market",69311492,https://images.mktw.net/im-220105/social,BMY,MarketWatch,"Shares of Bristol Myers Squibb Co. inched 0.56% higher to $68.34 Friday, on what proved to be an all-around positive trading session for the stock market,...",https://finnhub.io/api/news?id=3789c479c9763da53691ee06400316bfdfc5fd1640836075ddf9c8cab4ad8f05
company,1627038660,UK dividends calendar - next 7 days,69291658,,BMY,Alliance News,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=6713d9edbf9e2e2f13f88155b71c1f68239bb6f06087edfc48ebe50d91348001
company,1627036740,"Railway Pension Investments Ltd Buys Lowe's Inc, Bristol-Myers Squibb Company, International Business Machines Corp, Sells Verizon Communications Inc, Abbott Laboratories, Applied Materials Inc",69306528,,BMY,GuruFocus,,https://finnhub.io/api/news?id=0914579202f50d8b9785ff8a21ff8c713257583c0d1797bdb10aa1e88c7561b9
company,1627026300,"The Daily Biotech Pulse: Acorda Spikes On Distribution Deal, Alzamend Soars On Data, Pfizer-BioNTech To Supply More Vaccine Doses, 3 IPOs",69290315,https://cdn.benzinga.com/files/imagecache/og_image_social_share_1200x630/images/story/2012/medicine-1309148_1920_357.jpg,BMY,Benzinga,"Here's a roundup of top developments in the biotech space over the last 24 hours.
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs July 22)

Bio-Techne Corporation (...",https://finnhub.io/api/news?id=7a3cab79a259b9b661e9be7acf26d1f5792622f65d7b72f008a0ab67b8bd4804
company,1627022340,"PrairieView Partners, LLC Buys Schwab Fundamental International Small Company Ind, Vanguard Tax-Exempt Bond ETF, iShares MSCI USA ESG Optimized ETF, Sells iShares Short-Term National Muni Bond ETF, Xcel Energy Inc, Mastercard Inc",69288277,,BMY,GuruFocus,,https://finnhub.io/api/news?id=84baf5f70ee0721a5ed26252e61a28407860d3dd70f9cca885ff0303a78a8a4d
company,1626990609,Bristol Myers Squibb (BMY) Outpaces Stock Market Gains: What You Should Know,69279730,,BMY,Yahoo,"Bristol Myers Squibb (BMY) closed the most recent trading day at $67.96, moving +1.19% from the previous trading session.",https://finnhub.io/api/news?id=511b25ca43d83b70a7460ead4cf96a8b84038c7c8cc8a8ced6c5917643e2bbef
company,1626972060,"Bristol Myers Squibb Co. stock rises Thursday, outperforms market",69283405,https://images.mktw.net/im-220105/social,BMY,MarketWatch,"Shares of Bristol Myers Squibb Co. rallied 1.19% to $67.96 Thursday, on what proved to be an all-around great trading session for the stock market, with the...",https://finnhub.io/api/news?id=5afb96e26f658cc336ff1d8a2362778c44f639656915586d2f28778880c84afe
company,1626966603,Healthcare ETFs in Focus as Q2 Earnings Unfold,69274004,,BMY,Yahoo,The healthcare sector has been benefiting from COVID-19 vaccines or treatment with many more to come.,https://finnhub.io/api/news?id=cd779bc6ce7d1eef25ea51ac82418f3997100cd8dbeea477b79579b4e2c32577
company,1626964382,Why Bristol Myers Squibb (BMY) is a Top Value Stock for the Long-Term,69279734,,BMY,Yahoo,The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.,https://finnhub.io/api/news?id=b6b0dc00a3c12dfb52f745d4f4139a4a9ccaf60098053c9ab226de089ab88b28
company,1626956100,2 Dirt Cheap Dividend Stocks You Can Buy Right Now,69265912,https://s.yimg.com/uu/api/res/1.2/argK6rpDrBVsLmD.jlDTSQ--~B/aD05MzQ7dz0xNDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/motleyfool.com/5846dd8518600cd6f89f5e4abcdc23f7,BMY,Yahoo,"Two that fit the bill are pharma giants Bristol Myers Squibb (NYSE: BMY) and Pfizer (NYSE: PFE).  There aren't that many pharma giants that boast a lineup of drugs comparable to that of Bristol Myers, at least in terms of revenue-generating potential.  The company has over half a dozen products that rack up more than $1 billion per year.",https://finnhub.io/api/news?id=0c651eb71db87bb01e39b8d5b0a309dfcfc19fc93cad88d105fc6c6ad1ae61e7
company,1626947460,7 Stocks to Buy Hand Over Fist if the Stock Market Crashes,69265417,https://s.yimg.com/uu/api/res/1.2/imxOCqwKgoz6Ll8.2JpPrw--~B/aD05MzQ7dz0xNDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/motleyfool.com/fdcf969d8e852dc5ad899fa9958f4dae,BMY,Yahoo,Big market declines are the perfect opportunity for long-term investors to put their capital to work.,https://finnhub.io/api/news?id=f7853916a8d5cdc96fddde12f57aa6dbd8461657c2f4147f8acd12ae8a7755de
company,1626942885,"Pre-August Billionaire Flash: 63 Stocks, 41 Dividends, 3 Buys",69265834,https://static.seekingalpha.com/cdn/s3/uploads/getty_images/473252918/medium_image_473252918.jpg,BMY,SeekingAlpha,"Top ten pre-August net big-gain billionaire-held dividend dogs, BAX, RTX, LOW, DHI, INTC, XOM, MRK, CI, CVX, and GOLD ranged 16.37% to 36.17% in one-year broker-estimated net gains.",https://finnhub.io/api/news?id=8ecfdc026485890e80a34adcf83592e9b3e5dfa2b1f6914c9d9447321cefc06b
company,1626916680,Healthcare ETFs in Focus as Q2 Earnings Unfold,69288173,,BMY,TalkMarkets,,https://finnhub.io/api/news?id=9f05333ceba0c8b6b05a531cf704541cd28390373f41069abc5b048c407946dd
company,1626894127,Bristol Myers Squibb (BMY) Earnings Expected to Grow: Should You Buy?,69254756,,BMY,Yahoo,Bristol Myers (BMY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.,https://finnhub.io/api/news?id=3a901d12f1b1a7146e3a6234d12c1bacce3e016167236ebc081efc404e2e1e8b
company,1626885660,"Bristol Myers Squibb Co. stock rises Wednesday, still underperforms market",69283407,https://images.mktw.net/im-220105/social,BMY,MarketWatch,"Shares of Bristol Myers Squibb Co. inched 0.66% higher to $67.16 Wednesday, on what proved to be an all-around great trading session for the stock market,...",https://finnhub.io/api/news?id=ff02a5911dfc8d6a2c2a6a1db588a0418fa3860163283a5eebabdaee6ad0ae7f
company,1626871140,"Townsend Asset Management Corp  Buys Goldman Sachs Group Inc, Invesco NASDAQ Next Gen 100 ETF, Bristol-Myers Squibb Company, Sells Intel Corp, VanEck Vectors Video Gaming and eSports ETF, ConocoPhillips",69267818,,BMY,GuruFocus,,https://finnhub.io/api/news?id=fbb9197e7fdb3f7c7fff266daf6aba042bde6ae1502ee18c4fba733394cc38de
company,1626837300,LONDON BRIEFING: Bridgepoint rises 20% on GBP2.88 billion London debut,69243442,,BMY,Alliance News,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=164f1ef422465b42205808a5f9734bc34b88842224ad64a29104ab606cf6cfdd
company,1626825600,Catalent plans $100 mln expansion at vaccine plant in Italy,69242642,https://www.nasdaq.com/sites/acquia.prod/files/2021-07-21T041111Z_1_ZA8_RTRLXPP_2_LYNXPACKAGER.JPG?261230856,BMY,Nasdaq,"Catalent Inc plans a $100 million expansion of its plant in Agnani, Italy, where the contract drug manufacturer is currently filling millions of vials of COVID-19 vaccines for AstraZeneca and Johnson & Johnson",https://finnhub.io/api/news?id=1fd993c3920c5f7b17bf2316dc1ed71bdcea97b53230cec420e2a586805bd454
company,1626799260,"Bristol Myers Squibb Co. stock rises Tuesday, still underperforms market",69283408,https://images.mktw.net/im-220105/social,BMY,MarketWatch,"Shares of Bristol Myers Squibb Co. inched 0.54% higher to $66.72 Tuesday, on what proved to be an all-around favorable trading session for the stock market,...",https://finnhub.io/api/news?id=0cdc214c599dbb8d042821755532ffc7f516c01f2f1aee55686f6f25cab09544
company,1626778920,UK shareholder meetings calendar - next 7 days,69225926,,BMY,Alliance News,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=a9bf914772859aed4e0513f4a15ddb2ecaf6bfab6391f287c0a58d7a08df3bea
company,1626775080,"Got $5,000? Here Are 2 Cheap Warren Buffett Stocks to Buy",69227984,,BMY,Yahoo,"Warren Buffett likes good, cheap stocks, and two that certainly fit that mold are Bristol-Myers Squibb (NYSE: BMY) and Kraft Heinz (NASDAQ: KHC).  Bristol-Myers stock has increased by a mild 14% over the past year.  It hasn't been attracting the interest of retail investors, as they have instead gravitated toward stocks that have been doing well amid the pandemic, even high-risk meme stocks.",https://finnhub.io/api/news?id=8de7ed6ebafcb3aa42db86568e2b3fe78886af1dcbf5a3e66a06a328bb5f0889
company,1626763140,"Rnc Capital Management Llc Buys Bristol-Myers Squibb Company, Gilead Sciences Inc, Phillips 66, Sells DuPont de Nemours Inc, Oracle Corp, Kellogg Co",69223352,,BMY,GuruFocus,,https://finnhub.io/api/news?id=2d983a840ac760d262a4637238edff12ba8e594620b098b5cab18215fcdaad1b
company,1626760680,"Got $5,000? Here Are 2 Cheap Warren Buffett Stocks to Buy",69222645,https://www.nasdaq.com/sites/acquia.prod/files/2019-05/0902-Q19%20Total%20Markets%20photos%20and%20gif_CC8.jpg?1145987192,BMY,Nasdaq,"Do you have enough set aside in savings that you can justify investing $5,000 right now? If so, there are a couple of great opportunities out there that won't cost you a fortune and that you can safely hang on to for the long haul. These are also stocks that you will find in Berk",https://finnhub.io/api/news?id=8621fc85782edfa19276c3b3a0238f2f162586ba6c29125106d4798f9d0c1e11
company,1626726021,Will Small Biotech Stock Cytokinetics Undermine A Bristol Myers Buyout?,69213763,https://s.yimg.com/uu/api/res/1.2/5IKKpJXDmzCGkZBi4fOWJA--~B/aD01NjM7dz0xMDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/ibd.com/98d20e03b8c3f058cc3e48968fa1bc5d,BMY,Yahoo,"Cytokinetics said Monday its treatment improved blood flow for patients with a genetic heart disease, and the biotech stock sprinted.",https://finnhub.io/api/news?id=6328e0a444c9ef10d319fa90c03d5a737ff1519ca1c611118b4f40746e5bd3ba
company,1626712860,Bristol Myers Squibb Co. stock outperforms market despite losses on the day,69219745,https://images.mktw.net/im-220105/social,BMY,MarketWatch,"Shares of Bristol Myers Squibb Co. slid 1.40% to $66.36 Monday, on what proved to be an all-around poor trading session for the stock market, with the S&P...",https://finnhub.io/api/news?id=f1693a31ad88a84bfd980123c32a00a869b323b2eedb6c301714fae8c6e950bf
company,1626708723,Bristol Myers' (BMY) Opdivo+Yervoy Fails First-Line SCCHN Study,69209285,,BMY,Yahoo,Bristol Myers' (BMY) late-stage study evaluating Opdivo in combination with Yervoy as a first-line treatment for squamous cell carcinoma of the head and neck fails to meet goal.,https://finnhub.io/api/news?id=ef5fa5d8bcbfb59c6bfe3a75ae6e038859bdd25ebaffc106468e1578b223de02
company,1626705120,Analysts See Higher Success Chances For Cytokinetics' Heart Disease Candidate After Positive Phase 2 Data,69210835,https://cdn.benzinga.com/files/imagecache/og_image_social_share_1200x630/images/story/2012/aapharma_1104.png,BMY,Benzinga,"Today, Cytokinetics Incorporated (NASDAQ: CYTK) reported positive REDWOOD-HCM Phase 2 data showing CK-274 treatment for ten weeks resulted in substantial and...",https://finnhub.io/api/news?id=866d347e651a5500754ad43d05d957a98ebfdd72cdd6c3804151adb68e11e50d
company,1626704940,Cytokinetics Stock Is Surging. Heart-Drug Results Are Exciting Investors.,69259931,https://images.barrons.com/im-371700/social,BMY,MarketWatch,"Shares of small biotech Cytokinetics rocketed by as much as 60% Monday morning, on the results from a study of the firm's investigational drug for heart...",https://finnhub.io/api/news?id=e4f0f497b66b09e56dd9fc96c40fc4abdfe6475888bc32178006fc15f7f054e1
company,1626697686,Here's Why Cytokinetics Is Rocketing Higher Today,69222646,https://www.nasdaq.com/sites/acquia.prod/files/2019-05/0902-Q19%20Total%20Markets%20photos%20and%20gif_CC8.jpg?1292803432,BMY,Nasdaq,"What happened
Shares of Cytokinetics (NASDAQ: CYTK) are up 48.4% as of 12:00 p.m. EDT on Monday. Investors were caught off guard by some encouraging results from a clinical trial with CK-274, a potential new treatment for hypertrophic cardiomyopathy (HCM).",https://finnhub.io/api/news?id=29345aa23c639eab12d95029549a016aab2a3703a0bb4e9623814a9e66928b45
company,1626692280,UK shareholder meetings calendar - next 7 days,69207092,,BMY,Alliance News,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=c32b64dff6f39a9048ff153a4b09ef735bb29cadd4ccedde37c5f7de336fabbc
company,1626688800,Cytokinetics Soars on Positive Results of Heart Disease Treatment Test,69210492,https://s.yimg.com/cv/apiv2/social/images/yahoo_default_logo-1200x1200.png,BMY,Yahoo,Cytokinetics says the Phase 3 clinical trial for its heart disease treatment is expected to start before year-end.,https://finnhub.io/api/news?id=862bd53eaeaac62fd1acfcb49f1c5af958b46f0766d1faed0d595522bdf1a7cf
company,1626679920,Delta Defeats Bulls,69222761,,BMY,TalkMarkets,,https://finnhub.io/api/news?id=2a654dea19169370f1c66893c71d529ce71e6652ee22437b895307b5fdbac14f
company,1626676740,"Pioneer Trust Bank N A Buys Raytheon Technologies Corp, Amgen Inc, Chevron Corp, Sells Merck Inc, Exxon Mobil Corp, Alphabet Inc",69205406,,BMY,GuruFocus,,https://finnhub.io/api/news?id=6a991a33b965b3361b016d71eea586c1dd2c94a8c55fd3918d0bcfcfd413f4a4
company,1626674940,Compugen doses first patient in Phase 1/2 trial of COM701  Bristol-Myers,69205408,,BMY,Thefly.com,Compugen doses first patient in Phase 1/2 trial of COM701  Bristol-Myers CGEN BMY,https://finnhub.io/api/news?id=b4acbdaa426e3b87b04ec9fc9bb1d76c344498745906f57423080a0ead5fecff
company,1626674940,Compugen doses first patient in Phase 1/2 trial of COM701  Bristol-Myers,69205407,,BMY,Thefly.com,Compugen doses first patient in Phase 1/2 trial of COM701  Bristol-Myers CGEN BMY,https://finnhub.io/api/news?id=d1a3719fdc55c52e0e81e2ac27c752d18914c2978bba87ce19aca21d578f1317
company,1626659760,Cytokinetics price target raised to $44 from $26 at JMP Securities,69223695,,BMY,Thefly.com,"JMP Securities analyst Ja... CYTK, BMY",https://finnhub.io/api/news?id=e14e7f1e21345cb457b6558112a1f87c1ee3505e5ee06f975565cde24a3c95c3
company,1626526140,"Have $1,000? 2 Warren Buffett Stocks to Buy",69155986,,BMY,Yahoo,"When it comes to building a winning stock portfolio, it's often helpful to study the strategies of successful investors and incorporate them into your personal stock-buying game plan.  Today, we're going to look at two top stocks owned by Buffett's Berkshire Hathaway (NYSE:BRK.A) (NYSE:BRK.B) that long-term investors shouldn't hesitate to scoop up right now.  The company's initial public offering (IPO) was priced at $120 per share, but by early December, the stock was trading at just shy of $400.",https://finnhub.io/api/news?id=b068c75dddc546c052d32552332aa2aec27cfa890b45f7b89777db66a1d25bcf
company,1626511740,"Have $1,000? 2 Warren Buffett Stocks to Buy",69184849,https://www.nasdaq.com/sites/acquia.prod/files/2019-05/0902-Q19%20Total%20Markets%20photos%20and%20gif_CC8.jpg?1901559944,BMY,Nasdaq,"When it comes to building a winning stock portfolio, it's often helpful to study the strategies of successful investors and incorporate them into your personal stock-buying game plan. I often quote Warren Buffett's sage advice in my articles and firmly believe that investors of a",https://finnhub.io/api/news?id=2bc2aae1bba4fdfa09166ed2136637ac9ea0fc769c02af4007460a0aab99b66c
company,1626508635,Red Hot Inflation: Healthcare Stocks You Can Buy,69153051,https://static.seekingalpha.com/cdn/s3/uploads/getty_images/996828576/medium_image_996828576.jpg,BMY,SeekingAlpha,The healthcare sector is improving in our large cap sector ranking. Top scoring healthcare stocks worth adding to your watch list.,https://finnhub.io/api/news?id=3348a6b3acb8ebb98f2a6345e6c9aaab2465d200d98ce6a40adb35eaed9cbb4c
company,1626471909,Bristol Myers Squibb (BMY) Stock Moves -0.19%: What You Should Know,69113364,https://s.yimg.com/uu/api/res/1.2/XFzKRSTb2_xUaLSOCP9.Bg--~B/aD02MDI7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/a41b81fe729c761f3f94f42ff348f70c,BMY,Yahoo,"Bristol Myers Squibb (BMY) closed the most recent trading day at $67.30, moving -0.19% from the previous trading session.",https://finnhub.io/api/news?id=6a433a9e9a2c4d5ee2c40cd55c4a5b6fc9fdeb049ae37c6c88af1760ad9f37bd
company,1626454008,10 Best Blue Chip Dividend Stocks Hedge Funds Are Buying,69094586,https://s.yimg.com/uu/api/res/1.2/X88NecGa4zKgWQ7uN.jJOw--~B/aD02MDA7dz04MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/insidermonkey.com/3245b2d901e1e3872d975604e16b2820,BMY,Yahoo,"In this article, we will be looking at the 10 best blue chip dividend stocks hedge funds are buying. To skip our detailed analysis of blue-chip stocks and dividend investing, you can go directly to the 5 Best Blue Chip Dividend Stocks Hedge Funds Are Buying. Blue-chip dividend stocks may be among some of the more […]",https://finnhub.io/api/news?id=ca3e314be627d9d0ae8fdf4b29d4a567b549fff9c89d23f4f9e4715192ffaf08
company,1626453660,"Bristol Myers Squibb Co. stock falls Friday, still outperforms market",69201359,https://images.mktw.net/im-220105/social,BMY,MarketWatch,"Shares of Bristol Myers Squibb Co. shed 0.19% to $67.30 Friday, on what proved to be an all-around poor trading session for the stock market, with the S&P...",https://finnhub.io/api/news?id=90dc1f7107ae32d3138dc0dfa4aeb92e36cc78ca3502dc1c1e841130ba834582
company,1626437110,Bristol-Myers' Opdvio/Yervoy Combo Therapy Flunks In Head & Neck Cancer Trial,69090477,,BMY,Yahoo,"Bristol Myers Squibb & Co's (NYSE: BMY) Phase 3 CheckMate -651 data evaluating Opdivo (nivolumab) plus Yervoy (ipilimumab) combo in head and neck cancer failed to primary endpoints of the trial. The trial assessed Opdivo plus Yervoy combination to Extreme regimen (cetuximab, cisplatin/carboplatin, and fluorouracil) as a first-line treatment in platinum-eligible patients with recurrent or metastatic squamous cell carcinoma of the head and neck. The combination treatment did show a clear, positive",https://finnhub.io/api/news?id=e68a85b88d769a5568816a36f4cab276d496b2a0950dd6dcca22201f32790b07
company,1626433860,UK shareholder meetings calendar - next 7 days,69139732,,BMY,Alliance News,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=46780aea8b8f14b106692f9d66f14980e1845516bfe3fe7d12292a15f1be73fc
company,1626433834,Bristol Myers says late-stage trial of head and neck cancer treatment failed to meet main goals,69090478,https://s.yimg.com/uu/api/res/1.2/S8SCotpO9m2XQyQUIGU5dw--~B/aD02MzA7dz0xMjAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/marketwatch.com/96d076434b2a015a3010bd2787b8c856,BMY,Yahoo,"Bristol Myers Squibb Co. said Friday a late-stage study of a treatment for head and neck cancer failed to meet its main goals. The Phase 3 trial sought to compare Opdivo plus Yervoy to the EXTREME regimen (cetuximab, cisplatin/carboplatin and fluorouracil) as a first-line treatment in platinum-eligible patients with recurrent or metastatic squamous cell carcinoma of the head and neck. ""Although Opdivo plus Yervoy showed a clear, positive trend towards overall survival (OS) in patients whose tumo",https://finnhub.io/api/news?id=fc640f22192fe7f8092ca1946f9cea29d7bcf1857c5cd84dd9043aa7fb838c6d
company,1626433140,Bristol Myers Squibb Provides Update on CheckMate -651 Trial Evaluating Opdivo (nivolumab) Plus Yervoy (ipilimumab) Versus EXTREME Regimen as First-Line Treatment for Squamous Cell Carcinoma of the Head and Neck,69090479,https://s.yimg.com/uu/api/res/1.2/CTdO6UdT55lTodc5SNRD8A--~B/aD02Njt3PTQ4MDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/business-wire.com/267a510b24d712797c875646cd0a7d8c,BMY,Yahoo,"PRINCETON, N.J., July 16, 2021--BMS Provides Update on CheckMate -651",https://finnhub.io/api/news?id=8ac8a8597ce5d00e6f026f8ef2ba1eeeeaf375c59b9e0f1f999e6dc8c6575c9d
company,1626422700,Bristol-Myers' Opdvio/Yervoy Combo Therapy Flunks In Head & Neck Cancer Trial,69197813,https://cdn.benzinga.com/files/imagecache/og_image_social_share_1200x630/images/story/2012/aapharma_1073.png,BMY,Benzinga,Bristol Myers Squibb & Co's (NYSE: BMY) Phase 3 CheckMate -651 data evaluating Opdivo (nivolumab) plus Yervoy (ipilimumab) combo in head and neck cancer failed...,https://finnhub.io/api/news?id=e74405fc55e04abaff7feb026983c953345fcc242de1980020aced47ff7f35eb
company,1626421020,"The Daily Biotech Pulse: Moderna To Join S&P 500 Index, Thumbs Down For FibroGen's Anemia Drug, Corvus Shelves COVID Study",69197812,https://cdn.benzinga.com/files/imagecache/og_image_social_share_1200x630/images/story/2012/medicine-1309148_1920_355.jpg,BMY,Benzinga,"Here's a roundup of top developments in the biotech space over the last 24 hours.
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs July 15)

IVERIC bio, Inc. (NASDAQ:...",https://finnhub.io/api/news?id=c2507779ab8755d634cde31c977148b56326e8c22bfba9f2a1c8cfe7786f8362
company,1626419460,Bristol Myers Squibb Cancer Drug Study Falls Short of Endpoints,69074707,https://mw3.wsj.net/mw5/content/logos/mw_logo_social.png,BMY,MarketWatch,By Matt Grossman Bristol Myers Squibb Co. said Friday that a trial examining Opdivo plus Yervoy as a first-line treatment in some head-and-neck-cancer...,https://finnhub.io/api/news?id=b981a7b77b418c358ab5472f6eb2c033e6dc93b5af70acb7381ea03f2a8e96a7
company,1626419434,Bristol Myers says late-stage trial of head and neck cancer treatment failed to meet main goals,69074706,https://s.wsj.net/public/resources/MWimages/MW-GP644_MicroS_ZG_20180906154215.jpg,BMY,MarketWatch,Bristol Myers Squibb Co. undefined said Friday a late-stage study of a treatment for head and neck cancer failed to meet its main goals. The Phase 3 trial...,https://finnhub.io/api/news?id=ddbf63c6c8be5d616440186b7a64cd23820065b8a5c7c683dea6dfeac4d07fc5
company,1626418740,Bristol Myers Squibb Provides Update on CheckMate -651 Trial Evaluating Opdivo (nivolumab) Plus Yervoy (ipilimumab) Versus EXTREME Regimen as First-Line Treatment for Squamous Cell Carcinoma of the Head and Neck,69141325,,BMY,Business Wire,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=c43c721a1b31a618c1efd05303a60f114a59f5578c091d28876ea7587fe032f9
company,1626415260,Bristol-Myers says CheckMate -651 trial did not meet primary endpoints,69141326,,BMY,Thefly.com,Bristol-Myers says CheckMate -651 trial did not meet primary endpoints BMY,https://finnhub.io/api/news?id=135ec8225016b6479830662acc06358755d8c5f95223f34092966f56e890076c
company,1626412922,3 High Dividends I'm Buying Hand Over Fist,69062848,https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1032204372/medium_image_1032204372.jpg,BMY,SeekingAlpha,"Safe high-yielding stocks can be found in both bull and bear markets alike. Read more to know 3 picks that offer safety, growth and diversification.",https://finnhub.io/api/news?id=4401dd5e2944f33b162ef62b2af486ea4f366bb8fb0ec238fc84d3cf5b6dacd2
company,1626410340,"Demars Financial Group, LLC Buys Bristol-Myers Squibb Company, Invesco S&P 500 Equal Weight ETF, Alibaba Group Holding",69141327,,BMY,GuruFocus,,https://finnhub.io/api/news?id=6624363f9ffae0590634a64a956f91e5aca573af1b5d8d4c3f1641434fb3089d
company,1626404904,Buffett 46 July Holdings Include 28 Dividend Payers,69044260,https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1216027461/medium_image_1216027461.jpg,BMY,SeekingAlpha,This Buffett holdings list from Kiplinger first appeared 5/17/21 on line. YCharts and Dogs of The Dow also track this Buffett/Berkshire Batch. Here is your update from 7/13/21 YCharts data.,https://finnhub.io/api/news?id=1ebd39bdf9df92d0c72552fa006e32af6e4120399936c16dad9927958a39647d
company,1626403140,"Novartis, Eli Lilly and AbbVie Top 5-Year New Drug Productivity List",69140737,https://static.gurufocus.com/photos/companies/Drugs_Pharmaceuticals_Medicine_Sick.jpg,BMY,GuruFocus,Bristol-Myers is last with just 3 novel medicines brought to market,https://finnhub.io/api/news?id=cd626538e3fb5f559adbacd48c51bc896720157c753d1edfde5d9b0715c0f7f3
company,1626385809,Bristol Myers Squibb (BMY) Dips More Than Broader Markets: What You Should Know,68948645,https://s.yimg.com/uu/api/res/1.2/64vRzkiY9LXGPrpW4r2GRQ--~B/aD00Njc7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/b95cfdd8768bc3c4620e666dbcb0b248,BMY,Yahoo,"In the latest trading session, Bristol Myers Squibb (BMY) closed at $67.43, marking a -0.66% move from the previous day.",https://finnhub.io/api/news?id=934f595f47cd68d93312b5823bc0537159452645ff8180b01dd83c1f70d69e31
company,1626367260,Bristol Myers Squibb Co. stock outperforms competitors despite losses on the day,69074708,https://images.mktw.net/im-220105/social,BMY,MarketWatch,"Shares of Bristol Myers Squibb Co. slipped 0.66% to $67.43 Thursday, on what proved to be an all-around mixed trading session for the stock market, with the...",https://finnhub.io/api/news?id=b3243329a33fb9e94878ba4ac259e18c384ff2ef254d6a36dd0f755bb978bb4d
company,1626347640,UK shareholder meetings calendar - next 7 days,68799284,,BMY,Alliance News,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=351abcd69ee885bfed2ad696b0d00a5c813bda233dfb19854647b91c509c62fa
company,1626345526,"XOMA Buys Royalty, Milestone Interest In Checkmate's Vidutolimod From Kuros Biosciences",68811909,https://s.yimg.com/uu/api/res/1.2/gnV9ol6009SWgK83PZ8qyQ--~B/aD00MDA7dz02MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/Benzinga/71a445ca45656a1191ad9f3e751df0ae,BMY,Yahoo,"XOMA Corporation (NASDAQ: XOMA) has acquired the royalty interest position Kuros Biosciences holds in Checkmate Pharmaceuticals Inc's (NASDAQ: CMPI) vidutolimod (CMP-001), for $7.0 million upfront plus 6.5 million as sales milestones. Checkmate currently is enrolling patients in a study with anti-PD-1 refractory advanced melanoma in combination with Bristol Myers Squibb Co's (NYSE: BMY) Opdivo (nivolumab), a PD-1 blocking antibody. Checkmate also is pursuing a Phase 2/3 study in front-line melan",https://finnhub.io/api/news?id=9511bfee693e717c5626bdbb5f108f6c6070aa20aaf7f3febc7d1f7180e3d959
company,1626336420,"The Daily Biotech Pulse: Galapagos Sinks On Data, J&J Recalls Sunscreen Products, FibroGen Awaits AdCom Verdict, 3 IPOs",68770532,https://cdn.benzinga.com/files/imagecache/og_image_social_share_1200x630/images/story/2012/cells-1872666_1920_80.jpg,BMY,Benzinga,"Here's a roundup of top developments in the biotech space over the last 24 hours:
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs July 14)

Alexion Pharmaceuticals,...",https://finnhub.io/api/news?id=9bd072fc4371ef7b059dede82ab57b7595d131bc37968a016da17d9687997c04
company,1626331140,"LVW Advisors, LLC Buys Vanguard Russell 1000 Growth Index Fund, Vanguard Russell 2000 Index Fund, Broadstone Net Lease Inc, Sells Starbucks Corp, Greenlight Capital Re, iShares Global Tech ETF",68967934,,BMY,GuruFocus,,https://finnhub.io/api/news?id=cbb2bb8f4c4a76ce73520fa6088d8ac29e28a1600a95df7fb28deefbcf7ea22a
company,1626331080,"XOMA Buys Royalty, Milestone Interest In Checkmate's Vidutolimod From Kuros Biosciences",68784419,https://cdn.benzinga.com/files/imagecache/og_image_social_share_1200x630/images/story/2012/aapharma_1049.png,BMY,Benzinga,XOMA Corporation (NASDAQ: XOMA) has acquired the royalty interest position Kuros Biosciences holds in Checkmate Pharmaceuticals Inc's (NASDAQ:...,https://finnhub.io/api/news?id=325faf07b90410ee7b92463f4a309b06d21671182e94942c9f7772e7cd4e0929
company,1626281863,10 Best Psychedelic Stocks to Buy Now,68720966,,BMY,Yahoo,"In this article, we discuss the 10 best psychedelic stocks to buy now. If you want to skip our detailed analysis of these stocks, go directly to the 5 Best Psychedelic Stocks to Buy Now. Psychedelic treatments for mental health disorders like depression, anxiety, and post-traumatic stress have revolutionized the industry in the past few […]",https://finnhub.io/api/news?id=765575cc35f14a6565d1b06f948e3a9bfcb3b19c4fcbea9797563b2a5077a7f6
company,1626280860,Bristol Myers Squibb Co. stock underperforms Wednesday when compared to competitors despite daily gains,68729479,https://images.mktw.net/im-220105/social,BMY,MarketWatch,"Shares of Bristol Myers Squibb Co. inched 0.65% higher to $67.88 Wednesday, on what proved to be an all-around great trading session for the stock market,...",https://finnhub.io/api/news?id=cb16f09acfb141b684aaad0124ced2053f11a1f15fff0f2ffb8d3f288c4bedc8
company,1626269103,CEL-SCI: Pivotal Clinical Trial Results Point To Upside For Patients And Investors,68720736,https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1249041775/medium_image_1249041775.jpg,BMY,SeekingAlpha,"CEL-SCI announced successful Phase III clinical trial results of its drug Multikine, which could mean fresh upside for the shareholders. Read this article to learn more.",https://finnhub.io/api/news?id=e1970db96f1707c56df8b045590047e261c3792ba5d56f71d6eb01621836a4ae
company,1626261300,UK shareholder meetings calendar - next 7 days,68740575,,BMY,Alliance News,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=e9c41dc2a76db5a06a3041ae045ca0e8c67e0a0cbdffcce7908eea4b4529d5c3
company,1626253200,"Dividend Harvesting: Week 19 Update, $1,900 Invested, 39 Positions, $122.02 In Annual Dividends",68716748,https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1288664594/medium_image_1288664594.jpg,BMY,SeekingAlpha,"After 19 weeks and $1,900, the Dividend Harvesting Portfolio is generating $122.02 in estimated annual income and $10.37 in monthly estimated income.",https://finnhub.io/api/news?id=58cfb2db9a96a71647e36ee0a9adc833781828f3d4cd01c5b1225eb63c4dfae0
company,1626239700,Dialing For Stocks,68759088,,BMY,TalkMarkets,,https://finnhub.io/api/news?id=225b98c89e3e48261ced742ae5811c401552db2deed7a3d5be4c68f40374326e
company,1626194460,Bristol Myers Squibb Co. stock outperforms market despite losses on the day,68729493,https://images.mktw.net/im-220105/social,BMY,MarketWatch,"Shares of Bristol Myers Squibb Co. slumped 0.09% to $67.44 Tuesday, on what proved to be an all-around rough trading session for the stock market, with the...",https://finnhub.io/api/news?id=411d45b75bdd4f45827215c04340d0b774d401257c372e6467ba5687ef6a16b9
company,1626159900,Selloff Round 3,68742767,,BMY,TalkMarkets,,https://finnhub.io/api/news?id=75c06243d1e62fc53fce1919f798c3cb8c8239c4b2da575aaa78a2355845239f
company,1626158220,"Inozyme appoints Gayle Gironda as SVP, human resources",68776645,,BMY,Thefly.com,"Inozyme appoints Gayle Gironda as SVP, human resources INZY BMY",https://finnhub.io/api/news?id=4c09cdbbbbd2726e6c030bbf0d0f4ffbfd295ba0c0f4d1ae70562ba8cb2a74ac
company,1626151140,"Walter & Keenan Financial Consulting Co  Buys Invesco Variable Rate Preferred ETF, NVIDIA Corp, Vanguard S&P 500 ETF, Sells Berkshire Hathaway Inc, Magellan Midstream Partners LP, Boeing Co",68761079,,BMY,GuruFocus,,https://finnhub.io/api/news?id=d0907a329173705498ed1dd70b7d95af197077c6b09abd75df83c4b7b69b0604
company,1626108060,"Bristol Myers Squibb Co. stock rises Monday, outperforms market",69074713,https://images.mktw.net/im-220105/social,BMY,MarketWatch,"Shares of Bristol Myers Squibb Co. inched 0.51% higher to $67.50 Monday, on what proved to be an all-around favorable trading session for the stock market,...",https://finnhub.io/api/news?id=f9c306385e297aed390d610ab14373c78f4c44b386b33a06c262c594736a97b5
company,1626093540,"Graves-Light Private Wealth Management, Inc. Buys Invesco S&P 500 Quality ETF, Bristol-Myers Squibb Company, BTC iShares Core MSCI EAFE ETF, Sells Packaging Corp of America, Steel Dynamics Inc, Blackrock Muni Enhanced Fund Inc",68736363,,BMY,GuruFocus,,https://finnhub.io/api/news?id=f8b3909ffcde254e5f4eb935b9cffed94755e645a250278dac725cfd3b2e366a
company,1626010260,2 Biotech IPO Stocks You'll Want to Have on Your Radar,68685872,,BMY,Yahoo,"Initial public offerings (IPOs) can provide opportunities for investors to jump aboard promising stocks early.  In this Motley Fool Live video recorded on June 30, 2021, Motley Fool contributors Keith Speights and Brian Orelli discuss two upcoming biotech stock IPOs you'll want to have on your radar.  Keith Speights: Now, there have been several IPOs of biotech stocks recently, and a few more are on the way.",https://finnhub.io/api/news?id=1c5afbc4bb7e785b73ee6f947cbb96a95ac37df91cae8f4afb40c901b5a997c9
company,1625995860,2 Biotech IPO Stocks You'll Want to Have on Your Radar,69009808,https://www.nasdaq.com/sites/acquia.prod/files/2019-05/0902-Q19%20Total%20Markets%20photos%20and%20gif_CC8.jpg?1303823591,BMY,Nasdaq,Initial public offerings (IPOs) can provide opportunities for investors to jump aboard promising stocks early. That's especially the case with biotech stocks that go public.,https://finnhub.io/api/news?id=d6961b96900405028c6d9913eb684f2966826edb259ae1bf7067edbf86b06017
company,1625918460,Can Gilead Beat Bristol Myers Squibb With Its Cancer CAR-T Therapy?,68677051,,BMY,Yahoo,"Bristol Myers Squibb (NYSE: BMY) could have a big winner with Breyanzi, the chimeric antigen T cell (CAR-T) therapy that it gained with the acquisition of Celgene.  In this Motley Fool Live video recorded on June 30, 2021, Motley Fool contributors Keith Speights and Brian Orelli discuss whether or not Gilead will be able to beat BMS in treating large B-cell lymphoma.  Keith Speights: Bristol Myers Squibb impressed investors earlier this month with really positive data for its CAR-T therapy Breyanzi which was formerly liso-cel, which is easier to pronounce to me, I'll call it liso-cel, and those results were in treating second-line large B-cell lymphomas.",https://finnhub.io/api/news?id=f0a492d58141ed2a524a1bb84b9b7ca6ea26ae6e5ffc89a29c34af5e120cf22f
company,1625904060,Can Gilead Beat Bristol Myers Squibb With Its Cancer CAR-T Therapy?,69009809,https://www.nasdaq.com/sites/acquia.prod/files/2019-05/0902-Q19%20Total%20Markets%20photos%20and%20gif_CC8.jpg?901931865,BMY,Nasdaq,"Bristol Myers Squibb (NYSE: BMY) could have a big winner with Breyanzi, the chimeric antigen T cell (CAR-T) therapy that it gained with the acquisition of Celgene. However, the current king of CAR-T, Gilead Sciences (NASDAQ: GILD), won't be easily dethroned. In this Motley Fool L",https://finnhub.io/api/news?id=cd27d3004ed944d28d0316af1b81e791e962ccfc86aba5324592e2e1ac586438
company,1625867109,Bristol Myers Squibb (BMY) Gains But Lags Market: What You Should Know,68675287,https://s.yimg.com/uu/api/res/1.2/OL7xfT5pzuzwP2wxb1pcSw--~B/aD02MjU7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/7ea641b46fe75c0a913349e5e610d6a2,BMY,Yahoo,"Bristol Myers Squibb (BMY) closed the most recent trading day at $67.16, moving +0.7% from the previous trading session.",https://finnhub.io/api/news?id=e9e9da84037c3bdba413508d6c434fe6577114c5505d30135abe3b8ee7b26cf6
company,1625851325,Bristol-Myers (BMY) Gains 7.6% YTD: What to Expect in 2H,68675289,https://s.yimg.com/uu/api/res/1.2/i3fIqgr2ZurQ_myw3ly0.Q--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/a85eb7319e956e8beb6c9c5b0aadb1b7,BMY,Yahoo,Bristol-Myers (BMY) maintains momentum on new drug approvals despite some key established drugs facing challenges.,https://finnhub.io/api/news?id=a490ea54cac7434f2cf037480cca6c5820938416a5025f3a3a05542d5ef5cadc
company,1625848860,"Bristol Myers Squibb Co. stock rises Friday, still underperforms market",68674857,https://images.mktw.net/im-220105/social,BMY,MarketWatch,"Shares of Bristol Myers Squibb Co. inched 0.70% higher to $67.16 Friday, on what proved to be an all-around positive trading session for the stock market,...",https://finnhub.io/api/news?id=7a0d61546938e692928f62da0fd4d7e9a7b9388596423c970a338de0db1f75bd
company,1625848705,Bristol-Myers Squibb Is A High Yielding Blue-Chip That Should Appreciate,68668130,https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1277229026/medium_image_1277229026.jpg,BMY,SeekingAlpha,"Bristol-Myers Squibb stock appears ready for a new valuation and trading range, where the low to mid $60s should provide support.",https://finnhub.io/api/news?id=53313b8ae2ff5955b0e210167c6751ef68e484f1c7a683f3ede4f5e8e4a71952
company,1625811609,Nicholas Ward's Dividend Growth Portfolio: June 2021 Review,68660010,https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1234887973/medium_image_1234887973.jpg,BMY,SeekingAlpha,My portfolio's total returns were 3.36% in June. Read more to know why June was my best month ever in terms of dividend income.,https://finnhub.io/api/news?id=6fbc16a95473ea6f90b18f5751e0fadbd77f133b6dca7d7b87458276cbba94a1
company,1625806260,Recovery Friday,68755270,,BMY,TalkMarkets,,https://finnhub.io/api/news?id=00a35393e0751e9f6bd5b687ac39bac67cd14a238bb71b865890872fa6c72764
company,1625805540,"F&V Capital Management, LLC Buys Cummins Inc, Bristol-Myers Squibb Company, Newmont Corp, Sells Micron Technology Inc, PayPal Holdings Inc, Merck Inc",68742445,,BMY,GuruFocus,,https://finnhub.io/api/news?id=084ca1128f8e551e5fa2df0652b07f4f72979c2e6430210b879c104d9b6c15aa
company,1625800019,Will Teva Stock Rebound After A 10% Fall In A Month?,68934007,https://www.nasdaq.com/sites/acquia.prod/files/2019-05/0902-Q19%20Total%20Markets%20photos%20and%20gif_CC8.jpg?1623391051,BMY,Nasdaq,"We believe that Teva Pharmaceutical stock (NYSE: TEVA) is a good buying opportunity at the present time. TEVA stock trades near $10 currently and it is, in fact, down 28% from its pre-Covid high of around $13 in Feb 2020 – before the coronavirus pandemic hit the worl",https://finnhub.io/api/news?id=b948f193eb8b522642f433b0c0736e2ab2b1707c16e735d222f4ef4830e2a4c5
company,1625781009,Bristol Myers Squibb (BMY) Stock Moves -0.67%: What You Should Know,68684319,https://s.yimg.com/uu/api/res/1.2/HIalcDlt7JZPKSITVlxPuw--~B/aD02MDA7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/c2fdcaac033e049c74f38d188afcc9f9,BMY,Yahoo,"Bristol Myers Squibb (BMY) closed at $66.69 in the latest trading session, marking a -0.67% move from the prior day.",https://finnhub.io/api/news?id=d24cf94b90f06a5deaf0fcc6a5e66e77cc794eed3d182d147d077daf74155fdc
company,1625781009,Bristol Myers Squibb (BMY) Stock Moves -0.67%: What You Should Know,68657126,https://s.yimg.com/uu/api/res/1.2/HIalcDlt7JZPKSITVlxPuw--~B/aD02MDA7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/c2fdcaac033e049c74f38d188afcc9f9,BMY,Yahoo,"Bristol Myers Squibb (BMY) closed at $66.69 in the latest trading session, marking a -0.67% move from the prior day.",https://finnhub.io/api/news?id=5210716bb2fd607b07a767d6427bd180271bd4ae2b693ffc0ff626e38fb57107
company,1625762400,"Bristol Myers Squibb Co. stock falls Thursday, still outperforms market",68674871,https://images.mktw.net/im-220105/social,BMY,MarketWatch,"Shares of Bristol Myers Squibb Co. slumped 0.67% to $66.69 Thursday, on what proved to be an all-around poor trading session for the stock market, with the...",https://finnhub.io/api/news?id=4153e52de53706d4fbc03d27cc70e06b0a74e87ab4e7e234e28938b6813a54e5
company,1625761793,"After Hours Most Active for Jul 8, 2021 :  BMY, RIG, ALXN, QQQ, NYCB, AAPL, ATVI, NUVB, GSKY, CMCSA, VST, CNP",68770706,https://www.nasdaq.com/sites/acquia.prod/files/2019-05/0902-Q19%20Total%20Markets%20photos%20and%20gif_CC8.jpg?1937438011,BMY,Nasdaq,"The NASDAQ 100 After Hours Indicator is up 1.21 to 14,723.35.  The total After hours volume is currently 51,956,873 shares traded.The following are the most active stocks for the after hours session: Bristol-Myers Squibb Company (BMY) is unchanged at $66.69, with 3,028,333 shares",https://finnhub.io/api/news?id=3ad1880d0ab01550c42b3df34b1558fa4f9065aab09bac7860abb1e72fc2734f
company,1625752800,"After Second Look Oncopeptides' Melflufen Wins Head-To-Head Myeloma Trial, But Difference In OS Triggers FDA Hold",68656174,https://s.yimg.com/uu/api/res/1.2/MV6hE00u1icwI_COMkCsPw--~B/aD00MDA7dz02MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/Benzinga/139e93d599df6de8b1d41c9bafc2ef93,BMY,Yahoo,"Oncopeptides AB (OTC: ONPPF) has some good news and some bad news from the updated results from Phase 3 OCEAN study of Pepaxto (melflufen) plus dexamethasone in patients with relapsed / refractory multiple myeloma who have received 2 – 4 prior lines of therapy. The good news is that while preparing the clinical study report and regulatory documents, Oncopeptides discovered that the independent review committee lacked access to all the information in the clinical database. The discovery led to th",https://finnhub.io/api/news?id=04d4e31179d46f07150f124bb8bc9e8ccd0b90e6f5fe8f5866cc85e0ea2b4e6d
company,1625747940,"Hikari Power Ltd Buys AbbVie Inc, Merck Inc, Vanguard Health Care ETF, Sells Wells Fargo, Nutrien, Cisco Systems Inc",68866647,,BMY,GuruFocus,,https://finnhub.io/api/news?id=82e3e4d9515c5a52be1c88723b603c2b3994733e90028522e3754cdbc3bf1949
company,1625747940,"First Dallas Securities Inc. Buys Texas Pacific Land Corp, General Motors Co, Nordstrom Inc, Sells US Concrete Inc, The GEO Group Inc, Abbott Laboratories",68821840,,BMY,GuruFocus,,https://finnhub.io/api/news?id=f60cf49b17643eabee12ccb800765ae98e2956743e9f9c2a3382dbe1851aa99a
company,1625743620,Stay Away From Low-Growth Organon,68866648,https://investorplace.com/wp-content/uploads/2019/08/healthcare1600a.jpg,BMY,InvestorPlace,"Organon's low growth, lack of strong catalysts and likely average future dividend combine to make OGN stock unattractive.",https://finnhub.io/api/news?id=0fe8b6926ae656cff169b83de114f49eb26a32080b909952fa510d77bba7cf33
company,1625741553,"DGRO, MRK, CSCO, BMY: ETF Inflow Alert",68651547,https://www.nasdaq.com/sites/acquia.prod/files/2019-05/0902-Q19%20Total%20Markets%20photos%20and%20gif_CC8.jpg?2021449710,BMY,Nasdaq,"Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the iShares Core Dividend Growth ETF (Symbol: DGRO) where we have detected an approximate $101.9 million dollar inflow -- that's a 0.5% increase week ov",https://finnhub.io/api/news?id=6a960dfd73c4ce1a868d054656a17fae806916cacdd0e9b1d9149cc16aa747a6
company,1625740200,August 27th Options Now Available For Bristol Myers Squibb (BMY),68866649,,BMY,Stock Options Channel,"Staff article entitled August 27th Options Now Available For Bristol Myers Squibb (BMY), about stock options, from Stock Options Channel.",https://finnhub.io/api/news?id=c59d8fb8f11ed0e7d56755645682c2ccdc1a0776974c980679f71090f71619db
company,1625738400,"After Second Look Oncopeptides' Melflufen Wins Head-To-Head Myeloma Trial, But Difference In OS Triggers FDA Hold",68653483,https://cdn.benzinga.com/files/imagecache/og_image_social_share_1200x630/images/story/2012/aapharma_964.png,BMY,Benzinga,Oncopeptides AB (OTC: ONPPF) has some good news and some bad news from the updated results from Phase 3 OCEAN study of Pepaxto (melflufen) plus dexamethasone in...,https://finnhub.io/api/news?id=9a431f19d6717cc297885a4d7c32899e96965da92f4a9692001c965657c86dd7
company,1625732520,Top 5 Stocks To Buy For July 2021,68863560,,BMY,TalkMarkets,,https://finnhub.io/api/news?id=3b2ffebe322d50840ae0dcd5271f3ffe3a0a0a8bcbafafb7d0e7f9e52971bdf1
company,1625676060,Bristol Myers Squibb Co. stock outperforms market on strong trading day,68638342,https://images.mktw.net/im-220105/social,BMY,MarketWatch,"Shares of Bristol Myers Squibb Co. inched 0.74% higher to $67.14 Wednesday, on what proved to be an all-around great trading session for the stock market,...",https://finnhub.io/api/news?id=010ef695f5f3df1de2df91d3396942a3b7fc53c7cd073e1ebe2f725e4c0ba777
company,1625644680,OncoSec Stock Jumps On Anti-Cancer Gene Therapy Trial Collaboration With Merck In Melanoma,68758679,https://cdn.benzinga.com/files/imagecache/og_image_social_share_1200x630/images/story/2012/aapharma_940.png,BMY,Benzinga,OncoSec Medical Inc (NASDAQ: ONCS) will evaluate its DNA-plasmid interleukin-12 (IL-12) TAVO (tavokinogene telseplasmid) with Merck & Co Inc's (NYSE: MRK)...,https://finnhub.io/api/news?id=7afe9d04dbae6add3f46d01d897f360fd7cfdfe72cdec0c91b840d155a8cd446
company,1625589660,"Bristol Myers Squibb Co. stock falls Tuesday, underperforms market",68638343,https://images.mktw.net/im-220105/social,BMY,MarketWatch,"Shares of Bristol Myers Squibb Co. shed 0.45% to $66.65 Tuesday, on what proved to be an all-around poor trading session for the stock market, with the S&P...",https://finnhub.io/api/news?id=df9b787ed43fdd64cfc951c58bfc53c12f147105f1f4c1522c93bd53b4fd3f84
company,1625577608,Agenus says its Bristol Myers Squibb licensing deal has up to $1.3 billion in milestone payments,68612372,https://s.yimg.com/uu/api/res/1.2/S8SCotpO9m2XQyQUIGU5dw--~B/aD02MzA7dz0xMjAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/marketwatch.com/96d076434b2a015a3010bd2787b8c856,BMY,Yahoo,"Shares of Agenus Inc. were up 2.0% in premarket trading on Tuesday after the company said a licensing deal with Bristol Myers Squibb Co. had closed. As part of the agreement, Bristol plans to study an experimental Agenus immuno-oncology drug as a treatment for non-small cell lung cancer. Bristol will pay Agenus $200 million upfront, with up to $1.3 billion in possible milestones payments. Agenus' stock has gained 73.6% so far this year, while the broader S&P 500 is up 15.8.%",https://finnhub.io/api/news?id=59eaa5aaa266e5e16b4f70750669aa06e6bd48b5fce03194b95ad17eb24085d3
company,1625565300,3 Dividend Stocks That Are Dirt Cheap Right Now,68612367,,BMY,Yahoo,"Descriptions like ""income investor"" and ""value investor"" are thrown around as if they're mutually exclusive.  There aren't very many stocks that provide solid dividends that are also available at an attractive valuation.  Here are three dividend stocks that are dirt cheap right now.",https://finnhub.io/api/news?id=3bdc23019bb6dd6f2dcd8953f7729eaa1164d5c06b57c5b5fc499902743b9963
company,1625563208,Agenus says its Bristol Myers Squibb licensing deal has up to $1.3 billion in milestone payments,68629576,https://s.wsj.net/public/resources/MWimages/MW-GP644_MicroS_ZG_20180906154215.jpg,BMY,MarketWatch,Shares of Agenus Inc. undefined were up 2.0% in premarket trading on Tuesday after the company said a licensing deal with Bristol Myers Squibb Co. undefined...,https://finnhub.io/api/news?id=13ffa69fbb4c69e83cee320860bbfa87740633b4e32ccfb3a1aaa4b58971e02c
company,1625557080,"Agenus closes $200M upfront BMS collaboration, announces FDA acceptance of IND",68866651,,BMY,Thefly.com,"Agenus closes $200M upfront BMS collaboration, announces FDA acceptance of IND AGEN BMY",https://finnhub.io/api/news?id=bc8d976c68eaf6c8572b53a2a58c8e5624c9a8959e3b0fb8546f8b9937bd926a
company,1625550900,3 Dividend Stocks That Are Dirt Cheap Right Now,68646313,https://www.nasdaq.com/sites/acquia.prod/files/2019-05/0902-Q19%20Total%20Markets%20photos%20and%20gif_CC8.jpg?986137338,BMY,Nasdaq,"Descriptions like ""income investor"" and ""value investor"" are thrown around as if they're mutually exclusive. But they're not. There are many investors who equally belong to both groups.",https://finnhub.io/api/news?id=e22280d7b84bb60845b37c35d02de9ac9e3a81fa54b7233969000a78cba4cae5
company,1625475076,Best Biotech Stocks To Buy In July 2021? 3 To Watch This Week,68646483,https://www.nasdaq.com/sites/acquia.prod/files/2019-05/0902-Q19%20Total%20Markets%20photos%20and%20gif_CC8.jpg?2140636746,BMY,Nasdaq,"3 Top Biotech Stocks To Watch This WeekWhen looking for what stocks to buy in the stock market, investors could be turning towards biotech stocks once again. For one thing, the biotech industry is home to countless companies hard at work on the healthcare industry’s greates",https://finnhub.io/api/news?id=7734aa32de7229cc0a4b2edc5154f5511fe7f978b8c1182f245ce12ef4efd709
company,1625470200,The Dividend Growth 30: Beating The Market And Offering An Above-Average Yield,68603228,https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1287156325/medium_image_1287156325.jpg,BMY,SeekingAlpha,"The Dividend Growth 30 portfolio is an article series I started last summer. With no dividend cuts, dividend increases of up to 40%, and an above-average dividend yield, it is going well.",https://finnhub.io/api/news?id=e862a89a5d98c9ecff982b59a6407be66ba5bbb20b9b2f7ddbd4b42ae64608e7
company,1625251980,EXPLAINER: How could the indictment hurt Trump's company?,68866652,,BMY,"Associated Press, The",Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=70c218070844d301c65f309668fbdc1498fc27d4de9ac397c3958a0c1303e4f7
company,1625244060,"Bristol Myers Squibb Co. stock rises Friday, still underperforms market",68594137,https://images.mktw.net/im-220105/social,BMY,MarketWatch,"Shares of Bristol Myers Squibb Co. inched 0.59% higher to $66.95 Friday, on what proved to be an all-around favorable trading session for the stock market,...",https://finnhub.io/api/news?id=d8ad04bf85ec6aa5c232feba0b73e4802692410f49b5f3834c6257197abef8ce
company,1625215280,Why Epizyme Stock Is Falling This Week,68649158,https://www.nasdaq.com/sites/acquia.prod/files/2019-05/0902-Q19%20Total%20Markets%20photos%20and%20gif_CC8.jpg?1439241779,BMY,Nasdaq,"What happened
Shares of biotech Epizyme (NASDAQ: EPZM) have been a bit sickly this week, following the departure of one of its top executives. As of Thursday's market close, the stock was down nearly 13% from the start of the week.",https://finnhub.io/api/news?id=6c940acee69b6f002eec744f7bcbeab00a316daa83fa3f0680af11d8f003c640
company,1625176209,Bristol Myers Squibb (BMY) Stock Sinks As Market Gains: What You Should Know,68566980,https://s.yimg.com/uu/api/res/1.2/9naTdeJlVMX28sdlDpLdrQ--~B/aD02MDA7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/ac90b3d74679f6d01a122aa033d8a9a4,BMY,Yahoo,"Bristol Myers Squibb (BMY) closed at $66.56 in the latest trading session, marking a -0.39% move from the prior day.",https://finnhub.io/api/news?id=25374557e04f612f82334043c251c266372941ea02c769a760cfbd6bbf49d201
company,1625163960,EXPLAINER: How could the indictment hurt Trump's company?,68866653,,BMY,"Associated Press, The",Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=52f5714020c7982ae090f77c864798da7fa166392cd448b7e9cf08819ab46469
company,1625157660,"Bristol Myers Squibb Co. stock rises Thursday, still underperforms market",68594138,https://images.mktw.net/im-220105/social,BMY,MarketWatch,"Shares of Bristol Myers Squibb Co. inched 0.35% higher to $66.56 Thursday, on what proved to be an all-around great trading session for the stock market,...",https://finnhub.io/api/news?id=33fb21a7e9dda4478ab985d8fe8fb688e42d784ec706a043d8ece16dee2d1f12
company,1625133900,Could Vertex Pharmaceuticals Be a Prime Acquisition Target?,68551975,https://s.yimg.com/cv/apiv2/social/images/yahoo_default_logo-1200x1200.png,BMY,Yahoo,"Many investors expect that Vertex Pharmaceuticals (NASDAQ: VRTX) could make additional acquisitions in the not-too-distant future with its growing cash stockpile.  In this Motley Fool Live video recorded on June 23, 2021, Motley Fool contributors Keith Speights and Brian Orelli discuss whether or not Vertex might be a prime acquisition target.",https://finnhub.io/api/news?id=92fd43781d70c8ced87de022bbea7600f96b064071a79145b6782bd2bfff2126
company,1625083448,"Biotech Stock Roundup: NTLA Surges on Study Data, EXEL & ALT Down on Updates & More",68539944,https://s.yimg.com/uu/api/res/1.2/vtsVt8PEmb10KQ4cnwEJfQ--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/96776645e0ac7ab203b7d5e3b37251a6,BMY,Yahoo,"The biotech sector was in focus last week with pipeline updates from Intellia (NTLA), Exelixis (EXEL) and Regeneron (RGEN), among others.",https://finnhub.io/api/news?id=ab0c141dfeec092e6af43dbea20d6b55c9edc31468a4422a58b23dab16c46286
company,1625074936,15 Best Medical Stocks to Invest In,68535865,https://s.yimg.com/uu/api/res/1.2/1oLsdrS6atC3bH7.I3fY2Q--~B/aD01MDA7dz03NTA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/insidermonkey.com/b0231c6a276a136064d32e54071279f6,BMY,Yahoo,"In this article we will take a look at the 15 best medical stocks to invest in. You can skip our detailed analysis of these companies, and go directly to the 5 Best Medical Stocks to Invest In. The healthcare sector is set to grow in the coming years, as aging population, demand for life-saving […]",https://finnhub.io/api/news?id=7aede7352631d6c3a2e90f2646534154f8004525a25a158b30e64311a0e9b7c0
company,1625071260,"Bristol Myers Squibb Co. stock rises Wednesday, outperforms market",68551864,https://images.mktw.net/im-220105/social,BMY,MarketWatch,"Shares of Bristol Myers Squibb Co. inched 0.83% higher to $66.82 Wednesday, on what proved to be an all-around positive trading session for the stock market,...",https://finnhub.io/api/news?id=c783de0817073d6d88916bcd58a3d2bde65d34f53d0c7785732df581904339fa
company,1625066718,"Noteworthy Wednesday Option Activity: BMY, FE, W",68647485,https://www.nasdaq.com/sites/acquia.prod/files/2019-05/0902-Q19%20Total%20Markets%20photos%20and%20gif_CC8.jpg?1989384546,BMY,Nasdaq,"Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in Bristol Myers Squibb Co. (Symbol: BMY), where a total volume of 66,676 contracts has been traded thus far today, a contract volume which is representative of ap",https://finnhub.io/api/news?id=85d01cfccb8c8b33a880aba3623a84fe26cbd2bd7193be4c226dfcf71f599269
company,1625043603,"Bristol-Myers Squibb Company (BMY) Ex-Dividend Date Scheduled for July 01, 2021",69009817,https://www.nasdaq.com/sites/acquia.prod/files/2019-05/0902-Q19%20Total%20Markets%20photos%20and%20gif_CC8.jpg?959760481,BMY,Nasdaq,"Bristol-Myers Squibb Company (BMY) will begin trading ex-dividend on July 01, 2021. A cash dividend payment of $0.49 per share is scheduled to be paid on August 02, 2021.  Shareholders who purchased BMY prior to the ex-dividend date are eligible for the cash dividend payment.  Th",https://finnhub.io/api/news?id=32e526ef1a46e656de030da8b97843383fd0756a6d338db3c48355a97d3fe0f4
company,1625043060,Cantor biotech/biopharma analysts hold an analyst/industry conference call,68745031,,BMY,Thefly.com,Cantor biotech/biopharma analysts hold an analyst/industry conference call JNJ PFE BMY LLY IMAB TRIL GILD HCM MRKR HTBX MBIO,https://finnhub.io/api/news?id=d9b2fbcc23f425d3fab02a035d2c4979e5904958326c27d46d1482577edd3cc8
company,1625038860,Ultragenyx appoints Corsee Sanders to board of directors,68790796,,BMY,Thefly.com,Ultragenyx appoints Corsee Sanders to board of directors RARE BMY,https://finnhub.io/api/news?id=2c9b128507ade1dfcacc259cf5e9c1e62a56cbb85fb791376340fcfceebb8f86
company,1625028100,Tracking David Rolfe's Wedgewood Partners Portfolio - Q1 2021 Update,68532296,,BMY,SeekingAlpha,,https://finnhub.io/api/news?id=fa85cc8491a3f3a3b09a7708b99036d496305f46b2208099ee91e8dece1ab7c9
company,1624984860,"Bristol Myers Squibb Co. stock falls Tuesday, underperforms market",68531025,https://images.mktw.net/im-220105/social,BMY,MarketWatch,"Shares of Bristol Myers Squibb Co. sank 0.20% to $66.27 Tuesday, on what proved to be an all-around great trading session for the stock market, with the S&P...",https://finnhub.io/api/news?id=9406a966de19a7f66b963080136cff347e52bd4c5bf0145fe5fead112e73a2be
company,1624984477,"Notable ETF Outflow Detected - XLV, PFE, ABBV, BMY",68646493,https://www.nasdaq.com/sites/acquia.prod/files/2019-05/0902-Q19%20Total%20Markets%20photos%20and%20gif_CC8.jpg?1365476620,BMY,Nasdaq,"Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the The Health Care Select Sector SPDR— Fund (Symbol: XLV) where we have detected an approximate $138.5 million dollar outflow -- that's a 0.5% de",https://finnhub.io/api/news?id=f5d1fc32de8bf752d7033511319b2142ce40b9813221bca6dea1c0f8d34f44c4
company,1624964760,Bristol Myers Squibb Receives European Commission Approval for Opdivo (nivolumab) Plus Yervoy (ipilimumab) for the Treatment of Mismatch Repair Deficient or Microsatellite Instability–High Metastatic Colorectal Cancer After Prior Chemotherapy,68535256,https://s.yimg.com/uu/api/res/1.2/FfwZaq6FiaEmI6.JKyRc0A--~B/aD02Njt3PTQ4MDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/business-wire.com/cfb0356d016f2734a10d71f558bacb0c,BMY,Yahoo,"PRINCETON, N.J., June 29, 2021--BMS Receives EU Approval for Opdivo+Yervoy for the Treatment of MRD or Microsatellite Instability–High Metastatic Colorectal Cancer After Prior Chemo",https://finnhub.io/api/news?id=02aecfc732b6def3eb20215349d9be1f95e6762065b3625ed654e0ce7d88a7fc
company,1624960727,"Ex-Dividend Reminder: Sysco, Bristol Myers Squibb and Hannon Armstrong Sustainable Infrastructure Capital",68650382,https://www.nasdaq.com/sites/acquia.prod/files/2019-05/0902-Q19%20Total%20Markets%20photos%20and%20gif_CC8.jpg?428296901,BMY,Nasdaq,"Looking at the universe of stocks we cover at Dividend Channel, on 7/1/21, Sysco Corp (Symbol: SYY), Bristol Myers Squibb Co. (Symbol: BMY), and Hannon Armstrong Sustainable Infrastructure Capital Inc (Symbol: HASI) will all trade ex-dividend for their respective upcoming divid",https://finnhub.io/api/news?id=49744619c2f3a850085142ede8a3d0e1dbe7d0c003eeb4ce3d5df59195b69c3c
company,1624950660,Will This 2020 Biotech IPO Crush the Market This Year?,68647656,https://www.nasdaq.com/sites/acquia.prod/files/2019-05/0902-Q19%20Total%20Markets%20photos%20and%20gif_CC8.jpg?178746366,BMY,Nasdaq,"Cutting-edge pharma Legend Biotech (NASDAQ: LEGN) burst onto the scene at the 2017 American Society of Clinical Oncology (ASCO) meeting with fantastic early clinical trial results for its multiple myeloma treatment. Now, with even better data in hand after ASCO 2021, the company",https://finnhub.io/api/news?id=2f8829381312916667fd32a25e6b03353f85723c2b1423b063e10adeb5ee0944
company,1624911900,Analyst Expects Bristol to Settle Over $6 Billion Bet That Didn’t Pay Out,68513574,https://s.yimg.com/uu/api/res/1.2/cNHXon3TJMSqdXhRjTXumQ--~B/aD02NDA7dz0xMjgwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/Barrons.com/c24216771e9d25eb0f74da5f40ad05a7,BMY,Yahoo,Mizuho analyst Salim Syed pegs a potential settlement in the range of $3 billion to $4 billion stemming from Celgene acquisition.,https://finnhub.io/api/news?id=5e34fad46e0b4b858c91f49226591f67ce51625553bd2767deabcbda23af1fdc
company,1624900805,Bristol Myers (BMY) Gets Positive CHMP Opinion for Abecma,68513575,https://s.yimg.com/uu/api/res/1.2/i3fIqgr2ZurQ_myw3ly0.Q--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/a85eb7319e956e8beb6c9c5b0aadb1b7,BMY,Yahoo,"Bristol Myers (BMY) obtains positive CHMP opinion for cell immunotherapy, Abecma, for multiple myeloma and Opdivo for the indication of gastroesophageal junction cancer.",https://finnhub.io/api/news?id=a25b9320160a0984a08c6998338498dd8938ccb71753d73e82c22e571d1b958f
company,1624898460,"Bristol Myers Squibb Co. stock falls Monday, underperforms market",68531026,https://images.mktw.net/im-220105/social,BMY,MarketWatch,"Shares of Bristol Myers Squibb Co. dropped 0.51% to $66.40 Monday, on what proved to be an all-around mixed trading session for the stock market, with the...",https://finnhub.io/api/news?id=d2581d96a649c3b4bd499832078cdfdc99ac184f0d1389065f02c2d97161e2d7
company,1624897500,Analyst Expects Bristol to Settle Over $6 Billion Bet That Didn’t Pay Out,68531027,https://images.barrons.com/im-361081/social,BMY,MarketWatch,Mizuho analyst Salim Syed pegs a potential settlement in the range of $3 billion to $4 billion stemming from Celgene acquisition.,https://finnhub.io/api/news?id=33264c82b48d89173a4123ba4adff229fbe412198208e44723cb30f43cbc2950
company,1624894106,16 Best Beginner Stocks to Invest in Right Now,68512018,https://s.yimg.com/uu/api/res/1.2/ghwnDbxVChPIUe.6GnT19Q--~B/aD01MDA7dz03NTA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/insidermonkey.com/d44187d4f6b9c1b539a73233d02a987a,BMY,Yahoo,"In this article we will take a look at the 16 best beginner stocks to invest in right now. You can skip our detailed analysis of these stocks, and go directly to 5 Best Beginner Stocks to Invest in Right Now. Note that all hedge fund data is based on the exclusive group of 800+ […]",https://finnhub.io/api/news?id=d57050ce49b7da87ea9f634d50ea24743da47829408e01c7244d3c7ab125fc02
company,1624883880,Agenus price target raised to $11 from $8 at B. Riley,68510285,,BMY,Thefly.com,Agenus price target raised to $11 from $8 at B. Riley B. Riley AGEN BMY,https://finnhub.io/api/news?id=9e9c63abe0e5c46069ae914f05fd035e4407876418dc21dbfb76bf18a68a763b
company,1624701960,5 Buffett Stocks to Buy Hand Over Fist for the Second Half of 2021,68513327,https://s.yimg.com/uu/api/res/1.2/o_PvxzUqYxoocudrAqrJGg--~B/aD05MzM7dz0xNDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/motleyfool.com/68479f3f8df176d6d56613033e603843,BMY,Yahoo,"When Warren Buffett buys or sells a stock, Wall Street and retail investors tend to pay very close attention.  Since taking the reins of Berkshire Hathaway (NYSE: BRK.A)(NYSE: BRK.B) in the mid-1960s, Buffett's company has averaged an annual return of 20%.  Although Buffett isn't perfect, he and his investing team have a knack for identifying attractively valued businesses that have clear competitive advantages.",https://finnhub.io/api/news?id=a123018e9c7d6c357ded2a5ba8b701a0bcd0bb07073e6a21554fde6910e5ecf0
company,1624687560,5 Buffett Stocks to Buy Hand Over Fist for the Second Half of 2021,69009821,https://www.nasdaq.com/sites/acquia.prod/files/2019-05/0902-Q19%20Total%20Markets%20photos%20and%20gif_CC8.jpg?1373799347,BMY,Nasdaq,"When Warren Buffett buys or sells a stock, Wall Street and retail investors tend to pay very close attention. That's because the Oracle of Omaha's track record is virtually unsurpassed. Since taking the reins of Berkshire Hathaway (NYSE: BRK.A)(NYSE: BRK.B) in the mid-1960s, Buff",https://finnhub.io/api/news?id=483be3c906ee67c77cc9c9812c1995c9322a648c0e9222a9a7e8fdb613f4aab2
company,1624677764,Do These 3 Checks Before Buying Bristol-Myers Squibb Company (NYSE:BMY) For Its Upcoming Dividend,69009822,https://www.nasdaq.com/sites/acquia.prod/files/2019-05/0902-Q19%20Total%20Markets%20photos%20and%20gif_CC8.jpg?1584154510,BMY,Nasdaq,"Bristol-Myers Squibb Company (NYSE:BMY) is about to trade ex-dividend in the next four days.  The ex-dividend date is one business day before a company's record date, which is the date on which the company determines which shareholders are entitled to receive a dividend.  The ex",https://finnhub.io/api/news?id=3bd547093683225768f68ea4c8f1261a4bd9a476b39f1619b633007abfb32d50
company,1624639260,"Bristol Myers Squibb Co. stock rises Friday, outperforms market",68531028,https://images.mktw.net/im-220105/social,BMY,MarketWatch,"Shares of Bristol Myers Squibb Co. rose 1.35% to $66.74 Friday, on what proved to be an all-around favorable trading session for the stock market, with the...",https://finnhub.io/api/news?id=683a4600bce167ec997541b7a27667905e6246438ab535341d36e253b679ca77
company,1624618740,Bristol Myers Squibb Receives Positive CHMP Opinion for Opdivo (nivolumab) as Adjuvant Treatment for Esophageal or Gastroesophageal Junction Cancer Patients with Residual Pathologic Disease Following Chemoradiotherapy,68493936,https://s.yimg.com/uu/api/res/1.2/G.fmpR1V7qoM.vay_qKXYw--~B/aD02Njt3PTQ4MDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/business-wire.com/32674daf6ee2e1ebbf676618f1ee5953,BMY,Yahoo,"PRINCETON, N.J., June 25, 2021--BMS Receives Positive CHMP Opinion for Opdivo as Adjuvant Treatment for Esophageal or Gastro Junction Cancer Patients w/ RPD Following Chemo",https://finnhub.io/api/news?id=0fa353f75e548471d79b7f4d2315426cf5995796d303dd675e7ede2232928aea
company,1624618200,Bristol Myers Squibb Receives Positive CHMP Opinion for Anti-BCMA CAR T Cell Therapy Abecma (idecabtagene vicleucel) for Relapsed and Refractory Multiple Myeloma,68493937,https://s.yimg.com/uu/api/res/1.2/uioWXmZeBQqkRd5sHwMf8Q--~B/aD02Njt3PTQ4MDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/business-wire.com/975af9601357dbda82b968cb942d2414,BMY,Yahoo,"PRINCETON, N.J., June 25, 2021--Bristol Myers Squibb Receives Positive CHMP Opinion for Anti-BCMA CAR T Cell Therapy Abecma for Relapsed and Refractory Multiple Myeloma",https://finnhub.io/api/news?id=cbfab229f716b472d1f4f318e631a7fe533865107c36d9fbcf1e147b4535146d
company,1624606320,"The Daily Biotech Pulse: Roche Gets Authorization For COVID-19 Treatment, Nods For Sanofi-Regeneron In Europe, Osmotica Divestment, 2 IPOs",68511065,https://cdn.benzinga.com/files/imagecache/og_image_social_share_1200x630/images/story/2012/medicine-1309148_1920_348.jpg,BMY,Benzinga,"Here's a roundup of top developments in the biotech space over the last 24 hours.
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs June 24)

AngioDynamics, Inc. (NASDAQ...",https://finnhub.io/api/news?id=f7bbcabe25c726382b43a66c4ba51e8eec544a1308302042a6eea0f0ccb7ccc7
company,1624606080,Prothena price target raised to $65 from $29 at BTIG,68491171,,BMY,Thefly.com,Prothena price target raised to $65 from $29 at BTIG BTIG PRTA BIIB BMY,https://finnhub.io/api/news?id=5cb7ba97252b0149fe6c567dc156e2caba79ed7e35edf0667b2129472de92287
company,1624605300,Bristol Myers Squibb Gets Positive Opinion for Esophageal-Cancer Treatment From European Medicines Agency,68531029,https://mw3.wsj.net/mw5/content/logos/mw_logo_social.png,BMY,MarketWatch,"By Dave Sebastian Bristol Myers Squibb said it has received positive opinion for Opdivo, its treatment of esophageal or gastroesophageal junction cancer,...",https://finnhub.io/api/news?id=e279cb6a2f994f9715403842a77071a87b2141e26eca056eabb55375c07d54a5
company,1624604400,Thor Industries Is One Of The Best Buffett 'Fat Pitches' On Wall Street,68483807,https://static.seekingalpha.com/cdn/s3/uploads/getty_images/184616814/medium_image_184616814.jpg,BMY,SeekingAlpha,"Thor has built its global empire through major needle-moving merger and acquisition deals, most recently in December 2020.",https://finnhub.io/api/news?id=f5b80bc71cbfb6a2a01492a5e39f7222e1130ca6c14a639aed791ba799e92654
company,1624604340,Bristol Myers Squibb Receives Positive CHMP Opinion for Opdivo (nivolumab) as Adjuvant Treatment for Esophageal or Gastroesophageal Junction Cancer Patients with Residual Pathologic Disease Following Chemoradiotherapy,68485450,,BMY,Business Wire,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=0d79f8298f42351341fd72982cb663d75cbdbe65caf02860052b90ee2b39eb3e
company,1624603800,Bristol Myers Squibb Receives Positive CHMP Opinion for Anti-BCMA CAR T Cell Therapy Abecma (idecabtagene vicleucel) for Relapsed and Refractory Multiple Myeloma,68483672,,BMY,Business Wire,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=20d73b1436cd3effef4aa967f875eefec3667f1d0201d2fb1a18c8d82016f5c6
company,1624600800,Ignore Biogen: Here Are 3 Better Stocks,69009823,https://www.nasdaq.com/sites/acquia.prod/files/2019-05/0902-Q19%20Total%20Markets%20photos%20and%20gif_CC8.jpg?710653268,BMY,Nasdaq,"Investors have been flocking to Biogen since the U.S. Food and Drug Administration approved its Alzheimer's treatment, Aduhelm, earlier this month. The stock has climbed 30% in about two weeks. But I'm concerned about how far the stock can go from here. Aduhelm has drawn criticis",https://finnhub.io/api/news?id=542fedaab0477a4c1e85f42e41a30b943234ce46a58ec2511de5d37339f55aec
company,1624600800,Bristol-Myers receives positive CHMP opinion for Opdivo,68485452,,BMY,Thefly.com,Bristol-Myers receives positive CHMP opinion for Opdivo BMY,https://finnhub.io/api/news?id=24e7cee2c59e2123b1d238f8bce3a1ddb4452097ee783d543da35c3f1b17754c
company,1624600320,Bristol-Myers receives positive CHMP opinion for Abecma,68485453,,BMY,Thefly.com,Bristol-Myers receives positive CHMP opinion for Abecma BMY,https://finnhub.io/api/news?id=809ca4ac6405c7e3513d8696ac6d0cb2f46e213ee9352060fe7a827d58e938b4
company,1624552860,"Bristol Myers Squibb Co. stock rises Thursday, outperforms market",68531030,https://images.mktw.net/im-220105/social,BMY,MarketWatch,"Shares of Bristol Myers Squibb Co. inched 0.90% higher to $65.85 Thursday, on what proved to be an all-around positive trading session for the stock market,...",https://finnhub.io/api/news?id=338b53fff0868ebdd0b21b53b46402c8cdcef00163af4b9269b9579f2f394b6b
company,1624543260,General Electric names Peter Arduni as boss of GE Healthcare,68467794,,BMY,Alliance News,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=80e5187b1ce53f44e3b16b974920f9d66a50b975ab0a4028092a51ecb9a71dd8
company,1624526460,Prothena to Get $80M After Bristol Myers Exercises Option for Alzheimer's Treatment,68531031,https://mw3.wsj.net/mw5/content/logos/mw_logo_social.png,BMY,MarketWatch,By Chris Wack Prothena Corporation Plc said Bristol Myers Squibb Co. exercised its option under the global neuroscience research and development...,https://finnhub.io/api/news?id=c8f30c9c976ed625095e8fd286e5810bd7fd1535a0ce187d8078d3f7f4853c7b
company,1624520100,Prothena announces Bristol-Myers opt-in to enter exclusive license for PRX005,68467795,,BMY,Thefly.com,Prothena announces Bristol-Myers opt-in to enter exclusive license for PRX005 PRTA BMY,https://finnhub.io/api/news?id=2a008e477b5e5dd455516dd73d0246bcca511f29596a52056495b7c1fb26d051
company,1624512864,Update: Bristol-Myers Squibb (NYSE:BMY) Stock Gained 18% In The Last Three Years,68467456,https://s.yimg.com/uu/api/res/1.2/uXEXJ83T1Un1Z9DZlOT05A--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/61ae5b4abdbb9c040fe4f1989e525046,BMY,Yahoo,Investors can buy low cost index fund if they want to receive the average market return. But if you invest in...,https://finnhub.io/api/news?id=c7fa328ceffd188c002733fbd72820ffc9e9befb0ae15d94cd0672e40f0b2afd
company,1624466460,Bristol Myers Squibb Co. stock underperforms Wednesday when compared to competitors,68452191,https://images.mktw.net/im-220105/social,BMY,MarketWatch,"Shares of Bristol Myers Squibb Co. slid 1.03% to $65.26 Wednesday, on what proved to be an all-around poor trading session for the stock market, with the S&P...",https://finnhub.io/api/news?id=a852dd04bdba8ed305b4a75a7bb24865bfb3e8c946977b53d2c2a0a8bc64b561
company,1624452240,14 Biotech Stocks To Watch Over The Next 6 Months,68758692,https://cdn.benzinga.com/files/imagecache/og_image_social_share_1200x630/images/story/2012/lab.loweres.thisisengineering-raeng-qi7uskbzy_a-unsplash_copy_1.jpg,BMY,Benzinga,"Biotechs are at the mercy of several make-or-break catalysts that invariably have a big impact on stocks.
A case in point was the strong upside in Biogen Inc.'s (NASDAQ:...",https://finnhub.io/api/news?id=a88ad0338bfa33c3295d51aec6a340f394f6cb26184478b2f37a35b43c075ba0
company,1624442640,Which Is A Better Investment? Amgen Vs Bristol-Myers Squibb��� The Winner May Surprise You,68443068,,BMY,TalkMarkets,Content,https://finnhub.io/api/news?id=453316ff18b0bb50dbe37a8050ad4a9de1d62c92d91d624c412519049a2dcf22
company,1624423800,The 2 Best Pharma Stocks to Buy on Dips,68432674,,BMY,TalkMarkets,Content,https://finnhub.io/api/news?id=4b481afb63bd9e8e66c449c13a21c0b0152b05537d1525e7b9f92e184ee74e19
company,1624422360,Wednesday Is A Normal Day,68445827,,BMY,TalkMarkets,Content,https://finnhub.io/api/news?id=1023f03783069ea3684a9fa209712870dc18ef70f98d47de78ec938015b6a12d
company,1624412590,Bristol-Myers Squibb (NYSE:BMY) Seems To Use Debt Quite Sensibly,68472683,https://www.nasdaq.com/sites/acquia.prod/files/2019-05/0902-Q19%20Total%20Markets%20photos%20and%20gif_CC8.jpg?1490129428,BMY,Nasdaq,"David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the permanent loss of capital.'  So it seems the smart money knows that debt - which is usually involved in bankruptcies - is a very important factor, when you assess how",https://finnhub.io/api/news?id=a6054a1c3f69a6fde4e1eca3b8a17d70557747a6755836608ff36636d5c0b37e
company,1624380060,"Bristol Myers Squibb Co. stock falls Tuesday, underperforms market",68438611,https://images.mktw.net/im-220105/social,BMY,MarketWatch,"Shares of Bristol Myers Squibb Co. slid 1.33% to $65.94 Tuesday, on what proved to be an all-around great trading session for the stock market, with the S&P...",https://finnhub.io/api/news?id=59a8a3fa5996a97fa0a06593c1b26c4c23031f80782a913b590625cbbe43b855
company,1624314532,Does The Valuation Gap Between Merck Stock And Zoetis Make Sense?,68472503,https://www.nasdaq.com/sites/acquia.prod/files/2019-05/0902-Q19%20Total%20Markets%20photos%20and%20gif_CC8.jpg?1403776926,BMY,Nasdaq,"Zoetis stock (NYSE:ZTS) has risen 2x from levels of $92 that it was at on March 23, 2020, when broader markets made a bottom, to levels of $184 now, while Merck’s stock (NYSE:MRK)  has underperformed and gained only 26% of its value. Looking at valuation, Merck stock",https://finnhub.io/api/news?id=45cc65e6c0ca9dc9decd09713cddb6561335cde1c60496c84e8a6b9eb981e66d
company,1624309509,Bristol Myers' (BMY) Onureg Gets European Commission Approval,68406454,https://s.yimg.com/uu/api/res/1.2/SlGE5JR4xp73Vb5zTu29cQ--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/52b6d392b63705aefb517365eab38a95,BMY,Yahoo,"Bristol Myers (BMY) wins approval for acute myeloid leukemia drug, Onureg, in the European Union.",https://finnhub.io/api/news?id=c9602c1fb369b4b44ccdc8f58474c84818f0f01d7bc4c25c322fe66ba09f5b58
company,1624299167,The Fed Has Spoken: Stocks To Buy Now,68406462,https://static.seekingalpha.com/cdn/s3/uploads/getty_images/144366870/medium_image_144366870.jpg,BMY,SeekingAlpha,The Fed could begin raising rates sooner than 2023. Healthcare and utilities are climbing our sector ranking.,https://finnhub.io/api/news?id=1d006edecd43a3705474498a8cd68a29cf8b2df5b922b4f3dc42a83fc0448335
company,1624293660,"Bristol Myers Squibb Co. stock rises Monday, still underperforms market",68414139,https://images.mktw.net/im-220105/social,BMY,MarketWatch,"Shares of Bristol Myers Squibb Co. inched 0.54% higher to $66.83 Monday, on what proved to be an all-around favorable trading session for the stock market,...",https://finnhub.io/api/news?id=e1caa0fa2a0e0aee56c4bbe919491e3866418bf347384c21211f6992edfb4f83
company,1624278647,Exchanging Caterpillar For Home Depot: Narrowing Down Diversification Options,68398749,https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1016772602/medium_image_1016772602.jpg,BMY,SeekingAlpha,Home Depot boasts excellent historical performance with a solid strategy and respectable future anticipated performance.,https://finnhub.io/api/news?id=e0a6d79cd34469bd0a4e29ef5722edd20799c9edc5fba6e11d05e99c1c7a23a2
company,1624266039,"Upcoming Ex-Dividend Dates: June 22-July 5, 2021",68395005,https://static.seekingalpha.com/cdn/s3/uploads/getty_images/458975641/medium_image_458975641.jpg,BMY,SeekingAlpha,"If you buy stock before the ex-dividend date, you will receive the dividend. Read more to know high quality dividend stock and summary of ex-dividend dates for next two weeks.",https://finnhub.io/api/news?id=0b0c1fbe577be003e6423fa67bf9d4242db7c0896a1596e71d80c6393f70cf72
company,1624265988,Dividend Sleuthing: Bristol Myers Squibb,68395008,https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1251485261/medium_image_1251485261.jpg,BMY,SeekingAlpha,"Bristol Myers Squibb has a solid presence in cardiovascular, oncology, and immunology. Read more to know if BMY has a strong drug pipeline for potential continued growth.",https://finnhub.io/api/news?id=2bcad40ed3276e0f40e61f504e74f0ec4f89a638e2a5a716ea5b2605edde94f2
company,1624039746,Bristol-Myers (BMY) Partners Eisai for Antibody Drug Conjugate,68358544,https://s.yimg.com/uu/api/res/1.2/SlGE5JR4xp73Vb5zTu29cQ--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/52b6d392b63705aefb517365eab38a95,BMY,Yahoo,"Bristol-Myers (BMY) teams up with Eisai to co develop MORAb-202, an antibody drug conjugate (ADC).",https://finnhub.io/api/news?id=af4d329fc8435d9b6861990f5badb3911043b13b62e76dc915e786b2e1a010ee
company,1624034460,Bristol Myers Squibb Co. stock outperforms market despite losses on the day,68414140,https://images.mktw.net/im-220105/social,BMY,MarketWatch,"Shares of Bristol Myers Squibb Co. shed 0.45% to $66.47 Friday, on what proved to be an all-around rough trading session for the stock market, with the S&P...",https://finnhub.io/api/news?id=41ab0226920ba708038fb3747823a2b17903d784c05b93d0f06f5c78b74ef01d
company,1624023240,Bristol Myers Squibb Receives European Commission Approval for Onureg® (azacitidine tablets) as Frontline Oral Maintenance Therapy for Adults with Acute Myeloid Leukemia,68348657,https://s.yimg.com/uu/api/res/1.2/RjLdLdn99CSF4eVoBEfRDw--~B/aD02Njt3PTQ4MDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/business-wire.com/0eebaf232af3bfe35d141e98d5398e8b,BMY,Yahoo,"PRINCETON, N.J., Jun 18, 2021--BMS Receives European Commission Approval for Onureg® as Frontline Oral Maintenance Therapy for Adults with Acute Myeloid Leukemia",https://finnhub.io/api/news?id=51e4d4c76c2f3fb8d4cc9c96c70c73627e58f1de9bd8a06e707f872be1171929
company,1624022700,Bristol Myers Onureg Scores European Approval As Maintenance Therapy For Acute Myeloid Leukemia,68784424,https://cdn.benzinga.com/files/imagecache/og_image_social_share_1200x630/images/story/2012/aapharma_750.png,BMY,Benzinga,"The European Commission has granted full marketing authorization to Bristol Myers Squibb & Co's (NYSE: BMY) Onureg (azacitidine tablets)
The approval...",https://finnhub.io/api/news?id=d89f3ac983bee2f6a095be5cc4c0d56fd1572f1caa4aff8df996dd2f4eb34b5a
company,1624020480,Healthcare Portfolio Playbook: Time To Rebalance With MedTech,68356703,,BMY,TalkMarkets,Content,https://finnhub.io/api/news?id=ec29b44cd565b178c12f0b21951b272745757676f6e00693aab592a25ff31d35
company,1624020344,"Daily Dividend Report: ABBV,BMY,UDR,EQR,MEI",68356067,https://www.nasdaq.com/sites/acquia.prod/files/2019-05/0902-Q19%20Total%20Markets%20photos%20and%20gif_CC8.jpg?470219882,BMY,Nasdaq,,https://finnhub.io/api/news?id=a1ca58ca769087f8d96c15db24875f804c2b56368d86791a9a03d006ebb6f088
company,1624014351,"Bristol Myers Inks Licensing Pact For Eisai's Folate Receptor ADC Drug, Lays Out Over $3B For Rights",68358546,https://s.yimg.com/uu/api/res/1.2/LRKP3phfj3JWb2ocmUwWWA--~B/aD00MDA7dz02MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/Benzinga/fe6224cdf65e28fc9e4c9953412abda9,BMY,Yahoo,"Eisai Co Ltd (OTC: ESALY) and Bristol-Myers Squibb Co (NYSE: BMY) have entered into an exclusive global strategic collaboration agreement for the co-development and co-commercialization of MORAb-202, an antibody-drug conjugate (ADC). Bristol Myers will pay $650 million, including $200 million to Eisai's R&D efforts, for shared global rights to MORAb-202, the Japanese company's first ADC, which is a combination between an in-house folate receptor antibody and chemotherapy eribulin, marketed as Ha",https://finnhub.io/api/news?id=16cecaa8e3c9b86d98a7e77ea5823ab782328343d4ca0811320808bc201f19fe
company,1624013391,"ITOT, JNJ, PFE, BMY: Large Outflows Detected at ETF",68357908,https://www.nasdaq.com/sites/acquia.prod/files/2019-05/0902-Q19%20Total%20Markets%20photos%20and%20gif_CC8.jpg?604063144,BMY,Nasdaq,"Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the iShares Core S&P Total U.S. Stock Market ETF (Symbol: ITOT) where we have detected an approximate $97.1 million dollar outflow -- that's a 0.2%",https://finnhub.io/api/news?id=9113ca3514851fb70611ad84d1ea9f3a380435dc26a52a39a53164847af91f90
company,1624009980,Bristol Myers Gets EC Approval for Onureg in Acute Myeloid Leukemia,68414141,https://mw3.wsj.net/mw5/content/logos/mw_logo_social.png,BMY,MarketWatch,By Michael Dabaie Bristol Myers Squibb said the European Commission granted full marketing authorization for Onureg as a maintenance therapy in acute myeloid...,https://finnhub.io/api/news?id=17e164a08aacd2cd0b66e43691a4795d2226eb74a5bbaab59ed938277b7088c0
company,1624008840,Bristol Myers Squibb Receives European Commission Approval for Onureg® (azacitidine tablets) as Frontline Oral Maintenance Therapy for Adults with Acute Myeloid Leukemia,68350358,,BMY,Business Wire,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=6f6ceeb3c6e39f98c22c7c5cc4b2b433359a1ecdd50e63210b1a55c1bd8aa869
company,1624005420,Bristol-Myers receives European Commission approval for Onureg,68350360,,BMY,Thefly.com,Bristol-Myers receives European Commission approval for Onureg BMY,https://finnhub.io/api/news?id=11249fc2c8d3d3b00b674eab5fa06f9588ff290ba1f87a861555a7c7dd14edc6
company,1624002660,Jefferies a buyer of Prothena on Biogen`s negative Tau disappointment pullback,68348824,,BMY,Thefly.com,Jefferies a buyer of Prothena on Biogen's negative Tau disappointment pullback Jefferies PRTA BIIB BMY,https://finnhub.io/api/news?id=9bdd8e70c4c01e163c1a77d00294c61906065357d9975a0dcfed63932beeac39
company,1624002360,"The Daily Biotech Pulse: Orphazyme Falters At FDA, Athira's CEO Placed On Temporary Leave, 5 IPOs",68754800,https://cdn.benzinga.com/files/imagecache/og_image_social_share_1200x630/images/story/2012/medicine-1309148_1920_345.jpg,BMY,Benzinga,"Here's a roundup of top developments in the biotech space over the last 24 hours.
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs June 17)

10x Genomics, Inc. (NASDAQ...",https://finnhub.io/api/news?id=f032d7c8e99a7ada778da2d19edaf84dccdac849879496660f9de3ac9e2feb29
company,1623999900,"Bristol Myers Inks Licensing Pact For Eisai's Folate Receptor ADC Drug, Lays Out Over $3B For Rights",68784426,https://cdn.benzinga.com/files/imagecache/og_image_social_share_1200x630/images/story/2012/aapharma_743.png,BMY,Benzinga,Eisai Co Ltd (OTC: ESALY) and Bristol-Myers Squibb Co (NYSE: BMY) have entered into an exclusive global strategic collaboration agreement for the co-...,https://finnhub.io/api/news?id=13ea631e52c5ff867a545a107c375a4a1382de2a5181b4445c51a27d5675b466
company,1623990785,Tracking Ole Andreas Halvorsen's Viking Global Portfolio - Q1 2021 Update,68345392,https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1143979227/medium_image_1143979227.jpg,BMY,SeekingAlpha,Halvorsen's 13F portfolio value decreased from $36.37B to $33.58B. The number of positions decreased from 96 to 94.,https://finnhub.io/api/news?id=4a53492c9b2fca73293600fd042342efa842899959ed890321472f6acb0f52e8
company,1623982654,"Japanese stocks end lower; Toyota, financials weigh on Topix",68373189,https://www.nasdaq.com/sites/acquia.prod/files/2021-06-18T024431Z_1_ZX8_RTRLXPP_2_LYNXPACKAGER.JPG?713696291,BMY,Nasdaq,"Japanese stocks closed lower on Friday, with the Topix index dragged lower by financial stocks and Toyota Motor's retreat from a record high.",https://finnhub.io/api/news?id=dec8a6cad1cf76bfb19500e2e8819fbe3ecdf2d04be59e63743289640821e9e2
company,1623971994,"Bristol-Myers, Eisai in up to $3.1 billion deal to develop cancer drug candidate",68339610,https://static.reuters.com/resources/r/?m=02&d=20210617&t=2&i=1566104287&r=LYNXNPEH5G1HT,BMY,Reuters,Bristol-Myers Squibb Co and Eisai Co said on Thursday they had entered into an agreement worth up to $3.10 billion to jointly develop and market an experimental cancer drug.,https://finnhub.io/api/news?id=ff269be0169b8f4fcc78879ea5265db1eefb4b6f7f308d967cc8df6a40a01f30
company,1623971857,"UPDATE 1-Bristol-Myers, Eisai in up to $3.1 bln deal to develop cancer drug candidate",68340382,https://s.yimg.com/cv/apiv2/social/images/yahoo_default_logo-1200x1200.png,BMY,Yahoo,"Bristol-Myers Squibb Co and Eisai Co said on Thursday they had entered into an agreement worth up to $3.10 billion to jointly develop and market an experimental cancer drug.  Bristol-Myers would pay $650 million, including for research and development expenses to Eisai, which will also be eligible for up to $2.45 billion in milestone payments, the companies said.  Bristol-Myers in May entered into a $1.56 billion deal with Agenus Inc to exclusively develop and market its experimental drug for immuno-oncology treatments, including non-small-cell lung cancer.",https://finnhub.io/api/news?id=a1258684c0caa85068ca407e998dfcd696124a426c9eb2df6fbe4dfa258e6f06
company,1623971103,"Nikkei tracks Nasdaq's solid finish overnight, Toyota drags Topix",68373190,https://www.nasdaq.com/sites/acquia.prod/files/2021-06-18T024431Z_1_ZX8_RTRLXPP_2_LYNXPACKAGER.JPG?1544947970,BMY,Nasdaq,"Japan's benchmark Nikkei inched up on Friday as technology stocks tracked a strong finish on the tech-heavy Nasdaq index, while the broader Topix index fell after Toyota Motor retreated from its record high.",https://finnhub.io/api/news?id=08d193a40c9c95f26b98e505062891665fba58d2ea09778d642cf2719186c4e3
company,1623970050,"Bristol-Myers, Eisai in up to $3.1 billion deal to develop cancer drug candidate",68340383,https://s.yimg.com/uu/api/res/1.2/ksk9eq7Fd40PECQVR8hiZw--~B/aD01MzM7dz04MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/reuters.com/a6b2f3020f4761fc19634d01c8ea04be,BMY,Yahoo,"Bristol-Myers would pay $650 million, including for research and development expenses to Eisai, which will also be eligible for up to $2.45 billion in milestone payments, the companies said.  Bristol-Myers in May entered into a $1.56 billion deal with Agenus Inc to exclusively develop and market its experimental drug for immuno-oncology treatments, including non-small-cell lung cancer.",https://finnhub.io/api/news?id=02738e1d41c65e706520d989ea489178b8e1fc37038a78e99b52e97762f99cd3
company,1623969793,"Bristol-Myers and Eisai to jointly develop, market cancer drug",68339613,,BMY,Reuters,Bristol-Myers Squibb Co and Eisai Co on Thursday entered into an agreement to jointly develop and market an experimental cancer drug.,https://finnhub.io/api/news?id=c3561a6c0e4c7fd0dbd6d51dfb87cc1f8939d20bac67f863a7ff528a6b8e72e3
company,1623969000,Eisai and Bristol Myers Squibb Enter Into Global Strategic Collaboration for Eisai’s MORAb-202 Antibody Drug Conjugate,68340384,https://s.yimg.com/uu/api/res/1.2/3a4fIuQ1HSrZupsGDZJvtw--~B/aD02Njt3PTQ4MDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/business-wire.com/fd9fc83ec26205b703a97beda5be75fd,BMY,Yahoo,"TOKYO & NEW YORK, Jun 17, 2021--Eisai and Bristol Myers Squibb Enter Into Global Strategic Collaboration for Eisai’s MORAb-202 Antibody Drug Conjugate",https://finnhub.io/api/news?id=09af25c540aedd540c53abd1da540df828d11d6a094bb798e54d0136ed8e80d0
company,1623960960,Bristol Myers Squibb Announces Dividend,68340385,https://s.yimg.com/uu/api/res/1.2/SA_mZo5x.nTICMILr4UVsA--~B/aD02Njt3PTQ4MDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/business-wire.com/f2ce12a8195029ed39356e6b0bd74242,BMY,Yahoo,"NEW YORK, Jun 17, 2021--Bristol Myers Squibb Announces Dividend",https://finnhub.io/api/news?id=2c4cc6f5c921704caebb97f394e00b31d5272efd63f1433d5ed8a2c095e56bf3
company,1623957457,"Bristol-Myers, Eisai in up to $3.1 bln deal to develop cancer drug candidate",68357044,https://www.nasdaq.com/sites/acquia.prod/files/2021-06-17T225042Z_1_OR4_RTRLXPP_2_LYNXPACKAGER.JPG?576740277,BMY,Nasdaq,Bristol-Myers Squibb Co and Eisai Co said on Thursday they had entered into an agreement worth up to $3.10 billion to jointly develop and market an experimental cancer drug.,https://finnhub.io/api/news?id=b153c909e841ac632897717fe335a097edf889b4f135645f170ebc83c333593a
company,1623955393,"Bristol-Myers and Eisai to jointly develop, market cancer drug",68373192,https://www.nasdaq.com/sites/acquia.prod/files/2021-06-17T225042Z_1_OR4_RTRLXPP_2_LYNXPACKAGER.JPG?2060206298,BMY,Nasdaq,Bristol-Myers Squibb Co and Eisai Co on Thursday entered into an agreement to jointly develop and market an experimental cancer drug.,https://finnhub.io/api/news?id=37d1c7cf36164fd059bd8edbfe2376ac7eb5a09b162f3076d021807efbdb0ab7
company,1623954600,Eisai and Bristol Myers Squibb Enter Into Global Strategic Collaboration for Eisai’s MORAb-202 Antibody Drug Conjugate,68338030,,BMY,Business Wire,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=ea06cd76c3ac288484ca7a6c0416092d7f0dd40751654d2de2acc2010c01552b
company,1623948060,Bristol Myers Squibb Co. stock underperforms Thursday when compared to competitors,68414142,https://images.mktw.net/im-220105/social,BMY,MarketWatch,"Shares of Bristol Myers Squibb Co. sank 0.22% to $66.77 Thursday, on what proved to be an all-around poor trading session for the stock market, with the S&P...",https://finnhub.io/api/news?id=e8988af02c85862f969d93116ab9cf157d774c65e162cf0cecdaed097d8ea5e5
company,1623946560,Bristol Myers Squibb Announces Dividend,68335523,,BMY,Business Wire,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=bb35f9758df1fd4d4339248a9aff7bda9b47b44baeac2c555abdb30e8369fc73
company,1623942038,Supreme Court upholds Obamacare in latest ruling,68326511,https://s.yimg.com/ny/api/res/1.2/xOvZSe3z_xTUuTl4dS1y.w--/YXBwaWQ9aGlnaGxhbmRlcjt3PTIwMDA7aD0xMTI0/https://s.yimg.com/hd/cp-video-transcode/prod/2021-06/17/60cb639733777a2738aeb875/60cb639733777a2738aeb876_o_U_v2.jpg,BMY,Yahoo,"On Thursday, the Supreme Court released its highly anticipated decision on a challenge to the Affordable Care Act (ACA), also known as Obamacare. By a 7-2 vote, the court rejected the Republican-led challenge to the law.",https://finnhub.io/api/news?id=c7bbbbce9058665fa4976109a753ee58c34d41082f1f32cce243e97f9a2d4983
company,1623934888,Why Agenus Stock Is Marching Higher Today,68357048,https://www.nasdaq.com/sites/acquia.prod/files/2019-05/0902-Q19%20Total%20Markets%20photos%20and%20gif_CC8.jpg?1251182373,BMY,Nasdaq,"What happened
Shares of the small-cap immunotherapy company Agenus (NASDAQ: AGEN) were up by a healthy 9.98% as of 11:08 a.m. EDT Thursday morning. The biotech's stock is rising today in response to the Food and Drug Administration's acceptance of the company's Biologics License",https://finnhub.io/api/news?id=9ba6d13aea12ae9ff0058693ea6a7b9fe8a854485fc77030498e90476d62583e
company,1623932245,6 Investments With 14-20% Annual Upside,68328305,https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1282804749/medium_image_1282804749.jpg,BMY,SeekingAlpha,There are six stocks that have a great annual upside of 14-20%. Read more to know these six stocks and their likelihood of high ROR.,https://finnhub.io/api/news?id=45dc717d19eff6744ecf4a23ee064008414179d31bd04ac77df348bc4ffd0fe2
company,1623929476,Interesting BMY Put And Call Options For August 20th,68373194,https://www.nasdaq.com/sites/acquia.prod/files/2019-05/0902-Q19%20Total%20Markets%20photos%20and%20gif_CC8.jpg?1140950301,BMY,Nasdaq,"Investors in Bristol Myers Squibb Co. (Symbol: BMY) saw new options become available today, for the August 20th expiration.   At Stock Options Channel, our YieldBoost formula has looked up and down the BMY options chain for the new August 20th contracts and identified one put a",https://finnhub.io/api/news?id=001ac0d9aff3d9a412b207c767ef5632ed515fdccaa105ec6ddf42da7e3e47e4
company,1623925860,Interesting BMY Put And Call Options For August 20th,68329531,,BMY,Stock Options Channel,"Staff article entitled Interesting BMY Put And Call Options For August 20th, about stock options, from Stock Options Channel.",https://finnhub.io/api/news?id=1f210e3aaa77add0d3c012b25eb1bebc1f6593539afa70a9c6f57a7777b49524
company,1623917880,Warren Buffet Sold These 8 Stocks in Q1 and All Have Done Well in Q2,68325847,https://247wallst.com/wp-content/uploads/2018/06/berkshire-hathaway-warren-buffett.jpg,BMY,247WallSt,Warren Buffett reduced Berkshire Hathaway's holdings in 13 stocks during the first quarter of this year. Here's how eight of those stocks have performed so far in the second quarter.,https://finnhub.io/api/news?id=9e7651acbe8a1f719cc93a5297afdead7133358cab6618195885b44395e65c85
company,1623907980,"Bristol-Myers, Eisai enter agreement to co-develop, commercialize MORAb-202",68338720,,BMY,Thefly.com,"Bristol-Myers, Eisai enter agreement to co-develop, commercialize MORAb-202 BMY ESALY",https://finnhub.io/api/news?id=869e265c63980e4222ce3a4b81917f39e89159bf40f9873135693b1a08438ef4
company,1623861660,"Bristol Myers Squibb Co. stock falls Wednesday, underperforms market",68414144,https://images.mktw.net/im-220105/social,BMY,MarketWatch,"Shares of Bristol Myers Squibb Co. slumped 0.74% to $66.92 Wednesday, on what proved to be an all-around grim trading session for the stock market, with the...",https://finnhub.io/api/news?id=1979dde7b0b258280bde5e25e731fbce613e22782a2fa651a595160eb566d5a7
company,1623846600,"Why Kindred Biosciences, Aprea, Catabasis And Inhibikase Are Moving Today",68784427,https://cdn.benzinga.com/files/imagecache/og_image_social_share_1200x630/sites/all/themes/bz2/images/bz-icon.png,BMY,Benzinga,"Kindred Biosciences, Inc. (NASDAQ: KIN), Aprea Therapeutics, Inc. (NASDAQ: APRE), Catabasis Pharmaceuticals, Inc. (NASDAQ: CATB) and Inhibikase Therapeutics, Inc. (NASDAQ: IKT)...",https://finnhub.io/api/news?id=0d059b84b2246bf1446bc9039492c17ba2bc719029fe4e151aa64d20d006ef8d
company,1623834000,Inflation Non-Transitory? 3 Reasons Why Paul Tudor Jones Might Be Right And How To Position For It,68299375,https://static.seekingalpha.com/cdn/s3/uploads/getty_images/843522120/medium_image_843522120.jpg,BMY,SeekingAlpha,"Paul Tudor Jones recently shared his views on why inflation won't be transitory. Read more on the 3 reasons why he may be right, and our investment strategy to thrive in any environment.",https://finnhub.io/api/news?id=e227c51620371d5f50ffca34a6b0a9b7c284009ba32e5c57a113c952f11996ef
company,1623833100,"Dividend Harvesting: Building The Portfolio Brick By Brick On $100 A Week, Week 15 Update",68299080,https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1061700868/medium_image_1061700868.jpg,BMY,SeekingAlpha,Click here to read the week 15 update of Dividend Harvesting Portfolio.,https://finnhub.io/api/news?id=d8d7fbf49611fc5cb4a085561b7c180423644326c01c7b82e758eb45a374ed44
company,1623832740,"Orbimed Advisors Llc Buys Edgewise Therapeutics Inc, Silverback Therapeutics Inc, Gracell ...",68317171,,BMY,GuruFocus,GuruFocus Article or News written by insider and the topic is about: ,https://finnhub.io/api/news?id=04e587fadff0b32fbce0d8505cf9914e8b1360dd302f6a3f818777b0d9fd77bc
company,1623808560,Myovant and Partner Get Key Drug Approval,68309066,,BMY,GuruFocus,GuruFocus Article or News written by Barry Cohen and the topic is about: The treatment will be available later this month,https://finnhub.io/api/news?id=9ccc4d81472a1d5f87a17344c387eb7f6e975109daae7699d8c277b1a5a13ce5
company,1623775260,Bristol Myers Squibb Co. stock outperforms market on strong trading day,68304031,https://images.mktw.net/im-220105/social,BMY,MarketWatch,"Shares of Bristol Myers Squibb Co. inched 0.19% higher to $67.42 Tuesday, on what proved to be an all-around grim trading session for the stock market, with...",https://finnhub.io/api/news?id=16b6a949ab6be002cbe5087e1269ae474bc7fed4b2a3d4a5ef0c1071947170ef
company,1623771543,Exelixis (EXEL) & Bristol Myers Team Up for Genitourinary Cancers,68284826,https://s.yimg.com/uu/api/res/1.2/sb.6qRd7FfGt7.wCjWz2vw--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/675c0ae70cb5036ad2ceb9062f13afc2,BMY,Yahoo,Exelixis (EXEL) collaborates with Bristol Myers to evaluate its next-generation tyrosine kinase inhibitor in combination with immuno-oncology therapies in advanced solid tumors.,https://finnhub.io/api/news?id=8add5407804cb84e5e52816f24f6660eebeecf836de4eec177c0f13492caf390
company,1623749520,Is bluebird bio's Surge a Bellwether for Gene Editing Stocks?,68353364,https://www.nasdaq.com/sites/acquia.prod/files/2019-05/0902-Q19%20Total%20Markets%20photos%20and%20gif_CC8.jpg?2042666205,BMY,Nasdaq,"Pioneering biotech bluebird bio (NASDAQ: BLUE) has resumed clinical trials for its blood disorder gene therapies after getting clearance from the U.S. Food and Drug Administration (FDA). The stock is up more than 10% over the past five days in response, and the FDA's move bodes w",https://finnhub.io/api/news?id=a0b1edca62b809720ec59ca7e1515bb951b2bbd04b541b655b2fdbe0086cc36b
company,1623726499,Bristol Myers Squibb Stock Remains Undervalued After Positive Data From Clinical Trials,68357925,https://www.nasdaq.com/sites/acquia.prod/files/2019-05/0902-Q19%20Total%20Markets%20photos%20and%20gif_CC8.jpg?1639367322,BMY,Nasdaq,[Updated: 6/11/2021] BMS Positive Data From Clinical Trials,https://finnhub.io/api/news?id=cbf80bd1432545d4113713d6a5e6d0d807940ce6ab8beecfe2e0240cad07edca
company,1623696431,Is Bristol Myers Squibb Company (BMY) Going to Burn These Hedge Funds?,68265177,https://s.yimg.com/uu/api/res/1.2/JHvETdigvJCNdeKw8s0w4A--~B/aD03NzI7dz02MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/insidermonkey.com/ce5b7a84019f92c68a44a40942e27d60,BMY,Yahoo,"We know that hedge funds generate strong, risk-adjusted returns over the long run, therefore imitating the picks that they are collectively bullish on can be a profitable strategy for retail investors. With billions of dollars in assets, smart money investors have to conduct complex analyses, spend many resources and use tools that are not always […]",https://finnhub.io/api/news?id=3deef637fce00a890a1a61ca17def9a9d1bc54e6b27685715a1944d469f14e92
company,1623691260,"IPO Preview: WalkMe, Atai Life Sciences Highlight Week Of Many Offerings",68744033,https://cdn.benzinga.com/files/imagecache/og_image_social_share_1200x630/images/story/2012/stock-exchange-738671_1280_65.jpg,BMY,Benzinga,This week’s IPO lineup could feature a double digit number of companies hitting the public. Here is a look at some of the largest and most high profile companies going...,https://finnhub.io/api/news?id=fc1b1cff98106f5535c3e00b13513961cc14869c52dd121816885d2446f33b0c
company,1623688860,"Bristol Myers Squibb Co. stock falls Monday, underperforms market",68414148,https://images.mktw.net/im-220105/social,BMY,MarketWatch,"Shares of Bristol Myers Squibb Co. dropped 0.07% to $67.29 Monday, on what proved to be an all-around mixed trading session for the stock market, with the...",https://finnhub.io/api/news?id=63e507758345db44a94e988aec4e7409775b7503ed48ae69ceddec11beffe9aa
company,1623671645,Bristol-Myers Squibb Company (BMY) Investor Presentation - Slideshow,68260368,https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png,BMY,SeekingAlpha,The following slide deck was published by Bristol-Myers Squibb Company in conjunction with this event.,https://finnhub.io/api/news?id=5301b13bbbae669f20a88a5d913d6e166304acb38ca686c9ba04bb7de05049b4
company,1623670543,Johnson & Johnson Building Case With New Patient Survival Data For Darzalex In Multiple Myeloma,68260767,https://s.yimg.com/uu/api/res/1.2/mF9ZCdy6L5JIyM1b3ZqE4A--~B/aD00MDA7dz02MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/Benzinga/13dbd99fe068235b6fd1ea65e4233582,BMY,Yahoo,"Janssen Pharmaceutical, a unit of Johnson & Johnson (NYSE: JNJ), announced overall survival (OS) results from the Phase 3 MAIA study evaluating the Darzalex combo in patients with newly diagnosed multiple myeloma. After nearly five years of follow-up, median progression-free survival was not reached, and a significant overall survival benefit was observed. Adding Darzalex (daratumumab) to Bristol-Myers Squibb Co’s (NYSE: BMY) Revlimid (lenalidomide) and steroid dexamethasone (Rd) could slash the",https://finnhub.io/api/news?id=51c63b0f02a7bb85d4096af78c0b3c4f8869cd1f021e2b4d4e40e5f8ad70fb27
company,1623664260,"Here's Where to Invest $1,000 Right Now",68257122,,BMY,Yahoo,"Depending on your risk tolerance and investment preferences, there are a number of smart ways to put your money to work.",https://finnhub.io/api/news?id=9f6e4d791a386a9a0c01b6b58d74f90a1194fc7e560f28020ede2e3700c44b92
company,1623660360,Exelixis in Clinical Trial Collaboration with Bristol Myers,68300798,https://mw3.wsj.net/mw5/content/logos/mw_logo_social.png,BMY,MarketWatch,By Michael Dabaie Exelixis Inc. said it is in a clinical trial collaboration and supply agreement with Bristol Myers Squibb Co. for a Phase 1b trial...,https://finnhub.io/api/news?id=c8d443cc1610b8fa9b201f666ee04a50335cb6cd2861a06a463fcda3cefad408
company,1623659647,"Exelixis, Bristol Myers To Evaluate XL092-Immuno-oncology Therapies In Advanced Solid Tumors",68373197,https://www.nasdaq.com/sites/acquia.prod/files/2019-05/0902-Q19%20Total%20Markets%20photos%20and%20gif_CC8.jpg?894846260,BMY,Nasdaq,"(RTTNews) - Exelixis Inc. (EXEL) said Monday that it has reached a clinical trial collaboration and supply agreement with Bristol-Myers Squibb Co. (BMY) for STELLAR-002, a new phase 1b trial evaluating XL092 in combination with immuno-oncology therapies in advanced solid tumors.",https://finnhub.io/api/news?id=00e8d4c040c228ee6e18835b2b92ba5a4cb4d8c0a8986cec82ff2a87892afe41
company,1623657600,Exelixis Announces Clinical Trial Collaboration and Supply Agreement with Bristol Myers Squibb to Evaluate XL092 in Combination with Immuno-oncology Therapies in Advanced Solid Tumors,68257561,,BMY,Business Wire,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=6be6188fc93c4035c37693305fc6d96f6daec361298f63081ce63574e3b427ba
company,1623656100,Johnson & Johnson Building Case With New Patient Survival Data For Darzalex In Multiple Myeloma,68784429,https://cdn.benzinga.com/files/imagecache/og_image_social_share_1200x630/images/story/2012/aapharma_664.png,BMY,Benzinga,"Janssen Pharmaceutical, a unit of Johnson & Johnson (NYSE: JNJ), announced overall survival (OS) results from the Phase 3 MAIA study evaluating the...",https://finnhub.io/api/news?id=83e6a79847d40614a356eea2c7df1538f0800ff697fc43e989c9ea9373aa81b1
company,1623655419,Bristol Myers Squibb a Top Socially Responsible Dividend Stock With 2.9% Yield (BMY),68373198,https://www.nasdaq.com/sites/acquia.prod/files/2019-05/0902-Q19%20Total%20Markets%20photos%20and%20gif_CC8.jpg?1856720464,BMY,Nasdaq,"Bristol Myers Squibb Co. (Symbol: BMY) has been named a Top Socially Responsible Dividend Stock by Dividend Channel, signifying a stock with above-average ''DividendRank'' statistics including a strong 2.9% yield, as well as being recognized by prominent asset managers as being",https://finnhub.io/api/news?id=aac9b399bbe1be75f2ad17f1943205a3dfb661e2db8e06ebb876d6f82e2f3b62
company,1623654300,"Exelixis, Bristol-Myers enter supply agreement for STELLAR-002 trial",68258580,,BMY,Thefly.com,"Exelixis, Bristol-Myers enter supply agreement for STELLAR-002 trial EXEL BMY NKTR",https://finnhub.io/api/news?id=c9bd3e27beac1ed5b899af9dc1e67bdfe7e071b426012d3602a43ddf35b58bed
company,1623651780,Bristol Myers Squibb a Top Socially Responsible Dividend Stock With 2.9% Yield (BMY),68257562,,BMY,ETF Channel,"Staff article entitled Bristol Myers Squibb a Top Socially Responsible Dividend Stock With 2.9% Yield (BMY), about ETFs, from ETF Channel.",https://finnhub.io/api/news?id=fea9004bbfc2d2e1d65e7c6d97cfe851d7ec62a667fa82a351f777377ba369ca
company,1623649860,"Here's Where to Invest $1,000 Right Now",68356809,https://www.nasdaq.com/sites/acquia.prod/files/2019-05/0902-Q19%20Total%20Markets%20photos%20and%20gif_CC8.jpg?677524749,BMY,Nasdaq,"Even with all of the major U.S. stock indexes nipping at record highs, history is clear that it's always an opportune time to put your money to work in the stock market. That's because operating earnings growth over time tends to drive the major indexes higher. In other words, pa",https://finnhub.io/api/news?id=d61480544fa6cad8863236f7db750657174ed4baaa141a4909a938784cdd1dba
company,1623634800,Weekly Market Pulse: Who's The Boss?,68253301,https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1252473576/medium_image_1252473576.jpg,BMY,SeekingAlpha,"With CPI printing at 5% yoy, bond yields fell, though the trend for rates is still up. In the JOLTS report, April saw a rise of nearly 1,000,000 job openings from March to an all-time record",https://finnhub.io/api/news?id=b6fbb14bf06b3f9013b5aac027e1924ab19b2e27c216d3e1d9f1a1837f670334
company,1623589260,How Big Is Bristol Myers Squibb's Latest FDA Approval?,68244018,,BMY,Yahoo,"Bristol Myers Squibb (NYSE: BMY) recently picked up another U.S. Food and Drug Administration (FDA) approval for Zeposia in treating ulcerative colitis.  In this Motley Fool Live video recorded on June 2, Motley Fool contributors Keith Speights and Brian Orelli discuss just how big this FDA win is for Bristol Myers Squibb.",https://finnhub.io/api/news?id=b494fbf1e7fe850a59cf5f1550f04781d9c26c71a6af1369806665d4ca06d427
company,1623574860,How Big Is Bristol Myers Squibb's Latest FDA Approval?,68372058,https://www.nasdaq.com/sites/acquia.prod/files/2019-05/0902-Q19%20Total%20Markets%20photos%20and%20gif_CC8.jpg?1740705778,BMY,Nasdaq,"Bristol Myers Squibb (NYSE: BMY) recently picked up another U.S. Food and Drug Administration (FDA) approval for Zeposia in treating ulcerative colitis. In this Motley Fool Live video recorded on June 2, Motley Fool contributors Keith Speights and Brian Orelli discuss just how bi",https://finnhub.io/api/news?id=bd63e44b42f82f1bd9c6ba149d05b2d6791333a17ebdc05420c0396f5a62570e
company,1623572040,Investing Vs. Trading - Week In Review,68251709,,BMY,TalkMarkets,Content,https://finnhub.io/api/news?id=7a813d7afa564f6bb873b940561c3993aff8bf78a12b72422a6937532b7f9959
company,1623567600,"Magellan Midstream: Up 116%, And Set To Soar Even More",68240540,https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1215230330/medium_image_1215230330.jpg,BMY,SeekingAlpha,The key to Magellan's safety and quality is its low-risk business model and fortress balance sheet.,https://finnhub.io/api/news?id=d5ab97eff9c8903126d80a9b2429ae7203bd94a22107ef8ecf33ad9e74b9919c
company,1623480540,Here's Why Wall Street Is Betting Against Clovis Oncology,68360757,https://www.nasdaq.com/sites/acquia.prod/files/2019-05/0902-Q19%20Total%20Markets%20photos%20and%20gif_CC8.jpg?291605621,BMY,Nasdaq,"Betting against biotech stocks is a pretty scary way to make money -- and it's getting a whole lot scarier now that retail investors have learned how to work as a team to create short squeezes. Clovis Oncology (NASDAQ: CLVS), a commercial-stage biotech, has recently become a targ",https://finnhub.io/api/news?id=cd165e83bd7b4fcc128c6e5b8c24491f35b1a99a3d8a8eda1fca2101b85e1322
company,1623429660,Bristol Myers Squibb Co. stock outperforms competitors despite losses on the day,68236202,https://images.mktw.net/im-220105/social,BMY,MarketWatch,"Shares of Bristol Myers Squibb Co. slumped 0.07% to $67.34 Friday, on what proved to be an all-around great trading session for the stock market, with the...",https://finnhub.io/api/news?id=099f9b08bebf675c9b3fc2654b78c7200136f45df1f31ae10cf230ebe240dcaa
company,1623429484,Bristol Myers (BMY) Announces Data on CAR T Cell Therapy Breyanzi,68205769,https://s.yimg.com/uu/api/res/1.2/sb.6qRd7FfGt7.wCjWz2vw--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/675c0ae70cb5036ad2ceb9062f13afc2,BMY,Yahoo,"Bristol Myers (BMY) announces positive data on CAR T cell therapy, Breyanzi, in the second-line setting for patients with relapsed or refractory large B-cell lymphoma.",https://finnhub.io/api/news?id=e85af3ba4cfb2f4ecf3c284e20e5c0c3b7039ed52676341f919ac2a4da58b9e3
company,1623409205,Is BMY Stock A Buy As Shares Surge On Promising Cancer Treatment Data?,68209518,https://s.yimg.com/uu/api/res/1.2/1vovMzvSzF.dsh5iTosJzA--~B/aD02MDA7dz0xMDY1O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/ibd.com/c86151a606376a1cfc78202e4a0ae9c6,BMY,Yahoo,Is BMY stock a buy after Bristol Myers Squibb said a cancer drug called Breyanzi outperformed the standard treatment in patients with a form of lymphoma?,https://finnhub.io/api/news?id=08a8e393f88c384309ac35efaa0eef52755205c7216daa42bd220d68fee0991b
company,1623402900,"Bristol-Myers Squibb: Undervalued, With 13% Upside",68197912,https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1298788278/medium_image_1298788278.jpg,BMY,SeekingAlpha,"Bristol-Myers Squibb is well below average industry valuations. We compare BMY stock to industry valuations, profitability and leverage.",https://finnhub.io/api/news?id=7c1e99ccf63a54af8391be18704857d2a54b3d104d318cd4d1f78b8668fc2d3c
company,1623394800,Bristol Myers Squibb and Acceleron Present First Results from Phase 2 BEYOND Study of Reblozyl® (luspatercept-aamt) in Adults with Non-Transfusion Dependent (NTD) Beta Thalassemia,68200867,https://s.yimg.com/uu/api/res/1.2/.6yVVzkSNxcJ9cVGfcsHIg--~B/aD0xODM7dz00ODA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/0ca1bf5bb63e9147dd7f1c89601b3d7b,BMY,Yahoo,"PRINCETON, N.J. & CAMBRIDGE, Mass., Jun 11, 2021--BMS & Acceleron Present First Results from Phase 2 BEYOND Study of Reblozyl® in Adults with Non-Transfusion Dependent (NTD) Beta Thalassemia",https://finnhub.io/api/news?id=402e88f1384fa531ce533ec3a16d2481fabac167d0f974de1e0cae5ca7ce55fc
company,1623390900,3 Absurdly Cheap Stocks to Buy in a Ridiculously Expensive Market,68372062,https://www.nasdaq.com/sites/acquia.prod/files/2019-05/0902-Q19%20Total%20Markets%20photos%20and%20gif_CC8.jpg?459620073,BMY,Nasdaq,Stocks are so expensive that revered value investor Benjamin Graham might be spinning in his grave. The S&P 500's cyclically ​adjusted price-to-earnings (CAPE) ratio is at its highest level since early 2000 -- right before the dot-com bubble burst. It's even higher than the,https://finnhub.io/api/news?id=5f4e3d694adbfd91ba7fa7529ec7142bbb2dda60bf049e1a3d28ddab1258b8e9
company,1623390189,"BMY, Acceleron Announce New Data From Reblozyl Phase 2 Trial For Adults With NTD Beta Thalassemia",68373203,https://www.nasdaq.com/sites/acquia.prod/files/2019-05/0902-Q19%20Total%20Markets%20photos%20and%20gif_CC8.jpg?891371648,BMY,Nasdaq,"(RTTNews) - Bristol Myers Squibb (BMY) and Acceleron Pharma Inc. (XLRN) announced Friday the first data from the Phase 2 BEYOND study evaluating Reblozyl (luspatercept-aamt), a first-in-class erythroid maturation agent, plus best supportive care in adult patients with non-transfu",https://finnhub.io/api/news?id=531c9a74879386a8c294298554842ad37a3d7a5f21b93e56f54819f8c66d8fd5
company,1623380400,Bristol Myers Squibb and Acceleron Present First Results from Phase 2 BEYOND Study of Reblozyl® (luspatercept-aamt) in Adults with Non-Transfusion Dependent (NTD) Beta Thalassemia,68193153,,BMY,Business Wire,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=c13faf21ce67753f5b0fa22ea05732df4d1bd508329d4e2e58eb14bd2f2d02fd
company,1623373093,Bristol-Myers Squibb - Don't Miss Out On This,68188996,https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1251485261/medium_image_1251485261.jpg,BMY,SeekingAlpha,"I've been repeatedly banging the drum for pharma companies, but no pharma company is as clearly undervalued to fundamentals as is Bristol-Myers Squibb.",https://finnhub.io/api/news?id=c7039a6d00fab3c0f35ab15b728715f84decd21b8d2d5b73bba3e7f7e607ea23
company,1623356160,Bristol Myers Squibb and GRYT Health Evolve Virtual Patient Advocacy Experience,68189440,https://s.yimg.com/uu/api/res/1.2/8r_06URNzLTjXyjqwCSduQ--~B/aD05Mjt3PTQ4MDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/business-wire.com/a8eab628729ab8e811974f2a8e0c492b,BMY,Yahoo,Bristol Myers Squibb and GRYT Health Evolve Virtual Patient Advocacy Experience,https://finnhub.io/api/news?id=877f8ac5434b20ddef9b2eb971bdf928e66d5a64c5384d5bb5efcb5bd84e9c33
company,1623342132,S&P 500 Rides Falling Yields to Record Highs as Bond Bears Cower,68188092,https://s.yimg.com/cv/apiv2/social/images/yahoo_default_logo-1200x1200.png,BMY,Yahoo,By Yasin Ebrahim,https://finnhub.io/api/news?id=d591fa10b47c41069ede2137bce1b34a0cc9acb6b4274a9e044e6b6504e1c163
company,1623341760,Bristol Myers Squibb and GRYT Health Evolve Virtual Patient Advocacy Experience,68191444,,BMY,Business Wire,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=486143c94d0a8807671d5355ee9ad169dacc34646f2f8f3e412549df50ee0d50
company,1623339763,"Notable Thursday Option Activity: CCL, HCI, BMY",68351916,https://www.nasdaq.com/sites/acquia.prod/files/2019-05/0902-Q19%20Total%20Markets%20photos%20and%20gif_CC8.jpg?1885029623,BMY,Nasdaq,"Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in Carnival Corp (Symbol: CCL), where a total of 145,675 contracts have traded so far, representing approximately 14.6 million underlying shares.  That amounts to about 52.",https://finnhub.io/api/news?id=77f4952a50c60a997c90e86cd7fe41bb56f1abc05c4400031f5a32f33820f1bf
company,1623339247,Bristol-Myers Squibb Company (BMY) Presents at Goldman Sachs 42nd Annual Global Healthcare Conference (Transcript),68183493,https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png,BMY,SeekingAlpha,"Bristol-Myers Squibb Company (NYSE:BMY) Goldman Sachs 42nd Annual Global Healthcare Conference June 10, 2021, 09:40 AM ET Company Participants Chris Boerner - Executive Vice President and...",https://finnhub.io/api/news?id=32462b9ccbbc10ef11ca1e795f227ea96ed285747dffafca42a8dccf5882cc90
company,1623336294,Nicholas Ward's Dividend Growth Portfolio: May 2021 Review,68181712,https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1223992751/medium_image_1223992751.jpg,BMY,SeekingAlpha,"During May, I made 13 purchases and 0 sales. My passive income was up 17.2% y/y during May 2021.",https://finnhub.io/api/news?id=5f79cfc5d3d678353437905e83195fce28b9d714a686c5bd427a8bc274151bb5
company,1623333000,Bristol-Myers Higher on Progress With Lymphoma-Drug Trial,68183246,,BMY,Yahoo,Bristol-Myers Squibb shares climb after the drugmaker reports progress with a Phase 3 study of a lymphoma treatment.,https://finnhub.io/api/news?id=298bc8f7af8a2f8a2591dfc4eca04fb59c160963f57b8d58fc2bbc9c2393c6c9
company,1623330605,Bristol Up As New Therapy’s Phase-3 Trial In Lymphoma Is Positive,68183248,https://s.yimg.com/cv/apiv2/social/images/yahoo_default_logo-1200x1200.png,BMY,Yahoo,Bristol-Myers Squibb (NYSE:BMY) shares were up more than 3% Friday as the company’s phase-3 trial of a therapy to treat lymphoma revealed positive results.  Bristol Myers said it’s the first time a treatment beyond chemotherapy and stem cell transplant has demonstrated a benefit in relapsed or refractory large B-cell lymphoma.  Hematopoietic stem cell transplant is considered a gold standard treatment for these patients.,https://finnhub.io/api/news?id=f0141aba38e49af27d6fb14d317671db1dedd083647e51f7dc1e596236d80f90
company,1623328860,Bristol Up As New Therapy’s Phase-3 Trial In Lymphoma Is Positive By Investing.com,68181761,https://i-invdn-com.investing.com/news/LYNXMPEE6P1NM_L.jpg,BMY,Investing.com,Bristol Up As New Therapy’s Phase-3 Trial In Lymphoma Is Positive,https://finnhub.io/api/news?id=fd880de8e896c1768bdeb67b2dc4cc41a1085afcc684232bdd965ad219a2027d
company,1623328416,"Stocks making the biggest moves midday: RH, Signet Jewelers, Clover & more",68183450,https://image.cnbcfm.com/api/v1/image/105608122-1543937598855rh1.jpg?v=1543937683,BMY,CNBC,These are the stocks posting the largest moves in midday trading. ,https://finnhub.io/api/news?id=e371de12be132cd4c092d5bf43e40f11be70b7c22b3a7be60dc1b4f2df2d364b
company,1623323100,"Bristol Myers Squibb to Report Results for Second Quarter 2021 on July 28, 2021",68169754,https://s.yimg.com/uu/api/res/1.2/Ys3xvlf_kKmez1klBWQA3Q--~B/aD02Njt3PTQ4MDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/business-wire.com/46c14719108bf62877eeb414e0f23ca2,BMY,Yahoo,"Bristol Myers Squibb to Report Results for Second Quarter 2021 on July 28, 2021",https://finnhub.io/api/news?id=86d35062b54092c1c90f6c1db76dbcd51b7f797f9ea7598fdc4d5eb9b92bc26e
company,1623322980,Bristol Myers Shares Up After Lymphoma Study Meets Objectives,68174768,https://mw3.wsj.net/mw5/content/logos/mw_logo_social.png,BMY,MarketWatch,By Michael Dabaie Bristol Myers Squibb Co. shares were 3% higher to $67.22 in morning trading after a Phase 3 study in lymphoma met its main objective. The...,https://finnhub.io/api/news?id=4ba9c3a15649c92138d5779357a0ce25a44ce8b854406e155ccfc318695b13c3
company,1623322740,Bristol Myers Squibb Announces Positive Topline Results from Phase 3 TRANSFORM Trial Evaluating Breyanzi (lisocabtagene maraleucel) Versus Chemotherapy Followed by Stem Cell Transplant in Second-line Relapsed or Refractory Large B-cell Lymphoma,68169755,https://s.yimg.com/uu/api/res/1.2/QEUNbs3qjle44NinzXUGHw--~B/aD02Njt3PTQ4MDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/business-wire.com/a4aeca4300e039b1f676ba00ee06dbd5,BMY,Yahoo,BMS Announces Positive Topline Results from Phase 3 TRANSFORM Trial Evaluating Breyanzi Versus Chemotherapy Followed by Stem Cell Transplant....,https://finnhub.io/api/news?id=83336e5fbf1731fb4d1c1b9388404235b12756fa14b2a5241d854ccf07c0ea43
company,1623315525,Bristol-Myers Squibb: Strengthening Its Grip On The Oncology And Cardiovascular Disease Drugs Segment,68169517,https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1290196720/medium_image_1290196720.jpg,BMY,SeekingAlpha,"BMY has the strongest Dividend Coverage Ratio among its peers, giving investors strong assurance on future dividend payouts.",https://finnhub.io/api/news?id=710e4d7d19f39f4e3f30e66b78a1c29b56e0b48b676ae2b9d4a4a92354f0b7cf
company,1623315300,Early notable gainers among liquid option names on June 10th,68175375,,BMY,Thefly.com,Early notable gainers among liquid option names on June 10th NOW ENPH FFIV MRO BMY,https://finnhub.io/api/news?id=6ee9fcbda0c94746d3a6762a42c90141a7824a8196ab1c2c70162fbd75b50ca6
company,1623312780,"The Daily Biotech Pulse: US To Procure 500M Pfizer-BioNTech Vaccine Doses For Donation, Verona Out-Licenses COPD Drug, Nautilus Lists Through SPAC Deal",68770558,https://cdn.benzinga.com/files/imagecache/og_image_social_share_1200x630/images/story/2012/cells-1872666_1920_70.jpg,BMY,Benzinga,"Here's a roundup of top developments in the biotech space over the last 24 hours:
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs June 9)

Aethlon Medical, Inc. (...",https://finnhub.io/api/news?id=f4f3cfc5b8b226dd1bb6bb7dea8e747732fdd915fa177524349765992b321551
company,1623312360,Bristol Myers Squibb Says Phase 3 Lymphoma Study Meets Objectives,68174769,https://mw3.wsj.net/mw5/content/logos/mw_logo_social.png,BMY,MarketWatch,By Michael Dabaie Bristol Myers Squibb said a Phase 3 study of Breyanzi as a second-line treatment in adults with relapsed or refractory large B-cell...,https://finnhub.io/api/news?id=2e12b9f378f62f7954e6049e2cd2e800955dec5134b0b5cd7ff351c4be1dd92d
company,1623312000,"Bristol Myers Squibb: Buy, Hold, Or Sell This Dividend Growth Healthcare Stock?",68167975,https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1224202684/medium_image_1224202684.jpg,BMY,SeekingAlpha,BMY is one of the best dividend growth healthcare stocks you can find today. What is the stock worth? We detail our full valuation model.,https://finnhub.io/api/news?id=ee37b9f9944f3d5306b9d1365a1a4d5c3fb7c795d1752d12294c81098fc205f1
company,1623311964,BMY Reports Positive Results From Phase 3 Breyanzi Trial In Second-line Relapsed Or Refractory LBCL,68373205,https://www.nasdaq.com/sites/acquia.prod/files/2019-05/0902-Q19%20Total%20Markets%20photos%20and%20gif_CC8.jpg?1970749868,BMY,Nasdaq,(RTTNews) - Bristol Myers Squibb (BMY) announced Thursday positive topline results from Phase 3 TRANSFORM trial evaluating Breyanzi (lisocabtagene maraleucel) versus chemotherapy followed by stem cell transplant in second-line relapsed or refractory large B-cell lymphoma or LBCL.,https://finnhub.io/api/news?id=14dec9172e12b475347595b031cd22b7d510170542b5588ecc4a56facc619ddd
company,1623311281,Why Bristol Myers Squibb is a Top 25 Dividend Giant (BMY),68373206,https://www.nasdaq.com/sites/acquia.prod/files/2019-05/0902-Q19%20Total%20Markets%20photos%20and%20gif_CC8.jpg?601175808,BMY,Nasdaq,"Bristol Myers Squibb Co. (Symbol: BMY) has been named as a Top 25 ''Dividend Giant'' by ETF Channel, with a staggering $16.91B worth of stock held by ETFs, and above-average ''DividendRank'' statistics including a strong 3.00% yield, according to the most recent Dividend Channe",https://finnhub.io/api/news?id=02f7dda0953d3844f4eb545ab3a45f2de4bb2c881525ceb0ef867ad8ceda8b23
company,1623308700,"Bristol Myers Squibb to Report Results for Second Quarter 2021 on July 28, 2021",68181764,,BMY,Business Wire,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=d7913b347eded77c60bf850b1473a78a16eb7d50687303148ae4fb8b954a7fa1
company,1623308340,Bristol Myers Squibb Announces Positive Topline Results from Phase 3 TRANSFORM Trial Evaluating Breyanzi (lisocabtagene maraleucel) Versus Chemotherapy Followed by Stem Cell Transplant in Second-line Relapsed or Refractory Large B-cell Lymphoma,68179281,,BMY,Business Wire,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=52f6cf2b13ada082932a0658ef7ec27d61399c172b8e9dc4a061891c7fef25d7
company,1623307680,Why Bristol Myers Squibb is a Top 25 Dividend Giant (BMY),68179283,,BMY,ETF Channel,"Staff article entitled Why Bristol Myers Squibb is a Top 25 Dividend Giant (BMY), about ETFs, from ETF Channel.",https://finnhub.io/api/news?id=c0bffd5f3471cc65a02c8523acde90169a02e8df3ba22e0dbd1fd6e804d56d69
company,1623304860,Bristol-Myers Squibb Company Stock Appears To Be Fairly Valued,68179285,,BMY,GuruFocus,GuruFocus Article or News written by GF Value and the topic is about: ,https://finnhub.io/api/news?id=8f4d30e7f954977693516896d4a2689e199ac2b1aa1dda2329e96209f09fc812
company,1623304800,Bristol-Myers reports `positive` results from Phase 3 TRANSFORM trial,68179287,,BMY,Thefly.com,Bristol-Myers reports 'positive' results from Phase 3 TRANSFORM trial BMY,https://finnhub.io/api/news?id=9e9ae3ae7f0d55ce414dd64518a00b46ce77922849dc95d33a96fae0b6462b1c
company,1623301980,Unheeding Markets,68186007,,BMY,TalkMarkets,Content,https://finnhub.io/api/news?id=348ae93e593a0fc328887708cced09d1653aeb5105f43cd609f23e964d319b85
company,1623301570,Billionaires In June Love 63 Stocks: 41 Pay Dividends,68161610,https://static.seekingalpha.com/cdn/s3/uploads/getty_images/172409492/medium_image_172409492.jpg,BMY,SeekingAlpha,Kiplinger Investing publishes opportune buy lists for investors on-line. Two billionaires stock lists are here. 41 of these 63 billionaire-held stocks pay dividends.,https://finnhub.io/api/news?id=1ac591b9b72f80b04cb40fc33123a0aa6ab1b147099a45db8786c12f8ed7c0f9
company,1623297180,S&P 500 Rides Falling Yields to Record Highs as Bond Bears Cower By Investing.com,68186001,https://i-invdn-com.investing.com/news/LYNXNPEC0K0XM_L.jpg,BMY,Investing.com,S&P 500 Rides Falling Yields to Record Highs as Bond Bears Cower,https://finnhub.io/api/news?id=d52979bdfe82b7813ef560cd8c51ce1c593f28153777a7e5e61ecc307a473cda
company,1623291480,S&P 500 Shrugs off Inflation Spike as 'Don't Fight the Fed' Idea Returns By Investing.com,68186002,https://i-invdn-com.investing.com/news/LYNXMPEA5O134_M.jpg,BMY,Investing.com,S&P 500 Shrugs off Inflation Spike as 'Don't Fight the Fed' Idea Returns,https://finnhub.io/api/news?id=5582bf0d641ce9b9ed64f6f6358c08e7f5f0ba9ca04893a8338743a56b660c42
company,1623256860,"Bristol Myers Squibb Co. stock rises Wednesday, outperforms market",68149951,https://images.mktw.net/im-220105/social,BMY,MarketWatch,"Shares of Bristol Myers Squibb Co. rallied 2.67% to $65.40 Wednesday, on what proved to be an all-around poor trading session for the stock market, with the...",https://finnhub.io/api/news?id=ca3932acddf8897dbc24333aba4c96d676d91f1cf91778d868ec9ed0a2bbccd6
company,1623233160,3 Buffett Stocks to Buy Hand Over Fist in June,68113753,https://s.yimg.com/uu/api/res/1.2/SmXUuNN5u.._SxCD4gl7Ew--~B/aD05MzM7dz0xNDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/motleyfool.com/fd160a1594a5143b6ce9ded370026cf1,BMY,Yahoo,"When Berkshire Hathaway (NYSE: BRK.A)(NYSE: BRK.B) CEO Warren Buffett speaks his mind, Wall Street and investors pay close attention.  Since taking over at Berkshire Hathaway in the mid-1960s, Buffett has led his company's stock to an average annual return of 20% -- and this is without paying a penny in dividends.  In aggregate, Berkshire Hathaway's stock is up more 2,800,000% in 56 years.",https://finnhub.io/api/news?id=c16fcfe78f6659ed0be90ccf4474ed55a8a8b91d618c57dab1f51b5489de61a9
company,1623229200,3 Top Pharma Stocks to Buy This Month,68126084,,BMY,TalkMarkets,Content,https://finnhub.io/api/news?id=7cd3af1b238123eeeb425fcb02f11bf3a46def8ca51291dcafdcf52888a036a2
company,1623227940,"Orbimed Advisors Llc Buys Edgewise Therapeutics Inc, Silverback Therapeutics Inc, Gracell ...",68146099,,BMY,GuruFocus,GuruFocus Article or News written by insider and the topic is about: ,https://finnhub.io/api/news?id=44c6d95c77091e5268abcc2ee0575b0e58689a35d426014dafcd9966a43ad8e3
company,1623218940,Wednesday News And Catch-Up,68138998,,BMY,TalkMarkets,Content,https://finnhub.io/api/news?id=462889eb3938299cfa289ef4fe877f0aa77ead34d69439e9dfbdf539ab7b0623
company,1623170460,Bristol Myers Squibb Co. stock underperforms Tuesday when compared to competitors,68149952,https://images.mktw.net/im-220105/social,BMY,MarketWatch,"Shares of Bristol Myers Squibb Co. shed 1.65% to $63.70 Tuesday, on what proved to be an all-around mixed trading session for the stock market, with the S&P...",https://finnhub.io/api/news?id=aa21162fbeab58f5be78706772b6eb021437919c3e88498a78edfabb1ddc8270
company,1623157872,46 Berkshire/Buffett June Holdings Show 28 Paying Dividends,68068647,https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1222984395/medium_image_1222984395.jpg,BMY,SeekingAlpha,This Buffett holdings list from Kiplinger first appeared 5/17/21 online. YCharts and Dogs of The Dow also track this Buffett/Berkshire Batch. Here's your update from 6/3/21 YCharts data.,https://finnhub.io/api/news?id=af56ba33bc12b6d238730bf0e85a6f0fd0094b403eb6bff4360c2cddcf3f8644
company,1623148680,5 Healthcare Stocks to Buy for Their Game-Changing Potential,68068533,https://investorplace.com/wp-content/uploads/2019/10/healthcare-1.jpg,BMY,InvestorPlace,"These healthcare stocks are at the forefront of huge trends, including precision medicine and advances in diagnosis technologies.",https://finnhub.io/api/news?id=fbec90ca23c1cd0db9292d9a90ace80d41196f892a27a5cf3f8306a9b3563697
company,1623135600,NeoImmuneTech Announces First Clinical Trial Application Authorization Received in the EU for its Phase 2 Study of NT-I7 (efineptakin alfa) and Opdivo® (nivolumab),68069313,,BMY,Business Wire,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=201e45a3f2bd66e7b41a57aaa601a0690990c3efc6dd01489cb4c971da03a54c
company,1623104974,"$15,000 To The Corporate Portfolio - How To Invest",68017445,https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1250581414/medium_image_1250581414.jpg,BMY,SeekingAlpha,"Due to company reasons, I didn't actually transfer any capital to my corporate portfolio in April. However, in May/June, I transferred $15,000 into the account.",https://finnhub.io/api/news?id=4ef043a3cb730e0d338d8f39da89200ecb9de264fb8e8415479b59172457af36
company,1623084060,Bristol Myers Squibb Co. stock outperforms competitors despite losses on the day,68149955,https://images.mktw.net/im-220105/social,BMY,MarketWatch,"Shares of Bristol Myers Squibb Co. slumped 0.26% to $64.77 Monday, on what proved to be an all-around dismal trading session for the stock market, with the...",https://finnhub.io/api/news?id=561b44284127161bc228940abe37ac863f50ff7309bea1afd5c33813173d2a7f
company,1623073020,How a Cloud Is Lifting from Bluebird and Other Gene Therapy Stocks,68127269,https://images.barrons.com/im-349803/social,BMY,MarketWatch,"Cancer scares are dissipating from experimental treatments that insert functioning genes in patients whose damaged copies cause sickle cell, hemophilia and...",https://finnhub.io/api/news?id=dc98899f673b214ab17be8e9d370a51791d7ccce3c25abead2c399322329283a
company,1623057780,This Company Is More Investable Than It`s Ever Been And Is Rated A ���Buy���,68004890,,BMY,TalkMarkets,Content,https://finnhub.io/api/news?id=7bb0bfe3704f3cae8944e0b2d463c5b762683c42b62db8789ecc8c7e3ad70242
company,1623055920,"The Week Ahead In Biotech: Biogen, Alexion And Vertex FDA Decisions, Multiple Conference Presentations On The Deck",67992586,https://cdn.benzinga.com/files/imagecache/og_image_social_share_1200x630/images/story/2012/testeing.highres.national-cancer-institute-xknubmnjbkg-unsplash_copy.jpg,BMY,Benzinga,"Biopharma stocks advanced in the truncated week ended June 4 amid the broader market strength. The American Society for Clinical Oncology meeting got underway during the week,...",https://finnhub.io/api/news?id=caa26496ea61650bc297e89da30db14e064bf9ee6594d19983b6c2ba9c4ce28f
company,1623039900,FDA surprise,68002512,,BMY,TalkMarkets,Content,https://finnhub.io/api/news?id=f99610b3565ff9ecba6ffd14202e945d4c222a618f256f35a629f875933669cd
company,1622984760,Here's What Crushed Exelixis' Earnings,67993672,https://www.nasdaq.com/sites/acquia.prod/files/2019-05/0902-Q19%20Total%20Markets%20photos%20and%20gif_CC8.jpg?1138489216,BMY,Nasdaq,"Exelixis (NASDAQ: EXEL) continues to grow sales of its cancer drug Cabometyx, thanks in large part to data showing the drug works well in combination with Bristol Myers Squibb's (NYSE: BMY) Opdivo. In this video from Motley Fool Live, recorded on May 10, Fool.com contributors Bri",https://finnhub.io/api/news?id=a677a90ed09f5e0970315b8bbc11d9966f6b937e4c7fa2888699d6afeff6952f
company,1622880480,Is Editas the Best Genetics Stock to Buy?,67996933,https://www.nasdaq.com/sites/acquia.prod/files/2019-05/0902-Q19%20Total%20Markets%20photos%20and%20gif_CC8.jpg?401179969,BMY,Nasdaq,"There are some big opportunities in the gene editing space over the coming decades. In this Fool Live video clip, recorded on May 24, Fool.com Healthcare Bureau Chief Corrine Cardina, contributor Brian Orelli, PhD, and Chief Growth Officer Anand Chokkavelu discuss Editas Medicine",https://finnhub.io/api/news?id=bdb11eb71f3f41924da3b0e66edf02c960df14660d0ae9550a31f8f278793450
company,1622832666,"Top Stock Reports for Berkshire Hathaway, CocaCola & Oracle",67987981,https://s.yimg.com/uu/api/res/1.2/qEVqYePSiuo91LuV8HyunQ--~B/aD02MDA7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/4e067dcfead6ca72f3d024ca0e8efd5c,BMY,Yahoo,"Top Stock Reports for Berkshire Hathaway, CocaCola & Oracle",https://finnhub.io/api/news?id=986e6efd1bcf97564756e1fa1fc1e836be1e333e0f150b2973af35d801e43022
company,1622808870,"Bristol Myers Touts Opdivo Win in Esophageal Cancer, But Yervoy-Opdivo Combo Comes with Caution",68130573,https://s.yimg.com/uu/api/res/1.2/Zz_xJfrqDpaoR5Yp3jRqNg--~B/aD00MDA7dz02MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/Benzinga/70c8beb77d1e7b286db0c97bf9596654,BMY,Yahoo,"Bristol Myers Squibb & Co (NYSE: BMY) announced results from the Phase 3 CheckMate-648 trial, which had two Opdivo-based treatment combinations — Opdivo (nivolumab) plus chemotherapy, and Opdivo plus Yervoy (ipilimumab) in unresectable advanced or metastatic esophageal squamous cell carcinoma (ESCC). The data showed that both the Opdivo-based combination therapies beat out chemotherapy alone to extend the lives of ESCC patients whose tumors can’t be removed. Data will be presented at the 2021 Am",https://finnhub.io/api/news?id=fc9747320a5ceaf8cb306f71dfbb7e51b994de23052d8156c926c7a114945b96
company,1622807105,Is BMY Stock A Buy After Shares Hit A 16-Month High — And Then Plummeted?,68130575,,BMY,Yahoo,Bristol Myers Squibb released promising data for several cancer drugs and shares hit a 16-month high. Is BMY stock a buy?,https://finnhub.io/api/news?id=3f71799950e7711eda476039ec3b84d2c7f865ffcbe3649fe55eb5aff270cfb6
company,1622805540,Wall Street in Fives - Must Read Lists at Midday PSTH;VIVHY;AVGO;SQ;BTC;$BTC;AMC;ODP;TSM;FB;BMY;VIAC;VIACA;SENS;TRGP;CLGX;CRK;NGL;FATE;ASAN;SUMO;FIVE;LULU;PD,67983226,https://image.thefly.com/catalog/201810/img_66.png,BMY,Thefly.com,<p>Get caught up quickly on the top news and ...,https://finnhub.io/api/news?id=10a43c7e711e1ce66ad0a55afcbe9cb6c9e6624c161d74b37d9f9925d6d481b3
company,1622804340,Bristol Myers Squibb to Take Part in Goldman Sachs 42nd Annual Global Healthcare Conference,68130577,https://s.yimg.com/uu/api/res/1.2/0kza79vmhoWytEBx_ehxcw--~B/aD02Njt3PTQ4MDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/business-wire.com/f1985a989bba92f04ee72bd964f859c9,BMY,Yahoo,Bristol Myers Squibb to Take Part in Goldman Sachs 42nd Annual Global Healthcare Conference,https://finnhub.io/api/news?id=07937795048af07a304283cf0d95cfc20e90eb8c7eae8d275b7c47304b9c6abf
company,1622804050,"Noteworthy ETF Outflows: IVW, BMY, TGT, ADSK",67996640,https://www.nasdaq.com/sites/acquia.prod/files/2019-05/0902-Q19%20Total%20Markets%20photos%20and%20gif_CC8.jpg?1622062266,BMY,Nasdaq,"Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the iShares S&P 500 Growth ETF (Symbol: IVW) where we have detected an approximate $81.8 million dollar outflow -- that's a 0.3% decrease week over",https://finnhub.io/api/news?id=b43fd0dbc4de423f106fe166abbbb14a76b63d09bf98847e8eb92dd7297cd02d
company,1622799540,"The Daily Biotech Pulse: Merck, AstraZeneca, Novartis Among Early Presenters At ASCO, Sanofi Strikes Breast Cancer Study Pact",67992732,https://cdn.benzinga.com/files/imagecache/og_image_social_share_1200x630/images/story/2012/medicine-1309148_1920_341.jpg,BMY,Benzinga,"Here's a roundup of top developments in the biotech space over the last 24 hours.
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs June 3)

BioCryst Pharmaceuticals,...",https://finnhub.io/api/news?id=689043d7537a81272ff1cab803917371a4a1c58a9de45af9828346c83cd7b721
company,1622794440,"Bristol Myers Touts Opdivo Win in Esophageal Cancer, But Yervoy-Opdivo Combo Comes with Caution",68073407,https://cdn.benzinga.com/files/imagecache/og_image_social_share_1200x630/images/story/2012/aapharma_574.png,BMY,Benzinga,"Bristol Myers Squibb & Co (NYSE: BMY) announced results from the Phase 3 CheckMate-648 trial, which had two Opdivo-based treatment combinations — Opdivo...",https://finnhub.io/api/news?id=314f9997c26ef4780c5b5249f34db312140a2549fab68b90c378b54e2cf8ae01
company,1622789940,Bristol Myers Squibb to Take Part in Goldman Sachs 42nd Annual Global Healthcare Conference,68004896,,BMY,Business Wire,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=95f1202c4fdb53abfbb44321063aae07f353efaf326018cea8de4d6fc5a01409
company,1622784240,"Bristol-Myers sued for $6.4B over delayed Breyanzi approval, Reuters reports",68004898,,BMY,Thefly.com,"Bristol-Myers sued for $6.4B over delayed Breyanzi approval, Reuters reports BMY",https://finnhub.io/api/news?id=22641ca1efd40811f21ce183b6e7034043cac7b4c52fb6b7bbeab341ddf3c436
company,1622778300,A Better Switch,67987288,,BMY,TalkMarkets,Content,https://finnhub.io/api/news?id=8b169ed7f41a98413b3eb3c087cb11e184f7b33d5d6387486f6dfccaa6254d49
company,1622776860,Wall Street in Fives - Must Read Lists for Friday PSTH;VIVHY;FB;SQ;AMC;ODP;BBBY;GME;NOC;WFC;WKHS;WINT;SPCE;BMY;VIAC;VIACA;WMT;SENS;TRGP;CLGX;FATE;CRK;NGL;ASAN;AVGO;FIVE;LULU;PD,67983228,https://image.thefly.com/catalog/201904/img_457.jpg,BMY,Thefly.com,<p>Get caught up quickly on the top news and ...,https://finnhub.io/api/news?id=d24aadb2eb755aa0fd3ffab161af2e9215edea695821386640f6bbac4cca9a69
company,1622756471,Tracking David Abrams' Abrams Capital Management Portfolio - Q1 2021 Update,67971718,https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1311649881/medium_image_1311649881.jpg,BMY,SeekingAlpha,David Abrams’ 13F portfolio value increased ~25% this quarter from $3.55B to $4.44B. The number of positions decreased from 17 to 16.,https://finnhub.io/api/news?id=d26039be55ee6c755bdf68bace338ba25aefe3ea3ab795b92871c2c83a9e26fa
company,1622754060,Bristol Myers Squibb Presents Data from CheckMate -648 Showing Opdivo plus Chemotherapy and Opdivo plus Yervoy Significantly Improved Overall Survival Compared to Chemotherapy in Unresectable Advanced or Metastatic Esophageal Squamous Cell Carcinoma,68130578,https://s.yimg.com/uu/api/res/1.2/lNGLJg24KtakGNEzWrNkaA--~B/aD02Njt3PTQ4MDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/business-wire.com/e94ddb019d9ea0bf5b89a119d5c61609,BMY,Yahoo,BMS Presents Data from CheckMate -648 Showing Opdivo plus Chemotherapy and Opdivo plus Yervoy Significantly Improved Overall Survival.....,https://finnhub.io/api/news?id=3426825d7ca0c5e157a4d1bc1c395cdeb1133038905751b9ae3f17ad6040a962
company,1622747764,Bristol Myers Faces $6.4B Lawsuit Over Delayed Approval of Breyanzi Non-Hodgkin Lymphoma Drug: Reuters,68130579,https://s.yimg.com/uu/api/res/1.2/5JIZRZ0oGber9PlHtWehoA--~B/aD00MDA7dz02MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/Benzinga/83437194725089c86939642f2cc4ae15,BMY,Yahoo,"Bristol Myers Squibb Co (NYSE: BMY) was sued for $6.4 billion for allegedly delaying approval for Breyanzi cancer drug to avoid payments to shareholders of the former Celgene Corp, acquired in 2019 for $80.3 billion in cash and stock. According to a complaint in Manhattan federal court, Bristol Myers failed to use contractually required ""diligent efforts"" to win FDA approval for the non-Hodgkin lymphoma drug by December 31, 2020, deadline. The complaint said that BMY withheld or delayed the subm",https://finnhub.io/api/news?id=3b0328f8b593a7189a3658fe1a125581a7648c87baa19a5c441e607662850c68
company,1622739660,Bristol Myers Squibb Presents Data from CheckMate -648 Showing Opdivo plus Chemotherapy and Opdivo plus Yervoy Significantly Improved Overall Survival Compared to Chemotherapy in Unresectable Advanced or Metastatic Esophageal Squamous Cell Carcinoma,68004904,,BMY,Business Wire,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=a326ad052bcc26787059beb7840611ac40f63c3b17ed69bd4d3d27436f4650c8
company,1622734005,Bristol-Myers is sued for $6.4 billion over delayed cancer drug,67971551,https://static.reuters.com/resources/r/?m=02&d=20210603&t=2&i=1564374098&r=LYNXNPEH520ON,BMY,Reuters,"Bristol Myers Squibb Co was sued for $6.4 billion on Thursday for allegedly delaying its Breyanzi cancer drug to avoid payments to shareholders of the former Celgene Corp, which the drugmaker bought in 2019.",https://finnhub.io/api/news?id=505455ed73a26e40b0164bc293c784a9da8c1795854a14f1dad2d63c231da206
company,1622733360,Bristol Myers Faces $6.4B Lawsuit Over Delayed Approval of Breyanzi Non-Hodgkin Lymphoma Drug: Reuters,68784434,https://cdn.benzinga.com/files/imagecache/og_image_social_share_1200x630/images/story/2012/bristol_myers_squibb_moreton_wirral_-_img_0369_1.jpg,BMY,Benzinga,Bristol Myers Squibb Co (NYSE: BMY) was sued for $6.4 billion for allegedly delaying approval for Breyanzi cancer drug to avoid payments to shareholders of the...,https://finnhub.io/api/news?id=37ab4cc0f0a243b75bbe3a9b28889bb84b13576451e6e6ec706eb9492fe0023e
company,1622727830,Bristol-Myers is sued for $6.4 billion over delayed cancer drug,68130580,https://s.yimg.com/uu/api/res/1.2/t1a.GG2eAlEmqBYJFanxNg--~B/aD01MzM7dz04MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/reuters-finance.com/630dac35ab30e9271be4f689900f9bc5,BMY,Yahoo,"NEW YORK (Reuters) -Bristol Myers Squibb Co was sued for $6.4 billion on Thursday for allegedly delaying its Breyanzi cancer drug to avoid payments to shareholders of the former Celgene Corp, which the drugmaker bought in 2019.  According to a complaint in Manhattan federal court, Bristol Myers failed to use contractually required ""diligent efforts"" to win U.S. Food and Drug Administration approval for the non-Hodgkin lymphoma drug by a Dec. 31, 2020, deadline.  By missing the deadline, Bristol Myers was excused from owing an additional $9 in cash to Celgene shareholders for each share they held, enabling it to acquire Celgene at an ""enormous discount"" and enjoy a ""windfall,"" the complaint said.",https://finnhub.io/api/news?id=2ee99757807fff54af1883321f2f061b76fd80a9f9ad08613c53cb382f05605f
company,1622727456,Lawsuit says Bristol-Myers avoided $6.4 bln payment by delaying cancer drug,68130581,https://s.yimg.com/cv/apiv2/social/images/yahoo_default_logo-1200x1200.png,BMY,Yahoo,"A new lawsuit claims Bristol-Myers Squibb Co improperly delayed the development of a drug to treat non-Hodgkin's lymphoma to avoid paying $6.4 billion to shareholders of the former Celgene Corp, which the drugmaker bought in 2019.  According to a complaint filed on Thursday in federal court in Manhattan, Bristol-Myers would have owed the money had it won U.S. Food and Drug Administration approval by specified deadlines for three drugs that Celgene had been developing.  The lawsuit said Bristol-Myers failed to use contractually required ""diligent efforts"" to win approval of the cancer drug Breyanzi by the Dec. 31, 2020, deadline, excusing it from the payments.",https://finnhub.io/api/news?id=872b51c62680251facb8b6f7a2f2ace1d325c7cf0557b7c94390e6b19b2e5989
company,1622727456,Lawsuit says Bristol-Myers avoided $6.4 bln payment by delaying cancer drug,67971552,,BMY,Reuters,"A new lawsuit claims Bristol-Myers Squibb Co improperly delayed the development of a drug to treat non-Hodgkin's lymphoma to avoid paying $6.4 billion to shareholders of the former Celgene Corp, which the drugmaker bought in 2019.",https://finnhub.io/api/news?id=dece7e1305cd5d4ee44e853e69f60fc100fb1e1bd46c4b91eea85d23be295e81
company,1622722932,Bristol Myers (BMY) Gets EC Nod Opdivo+Yervoy in Mesothelioma,68130582,https://s.yimg.com/uu/api/res/1.2/SlGE5JR4xp73Vb5zTu29cQ--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/52b6d392b63705aefb517365eab38a95,BMY,Yahoo,The European Commission approves Bristol Myers' (BMY) Opdivo in combination with Yervoy for the first-line treatment of malignant pleural mesothelioma.,https://finnhub.io/api/news?id=a89bd7771730b1e7eff4a72d44f1c061962c93c10cb8b353ce8c80792b90987c
company,1622719407,Bristol-Myers is sued for $6.4 billion over delayed cancer drug,68000210,https://www.nasdaq.com/sites/acquia.prod/files/2021-06-03T134011Z_1_XV8_RTRLXPP_2_LYNXPACKAGER.JPG?619805225,BMY,Nasdaq,"Bristol Myers Squibb Co was sued for $6.4 billion on Thursday for allegedly delaying its Breyanzi cancer drug to avoid payments to shareholders of the former Celgene Corp, which the drugmaker bought in 2019.",https://finnhub.io/api/news?id=6845e5b53bd2adf7a363f183d666f44b18bdd5e6cf2eeb5f52fb9f28a3cdac8d
company,1622716740,"Hoylecohen, Llc Buys Schwab U.S. Small-Cap ETF, Microsoft Corp, Intel Corp, Sells Eaton Corp ...",67970851,,BMY,GuruFocus,GuruFocus Article or News written by insider and the topic is about: ,https://finnhub.io/api/news?id=8e8e9f0dad55ffe2b324a69f68d1b4d67f9b8909e1c18a379a68dcabd2cdbfde
company,1622713056,Lawsuit says Bristol-Myers avoided $6.4 bln payment by delaying cancer drug,68000211,https://www.nasdaq.com/sites/acquia.prod/files/2021-06-03T134011Z_1_XV8_RTRLXPP_2_LYNXPACKAGER.JPG?1176376352,BMY,Nasdaq,"A new lawsuit claims Bristol-Myers Squibb Co improperly delayed the development of a drug to treat non-Hodgkin's lymphoma to avoid paying $6.4 billion to shareholders of the former Celgene Corp, which the drugmaker bought in 2019.",https://finnhub.io/api/news?id=e508e5d05dce1ec3e167ff39f495cfd22ce5be1e622d432ecde37d23ff768105
company,1622708580,"The Daily Biotech Pulse: Merck Completes Organon Spin-Off, Auris Repositions As RNA Therapeutic Company With Trasir Purchase, Replimune's Readout",67992580,https://cdn.benzinga.com/files/imagecache/og_image_social_share_1200x630/images/story/2012/cells-1872666_1920_69.jpg,BMY,Benzinga,"Here's a roundup of top developments in the biotech space over the last 24 hours:
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs June 2)

BioCryst Pharmaceuticals,...",https://finnhub.io/api/news?id=28bdb4ecb4d1e7a1c2b6c770dcabac59ac5e40c3d189b465e071f472d00676d1
company,1622707200,Diversifying to Conquer: Fortress Biotech (FBIO) Partnering Expansion Driving Progress in Cancer Immunotherapy and Rare Disease Therapeutics,67994852,https://cdn.benzinga.com/files/imagecache/og_image_social_share_1200x630/images/story/2012/fort_bio.png,BMY,Benzinga,"The following article is sponsored by the clinical communications unit of Redington, Inc. The information contained in this article in no way represents investment advice or...",https://finnhub.io/api/news?id=1e69cf088b7517e857b85d4dfa70a18fdb1af318f099f5499cc18ddc6e89b11a
company,1622707067,Implied RYH Analyst Target Price: $312,67991794,https://www.nasdaq.com/sites/acquia.prod/files/2019-05/0902-Q19%20Total%20Markets%20photos%20and%20gif_CC8.jpg?981316353,BMY,Nasdaq,"Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itsel",https://finnhub.io/api/news?id=066df9eb83eb41f421c2150b94c1d4b0e6bdbb7a875c871f02121b58650c76fe
company,1622693340,"Bristol-Myers CheckMate -648 trial meets two, misses one primary endpoint",68004908,,BMY,Thefly.com,"Bristol-Myers CheckMate -648 trial meets two, misses one primary endpoint BMY",https://finnhub.io/api/news?id=368fc9f1bf17608b4972be4577620542d2369afe7ad5a04bcf7b87374f9f5b24
company,1622650443,Bristol-Myers Squibb Company (BMY) CEO Giovanni Caforio Presents at Bernstein's 37th Annual Strategic Decisions Conference (Transcript),67965744,https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png,BMY,SeekingAlpha,"Bristol-Myers Squibb Company (NYSE:BMY) Bernstein’s 37th Annual Strategic Decisions Conference Call June 2, 2021 10:00 ET Company Participants Giovanni Caforio - Chief Executive Officer...",https://finnhub.io/api/news?id=2bc117b32a8c98e78e2d318561c3d9b9441bdbf8262bd83bf07c3219a1057746
company,1622635200,Health Canada Approves OPDIVO® (nivolumab) plus YERVOY® (ipilimumab) as the First and Only Immunotherapy Treatment for Previously Untreated Unresectable Malignant Pleural Mesothelioma,68130583,https://s.yimg.com/uu/api/res/1.2/oK8w3RtveG1iZn6VScy.Ng--~B/aD01NTt3PTQwMDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/cnwgroup.com/041ef82f035eda1c9e102d7d7ab8d99a,BMY,Yahoo,"Today, Bristol Myers Squibb Canada (BMS) announced Health Canada's approval of OPDIVO® (nivolumab) 360 mg every three weeks or 3mg/kg every two weeks plus YERVOY® (ipilimumab) 1 mg/kg every six weeks (injections for intravenous use) for the treatment of adult patients with unresectable malignant pleural mesothelioma (MPM) who have not received prior systemic therapy for MPM.i This is the first and only dual immunotherapy treatment for the condition. Unlike traditional cancer therapies that targe",https://finnhub.io/api/news?id=6bb2e2db666781f73ecef6c837472c6b580b72665b51e109b12cec7392f3da6a
company,1622635200,LONDON MARKET CLOSE: FTSE 250 hits fresh record amid nonfarms caution,67976996,,BMY,Alliance News,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=0fbe0eb8ddaa01655f81468264d54e3e8353c16df4b218af0025825960225dbe
company,1622631540,Bristol Myers Squibb Receives European Commission Approval for Opdivo (nivolumab) Plus Yervoy (ipilimumab) as First-Line Treatment for Unresectable Malignant Pleural Mesothelioma,68130585,https://s.yimg.com/uu/api/res/1.2/CX59Pn7BiOZUEIlyGViodA--~B/aD02Njt3PTQ4MDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/business-wire.com/39147193337bd385c5665d1b15626d70,BMY,Yahoo,BMS Receives European Commission Approval for Opdivo Plus Yervoy as First-Line Treatment for Unresectable Malignant Pleural Mesothelioma,https://finnhub.io/api/news?id=bb501bdfe37ad87bedd3d5555910155bd3df9179be25c1de5fba6a8109a02120
company,1622631540,Bristol Myers Squibb Data at EULAR 2021 Highlight Commitment to Driving Advancements Across Multiple Immune-Mediated Rheumatic Diseases,68130584,https://s.yimg.com/uu/api/res/1.2/JZxKD2Nn9.8fnxq0cmKtvg--~B/aD02Njt3PTQ4MDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/business-wire.com/59e45d58061b0e2e968e27024f1c839a,BMY,Yahoo,Bristol Myers Squibb Data at EULAR 2021 Highlight Commitment to Driving Advancements Across Multiple Immune-Mediated Rheumatic Diseases,https://finnhub.io/api/news?id=dca030dcccff0cf38c4faa5dd19879e255d716c7b6c03d564f727232116d6d09
company,1622630544,May 2021 Portfolio Update - Dividends Upon Dividends,67964444,https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1216743367/medium_image_1216743367.jpg,BMY,SeekingAlpha,"In May, I continued investing in undervalued, appealing dividend-paying stocks. I made new investments into higher-yielding stocks in Communications, Energy, and Real Estate. See more here.",https://finnhub.io/api/news?id=b31ab86a3369e69a8a025eccab74f5d77e7c8b91db375060d7e9f039d4713020
company,1622627820,"Bristol Myers' Opdivo-Yervoy Combo Approved In Europe, Canada For Malignant Pleural Mesothelioma",68784437,https://cdn.benzinga.com/files/imagecache/og_image_social_share_1200x630/images/story/2012/aapharma_545.png,BMY,Benzinga,The regulatory authorities in Europe and Canada have approved Bristol Myers Squibb & Co's (NYSE: BMY) Opdivo (nivolumab) plus Yervoy (...,https://finnhub.io/api/news?id=515a698f76506c16776c93736eea6226becc0d91c794736c5b46fc55d9f0730b
company,1622627760,Bernstein to hold a virtual conference,67977004,,BMY,Thefly.com,Bernstein to hold a virtual conference STT MCD TXN BMY GLW ZBH BC RHHBY CAT NEE LNG HAIN LVS GILD AMAT ABBV EBAY AIG,https://finnhub.io/api/news?id=00560e288ab3db13bfe79607065a1dc2d364963ff3d0ace2377b973525cda78a
company,1622627220,Bloomsbury up on strong results; buys Head of Zeus for GBP8.5 million,67992364,,BMY,Alliance News,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=be9ef8edb983b919038eddd0dd1e73659bce305436dc8fc9424b31877d6c8430
company,1622626465,"Roche Is Facing Challenges, But Could Still Be Perfect For Certain Investors",67964276,https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1248493102/medium_image_1248493102.jpg,BMY,SeekingAlpha,"Roche's business is under pressure from biosimilars, but I see several reasons to still like the company. RHHBF stock can be a solid option for investors seeking reliable dividend income.",https://finnhub.io/api/news?id=0cee8bef51b2f17666f32960ec5cc3061471d6942383b644a6405b967167ef08
company,1622622069,Health Canada Approves Bristol Myers' Opdivo Plus Yervoy To Treat Mesothelioma - Quick Facts,68000213,https://www.nasdaq.com/sites/acquia.prod/files/2019-05/0902-Q19%20Total%20Markets%20photos%20and%20gif_CC8.jpg?1581467465,BMY,Nasdaq,"(RTTNews) - Bristol Myers Squibb Canada Co., an indirect wholly-owned subsidiary of Bristol Myers Squibb Co. (BMY) announced Wednesday Health Canada's approval of OPDIVO (nivolumab) 360 mg every three weeks or 3mg/kg every two weeks plus YERVOY (ipilimumab) 1 mg/kg every six week",https://finnhub.io/api/news?id=8aca810b5565b067e062e68c8a9a9076095010d668e5e03212d833dddada3c4b
company,1622622000,"The Daily Biotech Pulse: FDA Nod For Novartis, iRhythm CEO Quits Abruptly, Moderna Inks Vaccine Supply Agreements",67992490,https://cdn.benzinga.com/files/imagecache/og_image_social_share_1200x630/images/story/2012/medicine-1309148_1920_340.jpg,BMY,Benzinga,"Here's a roundup of top developments in the biotech space over the last 24 hours.
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs June 1)

Anika Therapeutics, Inc. (...",https://finnhub.io/api/news?id=39b609b8cb0de43112c8312e6b38239b9ec62db725d85e6bb82a6b9b7c5dd6a6
company,1622618643,EC Approves Bristol Myers' Opdivo Plus Yervoy To Treat Mesothelioma - Quick Facts,68000214,https://www.nasdaq.com/sites/acquia.prod/files/2019-05/0902-Q19%20Total%20Markets%20photos%20and%20gif_CC8.jpg?1340159159,BMY,Nasdaq,(RTTNews) - Bristol Myers Squibb (BMY) announced Wednesday that the European Commission (EC) has approved Opdivo (nivolumab) plus Yervoy (ipilimumab) for the first-line treatment of adults with unresectable malignant pleural mesothelioma (MPM).,https://finnhub.io/api/news?id=d99c9f115712921bc7be902e71ca61dca7eeeb548744fb32b56f5e4fd495f998
company,1622617620,LONDON MARKET MIDDAY: Stocks lack direction as investors eye US jobs,68004917,,BMY,Alliance News,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=29d174707d8b29886020ab4833a6766e34d08ba99c68ad798c103dd805a98db6
company,1622617140,Bristol Myers Squibb Receives European Commission Approval for Opdivo (nivolumab) Plus Yervoy (ipilimumab) as First-Line Treatment for Unresectable Malignant Pleural Mesothelioma,68004920,,BMY,Business Wire,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=4bea065dbea3d55af882faaa805baafdfa0bfc80fab6f0e4357b922b99f44e65
company,1622617140,Bristol Myers Squibb Data at EULAR 2021 Highlight Commitment to Driving Advancements Across Multiple Immune-Mediated Rheumatic Diseases,68004918,,BMY,Business Wire,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=e3dfcd05be34600b8c714c7bed19b6c342d733de073a08816294c8757b4d5eaf
company,1622614860,SMALL-CAP WINNERS & LOSERS: Caffyns in fast lane as profit surges,67963492,,BMY,Alliance News,Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.,https://finnhub.io/api/news?id=bca7625f36857f6c88bba959815ccde965e0f833ad9853cdba359df9e8178c2b
